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CHAPTER 1.  
Setting an advocacy agenda using community-engaged research in Duchenne/Becker 
muscular dystrophy
Community Engagement
Community engagement is a form of public participation that is defined as “the process of 
working collaboratively with groups of people affiliated by geographic proximity, special 
interests, or similar situations with respect to issues affecting their wellbeing.”1 It is an approach, 
rather than a specific method, which values and fosters collaborations among the individuals 
who are the focus of the program, initiative or study; the group(s) implementing the program; 
and others with influence such as community leaders and government agencies. Approaches 
can vary dramatically in the degree of community engagement, from passive involvement 
through information dissemination to the target community, to active partnership of community 
stakeholders as decision making members of the program leadership team.2
Underlying community engagement approaches is the concept of empowerment through 
participation. In this context, participation has been described as: “…the process that 
increases a community’s capacity to identify and solve problems.”3 Meaningful community 
participation includes the generation of ideas, contributions to decision making, and a shared 
responsibility for the program or intervention.4 The approach is grounded in principles of 
fairness, justice, and self-determination.4 In recent decades, public participation has evolved 
from an adversarial approach characterized by resistance to the establishment to active
solicitation of stakeholder input by public authority figures.5
Community-Engaged Research
Community-engaged research (CEnR) is a collaborative research approach where researchers 
engage stakeholders to propose and answer questions of interest and relevance to the 
stakeholder community. In this thesis, we integrated the perspectives and preferences of a
broad range of stakeholders into the research process, including patients, caregivers, clinicians, 
patient advocates, clinical researchers, and clinical trial sponsors. CEnR is often used as a 
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catalyst for changing policies, programs, and practices.1 It presupposes that people affected by 
the research have a right to influence what research is done and how it is conducted,6 and that
“…health issues are best addressed by engaging community partners who can bring their own 
perspectives and understanding of community life and health issues to a project.” 4 The
increased relevance that comes from community engagement is expected to improve the 
uptake of the evidence and the likelihood that patients will achieve the health outcomes that are 
important to them.7
Without community engagement, researchers risk imposing their own concepts of the most 
important health or policy concerns on a disease community. This could result in research that 
is less relevant to the community that channels resources away from the most important 
challenges.8 Even clinicians expert in managing the health care needs of a patient population 
are oriented toward inquiry about health or healthcare, rather than the lived experience of the 
patient. 7 
A challenge of public engagement is that the approach is poorly conceptualized, spanning
theoretical principles to nuanced, measurable engagement efforts. 5 To improve 
conceptualization, five core principles of CEnR were identified: understanding the definition and 
scope of community engagement in the research process; developing strong partnerships 
between communities and researchers that include mutual understanding of needs, capacities, 
and goals; facilitating equity of power, expertise, and responsibility while encouraging diverse 
perspectives; building capacity in all partners; and effective information dissemination based on 
bi-directional, transparent communication and mutual decision making about results 
dissemination.9 Similarly, dimensions of community participation in biosciences include 
participant education, empowerment in goal setting, control over resources, the capacity to exit 
without penalty, opportunities to influence outcomes, measurement of outcomes, and within-
group communicative capacity. 5 Strong partnerships help community members feel ownership 
over the program outcomes and to empower them to become agents for change.3 An important 
caveat is that CEnR must not reduce scientific rigor. 7
A review of community engagement in research partnerships identified areas in 
which community engagement has made a positive impact. 6 These include: influencing the
research agenda; improving study design, research tools and outcome measures; and




research found that researchers developed respect for and rapport with the community and 
greater insight into their areas of research. 10 There were both positive and negative impacts on 
the community involved in the research—increased knowledge and awareness about their 
condition, but also perceptions of insufficient training to contribute to research and a sense of 
being overburdened.10
Community-engaged research is most often described in the context of major public health 
issues and/or research in traditionally underserved communities. 6 In this thesis community 
engagement is employed in a different context: a rare, progressive, fatal disorder with high 
unmet needs (described further below). Use of community engagement is compelling in this 
community because there are many competing needs and limited resources. Arguably the most 
impactful research would be done after engaging with the community and identifying the most 
feasible and pressing research needs.7 The research was intended to be translational in that it 
would directly inform the planning of an advocacy agenda. 
To better characterize the public engagement used in this thesis, we present a model that
describes a continuum of approaches to community-engaged research. The model is adapted
from the United States-based ACQUIRE group’s Active Community Engagement (ACE) 
Continuum;2 the adaptations were based on the literature1-9 and our experience. The model 
describes “stakeholder” engagement. Depending on the research objectives, stakeholders in 
disease communities may extend beyond patients and caregivers to also include clinicians, 
clinician researchers, industry groups, and advocacy organizations. The model is revisited in the 
concluding chapter to explore the depth and breadth of engagement in this thesis and to assess
the CEnR approaches employed.
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Duchenne and Becker Muscular Dystrophy
Duchenne and Becker muscular dystrophy (DBMD) are rare X-linked neuromuscular disorders 
that occur primarily in males. The progressive muscle wasting that is the hallmark of the 
conditions is caused by mutations that alter production of the dystrophin protein.11 Of the two
conditions, Duchenne muscular dystrophy (DMD) is more severe and more common, with an 
incidence between 1:3500 and 1:6200.12 Symptoms may appear as early as infancy and 
diagnosis usually occurs around age 5.13,14 The phenotype includes progressive muscle 
weakness and death occurs typically in the late 20s.13 Becker muscular dystrophy (BMD) is 
about a third as frequent and is more heterogeneous, ranging from a course similar to 
Duchenne to much milder presentations with later onset. 12 Several studies have shown high 
caregiving demand, burden, and stress,15-19 and lower psychosocial and health-related quality of 
life20-21 in caregivers of children with DBMD. Managing Duchenne places serious financial
burden on the family.22
The first multi-system care guidelines for DBMD were published in 2009.23 The standard-of-care 
treatment for DBMD includes the off-label use of corticosteroids, which stabilize muscle strength, 
delay loss of ambulation, and improve cardiopulmonary function.23-24 There are no U.S. Food 
and Drug Administration (FDA) approved treatments for DBMD. In 2014 the European 
Medicines Agency (EMA) granted conditional approval for a drug that targets approximately 
13% of patients with Duchenne.25 Several other potential therapies are under clinical trial26 or 
have recently completed clinical trials.27 These potential treatments represent a new opportunity 
to intervene in a fatal disorder. 
The DBMD field is at a time of tremendous advancement with robust pre-clinical research and a 
wide range of targets that span numerous primary and secondary pathways (for examples and a 
lay summary,
see http://www.parentprojectmd.org/site/PageServer?pagename=Advance_pipeline). These
advancements have led to increased optimism among families, clinicians, and the advocacy 
community. However, most patients do not have access to novel, potentially disease-modifying 
therapies because participation in clinical trial is not available to them. The large majority of 
families have thus seen only modest changes in the management of their children with DBMD—
though it is important to note that those improvements in care have led to advances in
lifespan.12,24 Families with access to clinical trials have to make difficult decisions about whether 
to enroll their child in a clinical trial, and if so, which trial to choose. Given the considerable 
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needs imposed by both the disorder and this time of growth in knowledge and opportunities, 
DBMD provides an appealing model for conducting community engagement to help ensure that 
research is focused on timely and pressing needs. 
Aims and Community-Engaged Approaches of the Thesis Studies
The research studies included in this thesis were developed to inform the priorities and agenda 
of a DBMD advocacy organization called Parent Project Muscular Dystrophy (PPMD). The 
studies represent a range of research aims, methodologies, and levels of community 
engagement. Prior to each study, community engagement identified areas of need; the four 
distinct areas of significant need are introduced below and described in each subsequent 
chapter of the thesis. 
Informing interventions for mother caregivers using a stakeholder advisor 
approach: The Mothers’ Wellbeing Study (Chapter 2)
The impetus for the first study came from years of anecdotal reports to the advocacy 
organization about mothers’ unmet caregiving and support needs. A small body of published 
literature confirms the impact of caring for children with Duchenne or Becker muscular 
dystrophy on caregivers. However, mothers’ anecdotal communications highlighted important 
gaps in the literature—as well as a gap in understanding and addressing their needs, they 
spoke to understanding areas of strength and benefits conferred by the caregiving experience, 
and undertaking efforts to enhance their adaptation to caregiving for a child with DBMD. 
Therefore, the goal of the study was to inform PPMD’s ongoing and future efforts to improve 
wellbeing in mothers of individuals with DBMD. Chapter 2 presents cross-sectional data on
mothers’ unmet support needs and longitudinal data from the same sample on predictors of
Duchenne-specific adaptation. In this CEnR approach we involved key stakeholders as advisors 
in the development of the longitudinal survey study. These advisors guided study objectives, 
aims, and methods, and helped maintain a focus on obtaining results that might lead to 
meaningful interventions. Advisors and parent pilot testers reviewed validated measures and
informed the development of novel items on mothers’ needs and strengths. The advisors and




Influencing regulatory decision making using a collaborative, community-led
approach: Duchenne Treatment Preferences Study (Chapters 3-5)
   
The second study was developed to answer specific policy-related questions of immediate 
relevance to the DBMD population. As clinical trials in DBMD have progressed, questions 
emerged from trial sponsors and regulators about parents’ and patients’ treatment preference 
and risk tolerance. Historically, most patient and caregiver feedback is provided to regulators 
through testimonials. This approach has many limitations; the most significant is that those who 
provide testimonials may not represent the views of the entire patient population.28,29 Thus, 
regulators are being asked to incorporate additional patient and caregiver input to include the 
views of larger groups of stakeholders,30 and draft FDA Guidance indicated a willingness to 
include quantification of treatment preferences and risk tolerance in the regulatory process.31 An 
overarching objective of the program was to develop a replicable model for advocacy directed at 
informing regulators’ benefit-risk assessments.
This research program was intended to engage parents of individuals with DMD about both the 
DMD disease impact and their treatment preferences and risk tolerance. Three manuscripts 
have emerged from this study and are included in this thesis. We explored one aspect of 
disease impact, parental DMD-related worries, by using Best-Worst Scaling (BWS) Case 1 
(Chapter 5). BWS Case 1 is used to assess participants’ relative preferences for a series of 
related items that could otherwise be evaluated using a rating or ranking scale.32 However, 
advantages of BSW Case 1 to rating scales have been demonstrated.32 During the worries 
tasks, parent participants were presented with 16 sequential sets of worry items. For each task 
participants identified the items that were most and least worrying over the past 7 days. 
The treatment preferences task described in chapters 3 and 4 used a more complex form of 
BWS, called BWS Case 2, as well as simple conjoint analysis. Both BWS Case 2 and conjoint 
analysis involve participants stating their preferences about treatment profiles that are 
presented to them.32 The treatment profiles typically include different levels of treatment benefit 
and levels of risks, harms and/or burden. For the BWS Case 2 tasks, participants were 
presented with 18 simulated treatment profiles and asked to identify the best and worst aspects
of each. Every treatment profile was followed by a simple conjoint task where participants 
indicated acceptance or rejection of the treatment, if it were available. The article under Chapter 
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3 reports the results of the BWS case 2 analysis, while Chapter 4 describes a comparison of the 
BWS and conjoint approaches.
The development and implementation of this study included rounds of community education
about the objectives of the study and the study implications. It was led by PPMD with 
considerable organization investment. The process included extensive reporting back to 
stakeholders and was described and received as a community project. Study decision making 
rested with a small study team comprising the researchers, the President of PPMD, and several
other advocacy organization staff members and volunteers with a range of backgrounds. 
Stakeholder advisors including families, clinician investigators, and industry professionals, all of 
whom had extensive input into the development of the items in the treatment preferences task. 
Items for the Duchenne worries task were developed by five parent volunteers. 
Informing clinical trial processes and informed consent procedures using a 
community-based participatory research approach: Clinical Trial Expectation and 
Decision Making Studies (Chapters 6-8) 
The third thesis topic assesses the implications of a relatively new phenomenon in DBMD—
access to clinical trials. The research under this topic included two separate studies that 
explored the experiences and perceptions of parents whose children were enrolled in Duchenne
clinical trials. The first was a pilot study to understand positive and negative outcomes of one
trial sponsor’s community engagement in trial development. An article describing that study is 
included as Chapter 6. The second was a community-based participatory research study with a 
focus on trial decision making in a range of DMD clinical trials. Two manuscripts from the 
second study are included as Chapters 7 and 8.
The pilot study was initiated with the support of PPMD and the qualitative interview themes were 
developed with their input, with an expectation that results would be used to influence 
community engagement for future clinical trials. Unexpectedly, the clinical trial failed 
immediately before the study was submitted for IRB review. Thus, the focus of the study shifted 
to parents’ expectations of the trial and response to the trial failure.  
The findings from the pilot study (Chapter 6) emphasized the need to extend our 




making processes. Our intention to improve and nuance existing notions of therapeutic 
misconception, optimism, and mis-estimation (collectively called “therapeutic error”33) led to a
project on parents’ expectations, hopes, and clinical trial experiences in a broad range of DMD 
trials. The project used a community-based participatory research (CBPR) approach, in which 
advocates, clinicians, caregivers, and social science researchers identified the research 
agenda, design and delivery and led the research program.4,5 The CBPR study included a 
qualitative phase and a subsequent survey phase (the latter is not described here). The
interview study explored perceptions of parent decision makers as well as clinician investigators 
at trial sites. Results were intended to inform a conceptual decision making framework, 
recommendations to trial sponsors and advocacy organizations, and the development of a 
subsequent survey. Chapter 7 reports on parents’ perceived benefits of trial participation, and 
Chapter 8 integrates study results and the CBPR team’s guiding principles to support a decision 
making framework for clinical trial participation.
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Duchenne and Becker muscular dystrophy (DBMD) cause significant emotional and care-related 
burden on caregivers, but studies have not assessed predictors of disease-specific adaptation.
Using a community-engaged approach focused on supporting mothers in positive aspects of 
caregiving, this study aims to assess mothers’ unmet needs and identify predictors of mothers’ 
psychological adaptation to DBMD.
Mothers of at least one living child with DBMD completed an online survey (n=205) and a two-year 
follow up (n=144). The surveys measured unmet needs, DBMD-related adaptation, optimism, 
resilience, perceptions of caregiving, and child’s functional status. 
The greatest unmet support needs were in managing future uncertainty and DBMD fears. Unmet 
needs were modestly but significantly higher for mothers of ambulatory children (M=1.43) than 
nonambulatory (M=1.12), p=0.02. Mothers indicated a desire for more information on respite care
(40%). Increased psychological adaptation was predicted by resilience ( ) and
perceived positive impact ( ), controlling for mother’s age -.305, p<.001).
Child’s functional status did not predict adaptation. 
Clinicians should address unmet support and respite needs. Though increased caregiver burden 
is anticipated with disorder progression, burden did not predict psychological adaptation. Efforts 
to improve wellbeing should instead focus on fostering resilience and benefit finding, especially 
as mothers age. Additional exploration is needed to better understand the effects of increasing 
mother’s age and worsening child’s functional status on support needs and psychological 
adaptation.
INTRODUCTION
Duchenne and Becker muscular dystrophy (DBMD) are rare, progressive, X-linked diseases of 
muscle wasting.1 Duchenne muscular dystrophy is the more common and severe of the two 
disorders, with noticeable symptoms in early pediatric years.2 It leads to severe progressive 
muscle weakness that results in increasing care needs as the child ages, and death typically in 
the late 20s.3 Becker muscular dystrophy is more heterogeneous, ranging from a course similar 
to Duchenne to milder presentations with later onset and more slowly progressing weakness.2
Several cross-sectional studies have explored the impact of caring for a child with DBMD on 
parent/guardian caregivers. Studies have shown high caregiving demands and high perceived 
burden,4-7 stress,5,7,8 distress,5,9 and lower health-related quality of life (QoL) in caregivers.10
Chapter 2
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Psychological outcomes have been found to be associated with factors such as child’s illness 
progression, social support, and financial burden.4,5,9,10
However, survey and interview studies have also described components of DBMD caregiving 
that were perceived as beneficial, including an improved ability to appreciate life experiences and 
other positive coping strategies to manage the progressive disease course and chronic 
sorrow.11-14 Pangalila and colleagues’ (2012) cross-sectional study of parents of adults with 
DBMD found high subjective burden, but also high rating of care as important and rewarding. 4
Kenneson and Bobo5 found that general life satisfaction was associated with high social support, 
high resiliency, and high income. While Hatzmann and colleagues assessed factors associated 
with health-related quality of life,10 QoL is not specific to the caregiving experience and includes
both positive and negative domains. Further, causation cannot be assessed from the existing 
cross-sectional studies. No longitudinal studies have been reported that are able to identify 
predictors of disease-specific caregiver wellbeing. 
Studies of caregivers of other chronic disorder populations provide additional insight into
wellbeing. While at increased risk for adjustment problems, the majority of caregivers 
demonstrated good adjustment and reported adaptive coping.16 The importance of positive 
psychological responses to caregiving demands;17-20 quality of family relationships and social 
supports;10,18 time outside the home;21-24 and financial resources10, 24 have been demonstrated.
Though mothers caring for children with DBMD experience challenges to their wellbeing, unmet 
caregiving needs and DBMD adaptation can be explored in a positive framework of coping, 
optimism, and resilience. Disorder-specific adaptation is a wellbeing concept defined as a
dynamic process of coming to terms with the implications of a health threat and the outcomes of
that process.25 Our choice of psychological adaptation to DBMD as a study outcome measure 
reflects the positive personal impact reported by caregivers and is consistent with the 
preferences expressed during community engagement (described below). Predictor variables 
were chosen based on the literature and through community engagement, and are described 
further under the “Measures” section.
Aims and Hypotheses  
This study aims to: (i) assess mothers’ unmet support, respite, and financial needs; (ii) determine 
the impact of the child’s functional status on mothers’ unmet support needs; and (ii) to determine 
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whether psychosocial adaptation to DBM two years later can be predicted by baseline child’s 
functional status, mothers’ dispositional optimism, resilience, perceptions of DBMD caregiving,
and their coping self-efficacy.  
It was hypothesized the child’s functioning at the time of the baseline survey would be associated 
with mothers’ unmet support needs and psychological adaptation—specifically, that worse child 
function (i.e., more severe illness) would be associated with more unmet needs and negative 
impacts on adaptation. It was also hypothesized that mothers’ psychological adaptation as 
measured two years after the baseline survey would be associated with higher levels of
dispositional optimism, resilience, perceived positive impact of DBMD, perceived control, and 
coping efficacy, and with lower levels of worry about care and perceived caregiver burden. 
Longitudinal data collection is advantageous because it facilitates understanding of causality in 
assessing predictors of psychological adaptation. Such data will inform the development of 
interventions aimed at improving caregivers’ wellbeing, by identifying when interventions may be 
most necessary and which caregivers are most likely to develop adverse psychological 
outcomes so that interventions can be targeted more precisely.
MATERIALS AND METHODS
Approach
This study used a community-engaged research approach, in which advocates, clinicians, 
caregivers, and social science researchers identified the research agenda, design and 
delivery.26,27 Most notably, the focus of the project is responsive to a community-identified need 
to engage in needs assessment while appreciating and exploring positive perceptions and 
outcomes experienced by caregivers. The long-term objective is to develop interventions 
focused on meeting needs and improving adaptation rather than solely target negative impact on 
caregivers.
This longitudinal survey study was determined to be exempt by the Cincinnati Children's Hospital 
Medical Center Institutional Review Board. 
Participants
Participants were biological mothers of at least one living child with Duchenne or Becker 
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muscular dystrophy, who lived in the United States, were 18 years of age or older, and able to 
answer questionnaires in English. The online questionnaire was implemented using 
SurveyMonkey software. Participants completed the baseline survey between November 2011 
and October 2012, followed by a follow up survey that was distributed two years later.
Recruitment strategy
Recruitment was conducted through online and e-mailed advertisements and social media 
postings through the Duchenne Connect Registry (www.duchenneconnect.org) and Parent 
Project Muscular Dystrophy, and continued through snowball recruitment; and through 
face-to-face invitations and advertisements distributed at Cincinnati Children's Hospital Medical 
Center neuromuscular clinic. The total number of participants invited to the study is impossible to 
calculate given the variety of recruitment approaches, the use of social media and snowball 
recruiting, and overlap among the recruitment populations.
Procedure
Eligible mothers provided their contact information and each participant was asked to complete a 
baseline questionnaire. With the exception of two participants who requested mailed paper 
copies, the participants responded to surveys online using unique survey links for each 
participant. The unique link to a follow-up survey was sent by email at about 24 months after the 
baseline survey. 
Measures
Demographic/Disease Characteristics: Participants’ age, ethnicity, education, marital status, 
income, employment status, state of residence and mother’s carrier status were assessed. 
Additional items related to the child included: diagnosis (Duchenne, Becker, or intermediary 
phenotype), age, age at diagnosis, and functional status. The latter was measured using a 7-item 
categorization where a higher score means worse condition. The same functional assessment 
item has been used in the DuchenneConnect patient registry and is an adaptation of the stages 
in the Duchenne care guidelines.1
Personal Attributes
Dispositional optimism was measured with the 10-item Life Orientation Test Revised
(LOT-R).28 Dispositional optimism is associated with psychological wellbeing and physical health
across a range of disease populations.29 Cronbach’s alpha in this sample was 0.87. Resilience
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was measured using the Resilience Scale for Adults (RSA), which measures ‘protective 
resources’ that have been demonstrated to facilitate flexibility in coping.30 Cronbach’s alpha was 
0.94.
Perceptions of DBMD Caregiving
Perceived Caregiver Burden was measured using the 12-item Zarit Burden Interview (ZBI).31 A 
score of 17 or above may be used as cut off point to identify high burden.31 In this sample,
Cronbach’s alpha was 0.89. Perceived Personal Control was measured using five questions 
about control over DBMD in general, daily symptoms, long-term course, medical care and 
treatment, and control by others (adapted from Lipinski and colleagues).32 Cronbach’s alpha was 
0.79. Worry about Care for Child with DBMD was measured using three items purposively 
designed to assess amount, frequency, and intensity of DBMD-specific care worry (developed as 
suggested by McCaul and Goetz).33 Cronbach’s alpha was 0.89. Perceived Positive Impact 
was measured with one item purposively developed for the study (“How much of a positive effect 
does your child’s condition have on your entire family?”). Coping Self-Efficacy was assessed 
with the Coping Self-Efficacy Scale (CSES), a 26-item measure of perceived self-efficacy for 
coping with challenges and threats.34 Cronbach’s alpha was 0.97.
Mothers’ Unmet Needs
The unmet needs items were purposively designed based on the literature and through 
community engagement.
Unmet Support Needs includes eight items that assess a range of unmet needs related to 
coping with DBDM (see Table 2). It is modelled on a needs measure utilised in a previous 
study.35 It had high internal consistency with a Cronbach’s alpha coefficient of .91. Financial 
Need was measured with one item, “If I had more money I could better care for my child with 
DBMD” scored on a 4 point Likert-type scale. The Respite Care Needs items range from 
frequency of use, information needs, attitudes, worry, and child willingness (Table 3). Each item 
had 6-point Likert-type responses and a “My child is independent” option. The item “I could 
benefit from a break from caring for my child” reduced the internal consistency and was removed 
from the summed score. The Cronbach’s alpha was 0.73.
Psychological Adaptation to DBMD
The outcome variable, mothers’ psychological adaptation to DBMD, was measured with the 
20-item psychological adaptation scale (PAS), which is designed to measure adaptation to a 
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chronic condition or disease risk by patients or caregivers.36 Cronbach’s alpha was 0.96.
Statistical analyses
Data were initially explored with descriptive statistics and graphs. Separate one-way, 
between-groups analyses of variances (ANOVA) with approximation for homogeneity of 
variance, when appropriate, were conducted to assess whether child’s functional status 
(ambulatory, children in transition to the use of a wheelchair full-time, or non-ambulatory) was 
associated with differences in unmet needs. For the ANOVA analyses only, to allow sufficient 
sample sizes the baseline child function item was re-coded into three ambulation categories: 
ambulatory children, children in transition to the use of a power wheelchair full-time, and full-time 
users of power wheelchairs. 
We examined bivariate relationships among variables measured at baseline (child’s functional 
status, dispositional optimism, worry about care, perceived control, caregiver burden, resilience,
coping efficacy, and unmet support needs) and the outcome variable measured at the two-year 
follow up (mothers’ psychological adaptation to DBMD). To assess predictors of psychological 
adaptation, all predictor variables with p<0.25 in the bivariate analysis were entered into a 
multiple linear regression, then progressively eliminated until only those with p-values of <0.05 
remained. Potential confounders (mother’s age, income, carrier status) were then entered one at 
changed by more than 10%. 
Prior to analysis, child’s functional status was chosen to include in analyses rather than child’s 
age or diagnosis. The clinical variability in the DBMD diagnostic categories1,2 makes anticipation 
of natural history or stage based on age difficult. Further, given the lower prevalence of Becker 




Two hundred and five mothers participated in the baseline survey, and 144 participated in the
follow up survey two years later (a 30% loss rate from the baseline survey cohort). This includes 
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two mothers who completed the baseline survey but did not complete the 2-year follow up 
because their affected child died between survey points.
At the time of the baseline survey, one hundred and ninety-two (93.2%) identified as Caucasian, 
11 (5.3%) as Hispanic, 6 (2.9%) as Asian, and 7 (3.4%) as “other”; respondents had the option of 
endorsing more than one category. The mean age of the mothers was 44.0 years (SD=8.7), with 
a range of 27 to 71. The majority of participants had at least a college degree (136, 67.4%) and 
was employed or attending school part- or full-time (145, 71.5%). The median household income 
was $50,000-$99,999. One hundred and seventy-seven (86.3%) were married or in a long-term 
committed relationship, 24 (11.7%) were divorced or separated; 3 (1.5%) had never married, and
1 (0.5%) was widowed. Ninety-six participants (46.8%) reported being DBMD carriers; 78 
(38.0%) were non- carriers; and 31 (15.1%) did not know whether they were carriers. 
The majority of participants had one affected child (184, 89.8%), 19 (9.3%) had two affected 
children, and two (1.0%) had three affected children. One hundred and seventy-four (84.9%) of
the affected children had DMD, 23 (11.2%) had BMD, and eight (3.9%) had an intermediate 
phenotype. The mean age of the affected child was 13.8 years (SD=7.2), with a range of one
year to 40 years.  
Mean child functional status was 3.5 (SD= 1.8, N=205) at baseline and 3.9 (SD=1.8, N=144) at 
2-year follow up, with higher numbers indicating worse function. Using baseline data, the 7-item 
child functional categorization was re-coded into three ambulation categories: ambulatory
children (83, 40.5%), children in transition to the use of a power wheelchair full-time (48, 24.4%), 
and full-time users of power wheelchairs (74, 36.1%). If the participant had more than one 
affected child, the functional status of the oldest living child is reported. 
There were no statistically-significant differences in median income, mean age, or mean child 
functional status between those who answered the first survey only and those who answered 
both the baseline survey and survey at year 2.  
Personal Attributes and Perceptions of DBMD Caregiving
Table 1 presents means and standard deviations of mothers’ perceptions of BDMD caregiving 
and their personal attributes. Defining a high ZBI score as 17 or above,31 48.2% of the mothers 
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reported high burden at baseline and 52.8% of the mothers reported high burden at two-year 
follow up. 





2 Year Mean 
(n=144)
Child function 1-7 3.5 (SD= 1.8) 3.9 (SD=1.8)
LOT-R 0-24 14.3 (SD= 4.6) __
RSA 1-5 3.9 (SD= 0.5) 3.9 (SD=0.5)
Zarit burden 0-48 17.1 (SD= 8.6) 17.7 (SD=8.6)
Control 1-11 5.5 (SD= 2.1) 4.6 (SD=2.1)
Worry 3-15 7.3 (SD= 2.9) ___
Positive impact 0-10 5.6 (SD= 2.9) ___




PAS 1-5 3.5 (SD=0.9) 3.6 (SD=1.0)




Mothers’ Needs  
Unmet Support Needs 
Table 2 shows the proportion of mothers reporting unmet support needs, as measured in the 
baseline survey. The three most frequently endorsed needs, with more than 50% responding 
medium or high need, were: specific ways to deal with uncertainty about the future; specific ways 
to manage fears related to DBMD; and specific ways to cope with being a mother of a child with 
DBMD. The mean score on the unmet psychosocial needs measure was M=1.31 (SD=0.7, range 
0 to 3). A modest but significant difference in mean needs scores was observed depending on 
the child’s functional status, F (2, 200) =4.0, p=0.02. Post-hoc comparisons indicated that the 
mean score for the ambulatory children (M=1.43, SD=0.6) was significantly higher than the mean 
for the non-ambulatory children (M=1.12 SD=0.8). The transition to wheelchair group (M=1.38
SD= 0.7) did not differ significantly from either the ambulatory or the non-ambulatory group.
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Table 2. Mothers’ Unmet Psychosocial Needs 
Don’t have 
this need










Specific ways to deal 








34.0% (69) 27.6% (56)
Specific ways to 
manage my fears 






28.1% (57) 34.0% (69) 21.2% (43)
Specific ways to cope 




17.7% (36) 22.2% (45) 32.0% (65) 21.2% (43)
Better ways to get the 




28.1% (57) 30.0% (61) 21.7% (44)
Ways of self-care that 





24.6% (50) 31.5% (64) 20.2% (41)
Specific ways to 
manage my sadness 




18.2% (37) 25.1% (51) 28.1% (57) 21.2% (43)
How to take time for 
healthy life choices 
(such as diet and 
exercise)
12.8% (30) 11.3% (23) 26.6% (54) 27.6% (56) 21.7% (44)
Whether the way I feel 
is normal





In response to the item eliciting perceived financial burden, the median was 3.0 and mean was 
2.76 (SD=1.17, range 1-4) and 60.7% (122) indicated “somewhat” or “very much”. No significant 
differences were observed in the perceived financial burden, F (2, 198) = 2.8, p=0.06, based on 
the child’s functional status. 
Respite Needs 
Across all of the respite items (see Table 3), approximately 30% of the participants rated their 
child as independent, making the question not applicable. Of the remaining participants for whom 
the questions were applicable, 26 (21%) agreed or strongly agreed to regularly using respite care, 
and 37 (27%) with having all of the information they need to find respite care. Seventy-six (57%) 
agreed or strongly agreed that they worried about allowing others to care for their child, and 70 
(53%) that their child was willing to be cared for by someone else. On the summed score, no 
significant differences were observed in the respite needs, F (2, 46) = .61, p=0.55, based on the 
child’s functional status. 
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Table 3. Mothers’ Respite Care Needs
Strongly 
disagree
Disagree Neutral Agree Strongly 
agree
N/A child is 
in-dependen
t 
I have all the 
information I need 
on how to find 
respite care






I regularly use 
respite care









care is more 












I am worried 
about allowing
someone else to 
care for my child*
5.4%
(11)








My child is willing 












I could benefit 
from a break from 














I don’t deserve a 
break from caring 
for my child*






* Items are reverse scored in calculation of summed score
Bivariate analyses
Bivariate analysis of predictor variables and unmet support needs (measured at baseline), and 
psychological adaptation (measured at two-year follow up), showed statistically-significant, 
positive relationships between the psychological adaptation and the predictors dispositional 
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optimism, resilience, perceived control, positive impact, and coping self efficacy. Higher mothers’ 
unmet support needs were associated with lower dispositional optimism, resilience, perceived 
control, and coping self-efficacy; and higher perceived burden. Worse child’s functional status 
was significantly associated with lower unmet support needs and resilience; and higher 
perceived caregiver burden and perceived positive impact (see Table 4). 
37
Table 4 Pearson Correlations Among Needs, Predictors, and Psychological Adaptation (PAS) 
Scale/Item Unmet support needs PAS (2 year follow up) Child function Mother age
Unmet support needs __ -.092 -.162* -.232*
PAS -.092 __ .006 -.336**
Child function -.162* .006 __ .494
**
Mother age -.232* -.336** .494** __
Household income -.167* -.133 -.060 .233**
LOT-R -.355** .190* .042 .197**
RSA -.391** .330
** -.166* -.002




Worry .453** -.084 .091 -.044
Positive impact -.089 .399
** .170* -.033
Coping self efficacy -.502** .348
** .009 .109
Spearman rho
* Correlation is significant at the 0.05 level (2-tailed).
** Correlation is significant at the 0.01 level (2-tailed).
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Multivariate analyses of psychological adaptation
A multiple linear regression was performed to assess predictors of psychological adaptation. The 
final model (see Table 5) included perceived positive impact (beta = .310, p<.001) and resilience
(beta = .264, p=.001) and which explained 30.5% of the variance in mothers’ psychological 
adaptation to DBMD, after controlling for effects of participants’ age and income. Worry about 
child’s care, perceived control, coping self-efficacy and perceived caregiver burden were no 
longer significantly associated with psychological adjustment.
Table 5: Predictors of Psychological Adaptation at 2 Year Follow-up (N=136)
Variable Beta coefficient T p
Household income -.088 -1.169 .245




Resilience .264 3,459 P=.001
Final model: R2 =0.325 F (4, 136) = 15.889, p<.001.  Adjusted R2 = 0.305, R = 0.570
DISCUSSION
This study provides clinically-relevant data about mothers’ needs, strengths, and adaptation to 
caregiving for a child with DBMD. The use of psychological adaptation to DBMD as our primary 
outcome reflected stakeholders’ attitudes that caring for a child with DBMD comes with benefits,
and clinical interventions should focus on addressing needs and fostering positive outcomes.
Greater resilience and positive impact predicted better psychological adaptation in mothers. 
Resilience is a multidimensional personal attribute that may be shaped by personality traits, 
evolving appraisals, social support systems, and family environments, and it is likely to be 
responsive to interventions.37-39 Positive impact is a representation of benefit finding—a
perception that major positive changes can come from a traumatic life experience.40  
Consistent with previously-reported studies5,6 we found that worse functional status in the child 
was associated with higher perceived caregiver burden, and approximately 50% of mothers 
reported a high level of burden. Higher perceived burden was also associated with higher unmet 
support needs. Although families, clinicians, and other stakeholders might anticipate increased 
burden to mothers with disorder progression, this study showed that burden did not predict 
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psychological adaptation, suggesting that mothers manage increasing caregiving burden over 
time. Interventions targeted at caregiver burden might not be the most effective methods to 
improve mothers’ psychological wellbeing. 
With regard to mothers’ needs, the least-met support needs were coping with challenging 
emotions: dealing with uncertainty about the future, and fears related to DBMD. Many clinicians 
may benefit from further training to address these areas. In addition, we identified a need to 
improve knowledge about, and use of, respite care. While research underscores the importance 
of social support,4,5 access to a full complement of social support may presuppose the 
caregiver’s ability to “get away” from caregiving responsibilities. Demonstrated benefits of respite 
include improving caregiver, sibling, and affected child wellbeing.41 However, our participants 
reported relatively infrequent use of respite care, despite a desire for respite and a perceived 
willingness of the affected child to accept such care. Our respite data are complicated by almost 
a third of participants indicating that the questions were not applicable because their child is 
independent, which is unexpected. This may reflect variability in knowledge about respite and 
access to respite care. Clinicians should anticipate that mothers may worry about allowing their 
children to be cared for by someone else, and support mothers in achieving higher levels of 
comfort.
We report unexpected relationships among mother’s age, child’s disease progression, unmet
support needs, and adaptation. A higher score on unmet support needs was modestly but 
significantly associated with less disease progression in the child, and was correlated with 
younger mothers’ ages. Higher psychological adaptation to DBMD was predicted by younger 
mothers’ age. However, child’s functional status was not a predictor of psychological adaptation. 
While mothers may be able to attribute more benefit to the DBMD experience and perceive that
more of their support needs are met as their children’s symptoms become more advanced, their 
resilience may be challenged as they age. It is also possible that there is a response shift in the 
function measure, where mothers of children in earlier stages provide more optimistic reports of 
their child’s functional status than mothers of children progressing to later stages of DBMD. 
Additional exploration is needed to better understand the effects of increasing mother’s age and 
worsening child’s functional status on support needs and psychological adaptation.
Though the study sample was broadly recruited through diverse sources, possibly increasing the 
representativeness of the sample, the study is limited by the opt-in nature that may have 
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generated participation bias. This could not be evaluated, as details on individuals who did not 
participate were not available. In addition, the response rate cannot be evaluated given the 
variety of recruitment approaches, the use of social media and snowball recruiting, and overlap 
among the recruitment populations. 
Though there was participant loss between the baseline and the survey two years later, there 
were no significant differences in income, age, and child functional status among those who 
participated only at baseline and those who participated two years later.
Traditionally underserved minority and low SES populations were under-represented in the 
survey, as were non-married mothers, which may have implications for the generalizability of the 
findings. For example, while the data do not support an increase in financial concerns as the 
disease progressed, most participants indicated that they would be able to better care for their 
children with more money. A more representative sample may have greater financial concern. 
Financial concerns may become more significant in the future, once new therapeutics (many of 
which are anticipated to be associated with high annual cost, similar to drugs for other rare 
disorders)42 are approved. The study should be repeated in a generalizable clinic-based sample 
to strengthen the basis for clinical recommendations.
Clinical Implications
Care guidelines for DMD recommend family support that includes professional assessment of 
caregivers and families followed by proactive psychosocial interventions to meet their needs.1
Our results highlight the need for systematic exploration of caregivers’ unmet support needs, 
especially those related to coping with DMD-related uncertainty and fear. Efforts to improve 
mothers’ wellbeing should focus on interventions to foster mothers’ resilience, especially as 
mothers age, and to enhance benefit finding through identification of positive aspects of living 
with DBDM on the caregiver and family. Interventions that target perceived burden may not be 
effective at improving long-term wellbeing. Further research should evaluate a brief needs 
assessment and an item measuring positive DBMD impact in clinical settings. The use of needs 
assessment instruments in clinical encounters is well characterized; for example, as described
by Boneskvi and colleagues.43 The single impact item offers a simple, positively-valenced 
assessment of finding benefit in a challenging situation, and use of the item may help identify 
mothers for whom psychosocial interventions may be targeted. Overall, the results of this study 
suggest that clinical interventions can address unmet needs while highlighting strengths and 
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wellbeing, rather than burden and deficit.
CONFLICT OF INTEREST
Associate Professor Bettina Meiser receives a Career Development Award Level 2 from the 
NHMRC. Holly Peay, Kathleen Kinnett, Pat Furlong, Kathryn Porter, and Aad Tibben declare no
potential conflict of interest.
ACKNOWLEDGEMENTS  
We are grateful to the women who participated in this study. Sheila Moeschen provided valuable
input into the survey development. Hadar Scharff provided database coordination and 
administrative support.
REFERENCES 
1. Bushby K, Finkel R, Birn’krant DJ, et al., Diagnosis and management of Duchenne
muscular dystrophy: part 1: diagnosis, and pharmacological and psychosocial 
management. Lancet Neurol 2010; 9: 77–93.
2. Flanigan KM: Duchenne and Becker muscular dystrophies. Neurol Clin 2014; 32(3):
671-688.
3. Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K: Survival in 
Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the 
impact of home nocturnal ventilation. Neuromuscul Disord 2002; 12(10): 926-9.
4. Pangalila RF, van den Bos GA, Stam HJ, van Exel NJ, Brouwer WB, Roebroeck ME: 
Subjective caregiver burden of parents of adults with Duchenne muscular dystrophy. 
Disabil Rehabil 2012; 34(12): 988-996.
5. Kenneson A., Bobo, JK: The effect of caregiving on women in families with 
Duchenne/Becker muscular dystrophy. Health Soc Care Community 2010; 18(5):
520-528.
6. Boyer F, Drame M, Morrone I, Novella JL: Factors relating to carer burden for families of 
persons with muscular dystrophy. J Rehabil Med 2006; 38(5): 309-315.
7. Nereo NE, Fee RJ, Hinton VJ: Parental stress in mothers of boys with duchenne muscular 
dystrophy. J Pediatr Psychol 2003; 28(7): 473-84.
Chapter 2
42
8. Reid DT, Renwick RM: Relating familial stress to the psychosocial adjustment of 
adolescents with Duchenne muscular dystrophy. Int J Rehabil Res 2001; 24(2): 83-93.
9. Daoud A, Dooley JM, Gordon KE: Depression in parents of children with Duchenne 
muscular dystrophy. Pediatr Neurol 2004; 31(1): 16-19.
10. Hatzmann J, Heymans HS, Ferrer-i-Carbonell A, van Praag BM, Grootenhuis MA: Hidden 
consequences of success in pediatrics: parental health-related quality of life—results from 
the Care Project. Pediatrics 2008; 122(5): e1030-1038.
11. Erby LH, Rushton C, Geller G: “My son is still walking”: stages of receptivity to discussions 
of advance care planning among parents of sons with Duchenne muscular dystrophy. 
Seminars in Pediatric Neurology 2006; 13: 132-140.
12. Kinnett K, Eakes GG, Cripe L, Duchenne muscular dystrophy: More adults are reaching 
adulthood – and facing new challenges with the disease, Advance Health Network August 
8, 2010. Date of last access Dec 15, 2014. Available 
from: http://nurse-practitioners-and-physician-assistants.advanceweb.com/features/articl
es/duchenne-muscular-dystrophy.aspx
13. Webb CL: Parents’ perspectives on coping with Duchenne muscular dystrophy. Child: 
Care, Health & Development 2005; 31(4): 385–396.
14. Tomiak EM, Samson A, Miles SA, Choquette MC, Chakraborty PK, Jacob PJ: 
Gender-specific differences in the psychosocial adjustment of parents of a child with 
Duchenne muscular dystrophy (DMD). Qualitative Research Journal 2007; 7(2): 2-21.
15. Samson A, Tomiak E, Dimillo J, Lavigne R, Miles S, Choquette M, Chakraborty P, Jacob 
P: The lived experience of hope among parents of children with Duchenne muscular 
dystrophy: perceiving the human beyond the illness. Chronic Illness 2009; 5: 103-114.
16. Wallander JL, Varni JW: Effects of pediatric chronic physical disorders on child and family 
adjustment. J. of Child Psychology and Psychiatry and Allied Disciplines 1998; 39: 29–46.
17. Farmer JE, Marien WE, Clark MJ, et al: Primary care supports for children with chronic 
health conditions: identifying and predicting unmet family needs. J. Pediatr. Psychol.
2004; 29(5): 355-367.
18. Cohen MS: Families coping with childhood chronic illness: A research review. Families, 
Systems and Health 1999; 7: 149–164.
19. Silver EJ, Westbrook LE, Stein REK: Relationship of parental psychological distress to 
consequences of chronic health conditions in children. J Pediatr Psychol 1998; 23: 5–15.
20. Thompson JL, Gil KM, Gustafson KE et al: Stability and change in the psychological 
adjustment of mothers of children and adolescents with cystic fibrosis and sickle cell 
43
disease, Pediatr Psychol 1994; 19(2): 171-188.
21. Kirk S: Families’ experiences of caring at home for a technology-dependent child: a review 
of the literature. Child Care Health Dev 1998; 24:101-114.
22. Brandon P: Time away from “smelling the roses”: where do mothers raising children with 
disabilities find the time to work? Soc. Sci. Med. 2007; 65: 667-679.
23. Thyen U, Kuhlthau K, Perrin JM: Employment, child care, and mental health of mothers 
caring for children assisted by technology. Pediatrics 1999; 103: 1235-1242.
24. Kuhlthau K, Hill S, Yucel, R, Perrin JM: Financial burden for families of children with 
special health care needs. Maternal and Child Health Journal 2005; 9: 207-218.
25. Biesecker BB, Erby L: Adaptation to living with a genetic condition or risk: a mini-review. 
Clin Genet 2008; 74: 401-407.
26. Staley K: Exploring impact: public involvement in NHS, public health and social care 
research. INVOLVE 2009. Accessed October 16, 2014. Available at: 
http://www.invo.org.uk/posttypepublication/exploring-impact-public-involvement-in-nhs-p
ublic-health-and-social-care-research/#.
27. Clinical and Translational Science Awards Consortium Community Engagement Key 
Function Committee Task Force on the Principles of Community Engagement: Principles 
of Community Engagement, 2nd Edition. Agency for Toxic Substances and Disease 
Registry, National Institutes of Health publication #11-7782. 2011. Accessed October 15, 
2014. Available at: http://www.atsdr.cdc.gov/communityengagement.
28. Scheier MF, Carver CS, Bridges MW: Distinguishing optimism from neuroticism (and trait 
anxiety, self-mastery, and self-esteem) – a reevaluation of the life orientation test. J Pers 
Soc Psychol 1994; 67: 1063–1078.
29.  Glaesmer H, Rief W, Martin A, Mewes R, Br¨ahler E, Zenger M, Hinz A. Psychometric 
properties and population-based norms of the Life Orientation Test Revised (LOT-R). 
British Journal of Health Psychology 2012; 17: 432-445.
30. Friborg O, Barlaug D, Martinussen M, Rosenvinge JH, Hjemdal O: Resilience in relation to 
personality and intelligence. Int J Method Psych 2005; 14(1): 29-42.
31. Bédard M, Molloy DW, Squire L, Dubois S, Lever JA, O'Donnell M: The Zarit Burden 
Interview: a new short version and screening version. Gerontologist 2001; 41: 652-657.
32. Lipinski SE, Lipinski MJ, Biesecker LG, Biesecker BB: Uncertainty and perceived personal 
control among parents of children with rare chromosome conditions: the role of genetic 
counseling. Am J Med Genet C Semin Med Genet 2006; 142C(4): 232-240.
Chapter 2
44
33. McCaul KD, Goetz PW: Worry; in National Cancer Institute: Health Behavior Constructs: 
Theory, Measurement & Research. Accessed October 16, 2014. Available at: 
http://cancercontrol.cancer.gov/brp/constructs/worry/w6.html
34. Chesney MA, Neilands TB, Chambers DB, Taylor JM, Folkman S: A validity and reliability 
study of the coping self-efficacy scale. Br J Health Psychol 2006; 11: 421-437.
35. Thewes B, Meiser B, Tucker M,  Tucker K: The unmet information and support needs of 
women with a family history of breast cancer: a descriptive survey. Journal of Genetic 
Counseling 2003; 12(1) 61-76.
36. Biesecker BB, Erby LH, Woolford S et al: Development and validation of the Psychological 
Adaptation Scale (PAS): use in six studies of adaptation to a health condition or risk. 
Patient Educ Couns 2013; 93(2): 248-254.
37. Rosenberg AR, Baker KS, Syrjala KL, Back AL, Wolfe J: Promoting resilience among 
parents and caregivers of children with cancer. J Palliat Med 2013; 16(6): 645-652.
38. Jowkar B, Friborg O, Hjemdal O: Cross-cultural validation of the Resilience Scale for 
Adults (RSA) in Iran. Scand J Psychol 2010; 51: 418-425.
39. Ahern NR, Kiehl EM, Sole ML, Byers J: A review of instruments measuring resilience. 
Issues Comp Pediatr Nurs 2006; 29(2): 103-125.
40. Lechner SC: Benefit Finding; in Lopez, Shane J (ed): The Encyclopedia of Positive 
Psychology. Blackwell Publishing, 2009. Blackwell Reference Online. Accessed October 
16, 2014. Available 
at: http://www.blackwellreference.com/public/book.html?id=g9781405161251_97814051
61251. 
41. Robertson J, Hatton C, Wells E et al: The impacts of short break provision on families with 
a disabled child: an international literature review. Health Soc Care Community 2011;
19(4): 337-71.
42. Zitter M: Managing drugs for rare genetic diseases: trends and insights. Manag Care
2005; 14(2): 52-64.
43. Bonevski B, Sanson-Fisher R, Girgis A, et al: Evaluation of an instrument to assess the 






Clinical Therapeutics/Volume 36, Number 5, 2014
A Community-Engaged Approach to Quantifying Caregiver
Preferences for the Benefits and Risks of Emerging Therapies
for Duchenne Muscular Dystrophy
Holly L. Peay, MS1; Ilene Hollin, MPH2; Ryan Fischer, BA1; and John F.P. Bridges, PhD2
1Parent Project Muscular Dystrophy, Hackensack, New Jersey; and 2Department of Health Policy
and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
ABSTRACT
Background: There is growing agreement that reg-
ulators performing benefit–risk evaluations should take
patients’ and caregivers’ preferences into consideration.
The Patient-Focused Drug Development Initiative at the
US Food and Drug Administration offers patients and
caregivers an enhanced opportunity to contribute to
regulatory processes by offering direct testimonials. This
process may be advanced by providing scientific evi-
dence regarding treatment preferences through engage-
ment of a broad community of patients and caregivers.
Objective: In this article, we demonstrate a
community-engaged approach to measure caregiver
preferences for potential benefits and risks of emerging
therapies for Duchenne muscular dystrophy (DMD).
Methods: An advocacy oversight team led the
community-engaged study. Caregivers’ treatment pref-
erences were measured by using best–worst scaling
(BWS). Six relevant and understandable attributes
describing potential benefits and risks of emerging
DMD therapies were identified through engagement
with advocates (n ¼ 5), clinicians (n ¼ 9), drug
developers from pharmaceutical companies and
academic centers (n ¼ 11), and other stakeholders
(n ¼ 5). The attributes, each defined across 3 levels,
included muscle function, life span, knowledge about
the drug, nausea, risk of bleeds, and risk of arrhyth-
mia. Cognitive interviewing with caregivers (n ¼ 7)
was used to refine terminology and assess accept-
ability of the BWS instrument. The study was imple-
mented through an online survey of DMD caregivers,
who were recruited in the United States through an
advocacy group and snowball sampling. Caregivers
were presented with 18 treatment profiles, identified
via a main-effect orthogonal experimental design, in
which the dependent variable was the respondents’
judgment as to the best and worst feature in each
profile. Preference weights were estimated by calculat-
ing the relative number of times a feature was chosen
as best and as worst, which were then used to estimate
relative attribute importance.
Results: A total of 119 DMD caregivers completed
the BWS instrument; they were predominately biological
mothers (67.2%), married (89.9%), and white (91.6%).
Treatment effect on muscle function was the most
important among experimental attributes (28.7%), fol-
lowed by risk of heart arrhythmia (22.4%) and risk of
bleeding (21.2%). Having additional postapproval data
was relatively the least important attribute (2.3%).
Conclusions: We present a model process for
advocacy organizations aiming to promote patient-
centered drug development. The community-engaged
approach was successfully used to develop and imp-
lement a survey to measure caregiver prefe-
rences. Caregivers were willing to accept a serious
risk when balanced with a noncurative treatment, ev-
en absent improvement in life span. These preferences
should inform the Food and Drug Administration’s
benefit–risk assessment of emerging DMD therapies.
This study highlights the synergistic integration of
traditional advocacy methods and scientific approach
to quantify benefit–risk preferences. (Clin Ther.
2014;36:624–637) & 2014 The Authors. Published
by Elsevier HS Journals, Inc. All rights reserved.
Key words: benefit–risk assessment, caregiver,
choice behavior, Duchenne muscular dystrophy,
patient preferences.
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INTRODUCTION
Duchenne muscular dystrophy (DMD) is a rare, life-
threatening, inherited neuromuscular disorder that oc-
curs in male subjects with an incidence of 1.3 to 2.9 per
10,000.1,2 Diagnosis usually occurs around age 5 years,
when differences in motor function become apparent,
but symptoms may appear as early as infancy.3,4 The
condition is associated with significant care-related5,6
and financial burden.7–9 Affected individuals have pro-
gressive muscular weakness, loss of ambulation that
typically occurs in the teen years, and premature death.3
The mean age of death is in the 20s and is commonly
caused by respiratory failure or cardiac disease.3,4
Currently, there are no therapies approved by the
US Food and Drug Administration (FDA) for DMD.
The standard-of-care treatment is the off-label use of
corticosteroids, which have been shown to stabilize
muscle strength, delay loss of ambulation by 2 to 5
years, improve cardiopulmonary function, and en-
hance quality of life.3,10–12 Several potential therapies
are under clinical trial that target a variety of primary
and secondary effect pathways.13
Similar to other conditions (including other rare
diseases14 and early-on in the HIV epidemic),15
patients and caregivers managing DMD seek to
accelerate approvals for drugs that may save lives.16
In the context of serious, rare disorders with limited
treatment options, patients and patient advocates
want regulators to be more permissive.17 Drugs
under trial for DMD represent a significant opport-
unity for families to intervene, and in public forums,
some parent advocates have demanded access to
drugs, even absent conclusive data on efficacy and
safety.18 DMD provides an appealing model for
assessing influences on treatment decision making
for serious, progressive disorders. The natural
history may lead to high-pressure decisions regarding
the use of novel therapies. The pediatric onset pro-
vides additional complexity, as the majority of treat-
ment decisions are made by parents/guardians who
are also the primary caregivers. These decisions may
later be re-evaluated by adolescent and adult DMD
patients who could have different treatment
preferences.19
There is growing agreement that regulatory benefit–
risk evaluations should be informed by the perspectives
of patients and caregivers who will ultimately make
treatment decisions and bear the associated risks.20 To
that end, in 2012, the FDA was congressionally
mandated to engage patients to understand the
impact of disease though the Patient-Focused Drug
Development Initiative.21 Although this program offers
patients and caregivers an unprecedented opportunity
to contribute to the regulatory process, the program is
limited in scope and approach, with initially only 20
disease areas being targeted for public comment
involving direct engagement with patients and
caregivers.22 Advocates who do not represent 1 of the
20 chosen disorders are left with little guidance about
how to provide input that is acceptable and useful to
the FDA. Existing models for FDA engagement are
largely limited to providing testimonial. Although such
direct engagement is a primary strength and a mainstay
of advocacy organizations’ efforts to inform decision
makers about their community’s needs and per-
spectives,23 there are limitations to focusing only on
patient and caregiver testimonials, such as questions
about how well those providing testimonial represent
the views of the entire patient population.20,24,25
Increasingly, decision makers are being asked to con-
sider alternative methods to quantify treatment prefer-
ences and risk tolerance that take into account the
views of large groups of stakeholders.26 Draft FDA
guidance has indicated a willingness to incorporate
such evidence into the regulatory process.27 Quanti-
tative preference elicitation methods allow stakeholders
to introduce formal evidence-based decision making
into the regulatory process and have been used to
explore decision making and preferences among a
variety of patient populations.20
The purpose of the present study was to demon-
strate a process by which a patient advocacy organ-
ization might develop scientific evidence on treatment
preferences. We aimed to model a replicable,
community-engaged approach to exploring preferen-
ces in a large sample of decision makers. Specifically,
our goal was to explore caregiver preferences for
emerging treatments for DMD. This study is not only
informative to those seeking to understand the
treatment preferences and risk tolerance of DMD
caregivers, but it serves to highlight principles of
patient-centered outcomes research28 by illustrating
how an advocacy organization can take leadership in
generating policy-relevant evidence.
MATERIALS AND METHODS
Parent Project Muscular Dystrophy (PPMD), an ad-
vocacy organization focused on finding a cure for




DMD, led the study. The advocacy oversight team
comprising PPMD staff members (a clinician, a scien-
tist experienced in drug development, and 2 caregivers
of individuals with DMD) collaborated with the
research team to design and implement the study.
The oversight team made study decisions through a
consensus process. Consistent with the preferences of
PPMD, the authoring research team was a smaller
team of PPMD staff and academic collaborators.
The teams began by defining a research question
about treatment preferences based on the stated needs
of the Duchenne community; they then identified the
study population (caregivers of individuals with
DMD) and a recruitment strategy. The teams choose
a stated preference method (described under the head-
ing “Methods”) that fit the study needs. In the
development of the treatment experiment (described
under the heading “Identifying Attributes and Lev-
els”), the team used a community-engaged approach
involving multidisciplinary stakeholder informants.
The survey was piloted by a small group of end-
users (described under the heading “Survey Pilot:
Cognitive Interview”), and it was modified based on
their input. Preliminary and final analyses were re-
ported to regulators, industry, and the Duchenne
community in an accessible and timely manner.
Methods
Methods to measure the preferences of patients,
caregivers, and other stakeholders are now well
established29,30 and are increasingly being applied
to study benefit–risk preferences.20 Although good
research practices have been created to aid in the
development of stated preference applications in
medicine,31 approaches such as conjoint analysis and
discrete choice experiments remain complex. They
require qualitative skills to appropriately identify
attributes and levels and develop supporting survey
text,32 as well as quantitative skills to design the
experiment33 and analyze results.34
The study used best–worst scaling (BWS) case 2, an
emerging stated-preference method that can be used to
scientifically assess preferences.35 Referred to as the
“profile case,” BWS case 2 presents profiles one at a
time to elicit preferences; Flynn et al36 fully described
the method and provide use guidance. BWS has been
recognized as an approach that is easier to design and
analyze than conjoint analysis and discrete choice;
however, this method is relatively novel in the context
of measuring benefit–risk preferences.20 The study
reported here presents a novel use of the BWS case
2.37,38 BWS is thought to be less cognitively demand-
ing on participants than discrete choice or conjoint
experiments.36 In addition, relevant to our aim of
demonstrating a replicable community-engaged
model, BWS benefits from a straightforward analytic
approach, the results of which are consistent with
more complex approaches39,40 that may be unfamiliar
to many researchers in the clinical domain. To guide
the development, implementation, and analysis of our
preference elicitation instrument, we used the stand-
ards outlined in the International Society for Pharma-
coeconomics and Outcomes Research checklist for
conjoint analysis27 and specific guidance on the use
of BWS.34
Identifying Attributes and Levels
BWS case 2 experiments use attributes (representing
topic areas) and levels (representing attribute variables,
such as amount of or impact on the attributes);
Figure 1 presents an example of a BWS case 2 task.
Identification of relevant and comprehensible attri-
butes and levels is required for a meaningful study
outcome. We used a stakeholder-informed approach to
identify attributes and levels that were clinically rele-
vant, meaningful, and understandable to caregivers.
The development of attributes and levels was informed
by PPMD’s 20 years of experience with patients and
families; extensive history consulting on, reviewing,
and funding clinical research; and an ongoing inter-
view study of clinical trial experiences.41
PPMD identified and invited stakeholder inform-
ants to participate (October–December 2012) through
an existing advocacy-facilitated industry roundtable,
PPMD’s grassroots family networks, PPMD’s clinician
database, or after self-nomination following commun-
ity notification of the program launch. Stakeholder
informants, including patient/disease advocates
(n ¼ 5), clinicians (n ¼ 9), drug developers from
pharmaceutical companies and academic centers (n ¼
11), and other stakeholders (n ¼ 5), participated in
group or individual sessions. Attributes and levels for
the emerging therapies were proposed and refined
through iterative rounds of stakeholder engagement.
Industry informants were important to successfully
identify appropriate attributes because of their ability
to forecast benefits and risks of premarket drugs. The
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oversight committee incorporated their informative
input while protecting against potential bias.
This approach yielded 420 potential benefit, ad-
verse effect, and risk attributes. Items were grouped
under themes and refined. Several attributes were
rejected by the oversight team for relevance, similarity
to other items, or concerns about the ability of the
target population to understand the attribute. Exam-
ples of attributes that were not chosen are the ability
to participate in day-to-day family activities and risks
to renal and hepatic function. The participation
benefit was considered to be less concrete and
treatment-associated than muscle function, and thus
was not chosen. The clinical implications of renal and
hepatic damage were difficult to describe in a brief and
accessible format. In addition, we chose not to use
quantitative risks in this survey because the average
US adult has only a basic level of quantitative
literacy.42
Through a consensus process, the advocacy over-
sight team ultimately selected 6 treatment attributes
with 3 levels each. The attributes and associated levels
were chosen to be reasonable based on drugs under
trial, with the notable exception that the highest risk
levels represent considerably more risk than has been
associated with drugs under trial, to date. The pro-
posed attribute list was again shared with stakeholder
informants. Based on their input, the final items (effect
on muscle function, life span, knowledge about the
drug, nausea, risk of bleeding, and risk of heart
arrhythmia) were chosen by the oversight group and
study team.
The BWS experiment attributes and levels are
presented in Table I. The functional benefits chosen
were “stops the progression of weakness” and “slows
the progression of weakness” because drugs under
trial are unlikely to result in a cure or significant
improvement in strength for patients with DMD. The
life span attribute was presented independently of the
weakness attribute because drugs that affect skeletal
muscle may not improve cardiac outcomes in DMD43
and thus may not improve longevity. Caregiver
participants were prompted to separate muscle
function from life span by use of this cardiac
example and a sample task. Given that the quality
of evidence and associated uncertainty may affect
preferences, we included an attribute relating to
knowledge about the drug, described as the number
of years of postapproval data. Nausea represents a
realistic, easily understood adverse effect that may
result in increasing burden as patients lose mobility.
The choice of bleeding was prompted by a Phase II
DMD trial that was terminated in 2011 (unpublished
data). Arrhythmia was chosen as an attribute that is
salient to caregivers because it is part of the DMD
natural history.44
Experimental Design
Following good research practices, we developed
the BWS case 2 experiment to accommodate the 6
attributes with 3 levels each.31 We applied a 3^6
main-effects orthogonal design, identified from the
SAS database of orthogonal arrays.45 This array
consisted of 18 full-profile combinations of the attrib-
utes and levels, the minimum such number necessary
to ensure no structural relationships (ie, correlations)
between the attributes.33
As illustrated in Figure 1, in each BWS task,
caregivers were presented with one of the treatment
profiles and asked to judge which aspects they thought
were the best and the worst. Before completing the tasks,
caregivers were presented with a detailed description of
all the attributes and levels to be considered in the task
Choose the best thing in this treatment by clicking the
circle under “best” and choose the worst thing by
clicking the circle under “worst.” You have to choose a
best thing and worst thing to move on. Remember
that a computer chose the combinations to make the
experiment work, and some of them seem bad. Even
so, please pick the best and worst thing.
Best Treatment













Figure 1. Example of best–worst scaling task.




Table I. Attribute, levels, and descriptions resulting from stakeholder engagement.
Attributes and Attribute Lvels Additional Description/Explanation in the Survey
Effect on muscle function “How the treatment affects muscle function”
i Stops the progression of weakness “Most people who take this treatment don’t get any
weaker over time.
ii Slows the progression of weakness “Most people who take this treatment continue to get weaker
over time, but more slowly than they would without
treatment.”
iii Does not change progression of
weakness
Lifespan “By this we mean how many extra years of life are expected
because of the treatment.”
i 5 year gain in expected lifespan “5 extra years of life”
ii 2 year gain in expected lifespan “2 extra years of life”
iii No extra gain to expected lifespan “0 extra years, meaning that the treatment may not change the
person’s lifespan at all.”
Knowledge about the drug “Important information about treatments comes after FDA
approval, from tracking people who take the treatment over
time. Tracking helps us better understand benefits, risks,
potential drug interactions, and how the treatment affects
people of different ages and stages of progression. Imagine
that everyone who takes the treatment is tracked.”
i 2 years of post-approval drug
information available
“The treatment has been on the market for 2 years and we have
data from 900 people with Duchenne.”
ii 1 year of post-approval drug
information available
“The treatment has been on the market for one year and we
have data from 200 people with Duchenne.”
iii No post-approval drug information
available
“The treatment has just been approved and no post-approval
data is available.”
Nausea
i No increased chance of nausea
ii Causes loss of appetite “A person taking the treatment loses his/her appetite”
iii Causes loss of appetite with
occasional vomiting
“A person taking the treatment loses his/her appetite and has
occasional vomiting”
Risk of bleeds “Risk of bleeding”
i No increased risk of bleeds
ii Increased risk of bleeding gums and
increased bruising
“Bleeding gums and increased bruising, without increased risk
of more dangerous bleeding”
iii Increased risk of hemorrhagic stroke
and lifelong disability
“Hemorrhagic (bleeding) stroke, which could lead to lifelong
disability in memory and reasoning. People found to have this
risk would have to stop taking the treatment.”
Risk of heart arrhythmia “Risk of heart rhythm problems”
i No increased risk of heart arrhythmia
ii Increased risk of harmless heart
arrhythmia
“Occasional, harmless heart arrhythmia”
iii Increased risk of dangerous heart
arrhythmia and sudden death
“Dangerous arrhythmia, which could lead to surgery to put in a
defibrillator and risk of sudden death. People found to have
this risk would have to stop taking the treatment.”
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(including warm-up questions where appropriate), de-
tailed instructions, and an explained example task.
Furthermore, we confirmed that these “treatments do
not currently exist” and that we were “interested in
knowing what [the caregiver] would choose if they did.”
As a matter of context, we informed the caregivers that
“we are imagining that these are approved treatments
provided by the doctor, and not treatments given during
a clinical trial” and asked them to “assume that all your
child’s medical bills, including the costs of the treatment,
are covered by health insurance.” We also assured
respondents that this “was not a test” and that there
were “no right or wrong answers.” Each task incorpo-
rated a full profile (ie, all 6 attributes were shown)
consisting of a specific level for each attribute. Prefer-
ences were elicited via caregivers making a judgment as
to what aspect constituted the best and then the worst of
the treatment.
Survey Instrument
The BWS instrument was included in a broader
survey. In addition to basic demographic questions, to
ensure that the study sample did not represent individ-
uals with unusually high risk-taking personality traits,
the participant section included the 6-item risk-taking
measure comprising items from the Jackson Personality
Inventory.46 The previously published mean (SD) score
for a physician group was 19 (4), with a range of 11 to
30. We also sought to describe caregivers’ numeracy by
using the 3-item short form (SNS-3) of the Subjective
Numeracy Scale (SNS).47 Poor numeracy has been
associated with ability to evaluate risks and benefits of
health options48 and to negatively affect utility
assessment.49 Previous research has determined a norm
mean score for the SNS of 4.03 (1.04), with a range of 1
to 6.50 Information collected about the affected children
included the number of children with DMD, age, where
the children lived, a mobility item (with 11 responses
ranging from independent walking outdoors to
remaining in bed) that represents disease progression,
insurance type (private vs government), and whether the
children ever experienced a life-threatening emergency.
Survey Pilot: Cognitive Interviewing
Cognitive interviews with 7 parents of individuals
with DMD of varying ages and disease stages were
used to assess comprehension, refine terminology, and
explore the acceptability of the instrument. The inves-
tigator (H.L.P.) observed the survey experience of the
interviewees by using videoconferencing. Interviewees
were asked to “think aloud” as they completed the
survey, and the investigator used verbal probes to
explore anticipated problem areas, assess understand-
ing of the survey elements, and evaluate willingness to
trade among the attributes and levels. The instrument
was then modified to the final version based on pilot
test feedback, again using a consensus process involv-
ing the study team and the advisory group.
Participants and Recruitment
Participants were caregivers (parents or guardians)
of at least 1 living child with DMD. The caregivers
lived in the United States, were at least 18 years of age,
and were able to complete an online survey in English.
Their affected child could be any age or at any stage of
the disease. The survey was administered online by
using the Qualtrics survey system (Qualtrics, LLC,
Provo, Utah) from January 17, 2013, to February 21,
2013. In the study advertisements, PPMD committed
to sharing the information learned from the survey
back to the DMD community. Recruitment occurred
with the use of newsletter notices, social media,
recruitment e-mails from PPMD, the DuchenneCon-
nect self-report registry, and through word-of-mouth
recruiting. The anonymous survey was determined to
be exempt by the Western Institutional Review Board
(no. 1-756840-1).
Statistical Analysis
In BWS, the dependent variable is the participants’
judgment about the best and worst feature in each
profile presented to them.51 Although the results from
a BWS can be estimated by using complicated
techniques such as conditional logit52 or hierarchical
Bayes,53 one of the benefits of the method is that it can
be analyzed very simply. The simplest techniques
focus on the number of times a particular level of an
attribute was chosen as best and as worst when it was
available in the choice task (unpublished data). A
relative best-minus-worst (BW) score can be calculated
by subtracting the number of times a feature was
chosen as worst from the number of times it was
chosen as best, then dividing by the total number of
times it was available to be chosen. Early applications
of this method have demonstrated a very high level of
correlation between such simple techniques and more
complicated regression-based techniques.39,40 As with
all techniques used to estimate ordinal, multinomial




outcomes, our scoring approach assumes equal spac-
ing between things that were chosen as best (BW
score, 1), those that were not chosen (BW score, 0),
and those chosen as worst (BW score, –1).
We chose to estimate the importance weights for
each level by using the relative BW score because it
could be easily understood by the broadest readership
(including the community of patients and caregivers
that we engaged in developing this survey). In addition
to the simplicity of the BW score, this approach has
several advantages. First, regression-based techniques
require the use of the omitted category39 or the use of
complex effects coding procedures40 to estimate cho-
ice models. Second, by using this simple approach, we
have ensured that all estimated parameters remain on
the same ratio scale. This method allows comparisons
to be made across the attributes, as well as identi-
fication of global best and worst attribute levels
across all the attributes. Because the BW score is
estimated as a mean across the sample, we also report
the SEs for these means. This process allows us to
conduct t tests to determine whether the scores were
significantly different from zero. We did this for each
attribute level and have reported the P values for
each test.
Finally, we used the relative BW score for each level
within each attribute to assess the overall importance
of each attribute, conditioned on the levels chosen.54
With this technique, relative attribute importance was
estimated by subtracting the lowest relative BW score
associated with a level of that attribute from the
highest relative BW score associated with a level of
that attribute. We then divided each difference by the
sum of all differences across the 6 attributes and
reported the result as a percentage.
RESULTS
A total of 124 caregivers who self-identified as being a
parent or guardian of an individual with DMD began
the treatment experiment. Two individuals dropped
out after the first treatment task; 1 dropped out after
the third treatment task; 1 dropped out after the fifth
treatment task; and 1 dropped out after the 15th
treatment task. The remaining 119 caregivers com-
pleted the entire survey.
Table II summarizes the characteristics of the
sample. Caregivers were predominantly white, mar-
ried, biological mothers, and had 1 affected child.
Education level ranged from high-school or General
Educational Development diploma to graduate or
professional degree; the median response was "4-year
college degree.” Annual household income ranged
from “o$25,000” to “4$100,000”; the median
response was “$75,000 to $100,000.” Caregivers’
ages ranged from 28 to 66 years (mean, 43.7 years),
and the age of the affected children ranged from 2 to
38 years (mean, 12.1 years). Slightly more than one
half of the children were reported as having partici-
pated in clinical research and more than one third in a
clinical trial. Almost all of the affected children lived
in the home of the caregiver (n ¼ 117 [98%]). The
majority of the affected children used private insur-
ance for their medical care (n ¼ 101 [85%]), although
34% (n ¼ 40) endorsed that their child used a state/
government program. Caregivers reported that 19%
(n ¼ 22) of their children had experienced a life-
threatening emergency.
The affected children represented a range of disease
progression. When these children were dichotomized
into an “ambulatory” group, defined as those who
could walk independently outdoors for at least short
distances, and a “nonambulatory” group, defined as
those who could not walk outdoors without help, 75
(64%) were parents with children in the ambulatory
group and 43 (36%) were parents with children in the
nonambulatory group.
The mean (SD) risk-taking score was 17 (4), with a
range of 7 to 30 (higher scores indicate more risk-
taking endorsement). The caregivers in this study
scored significantly lower on the risk-taking score
than the physician reference group41 (mean, 19 [4];
P o 0.005), indicating lower risk-taking personality
traits. The mean SNS-3 score was 4.90 (1.1), with a
range of 2.33 to 4.87, which was higher than the
reference population.42 This result was consistent with
the high educational levels reported in our study (68%
with at least a college degree).
Table III presents relative BW scores, SEs, and P
values, and Figure 2 diagrams the relative utility of
each level as measured by using relative BW scores.
All of the BW scores were significant at P o 0.001
except for “no increased chance of nausea,” “no
postapproval drug information available,” and “no
increased risk of bleeding.” By a large margin, the
highest utilities as measured by using relative BW
scores were for “stops progression of weakness”
(0.877) and “slows progression of weakness”
(0.800). These scores had almost twice the utility of
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the next-highest score, “5-year gain in expected life
span” (0.464). The “2-year gain in expected life span”
had a similar priority to the “5-year gain in expected
life span” (0.408).
Caregivers attributed the highest negative BW
scores to “increased risk of dangerous heart arrhyth-
mia and sudden death” (–0.786), followed by “in-
creased risk of hemorrhagic stroke and lifelong
disability” (–0.720). This was followed by “causes
loss of appetite with occasional vomiting” (–0.280).
Although the 2 most serious risks had high negative
scores, either (but not both) could be offset by a
treatment that stopped the progression of weakness.
The amount of knowledge about the drug was not
given high relative BW scores at any level, with mean
scores ranging from 0.056 to –0.021.
Table IV includes the relative attribute importance
for the entire group of caregivers. At the attribute
level, effects on muscle function accounted for the
largest proportion of the variance (28.7%), followed
by arrhythmia (22.4%), bleeding (21.2%), life span
(17.3%), nausea (8.1%), and knowledge about the
drug (2.3%).
DISCUSSION
Although the FDA is committed to patient-centered drug
development, the agency has limited resources. Repre-
senting a disease community that was not selected for
the congressionally mandated community engagement
program, PPMD led a study to proactively inform the
FDA’s benefit–risk assessments. The process we used can
be a model for facilitating patient-centered drug develop-
ment through an exploration of the priorities and
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Note: In some cases, percents do not add to 100%
because of missing values.
GED ¼ General Educational Development diploma.
*Ability to walk independently outside for at least short
distances.




preferences of patients, families, and other stakeholders.
Although the individual stories of highly motivated
advocates are powerful and influential, it is difficult to
know whether these testimonials represent the perspec-
tives of the majority of patients and families. We
describe a successful community-engaged process to
understand treatment preferences in a large group of
decision makers supported by the use of best/worst
scaling. To the best of our knowledge, this study
represents the first time a patient advocacy organization
has led a quantitative preferences study of this complex-
ity, highlighting a successful advocacy/academic collab-
oration that integrates traditional advocacy methods,
family-centered outcomes research, and a scientific
approach to quantifying preferences.
Within the context of our experiment, caregivers
attributed very high scores to stopping or slowing the
progression of muscle weakness. Change in life span
was not scored as highly. Feedback during cognitive
interviewing suggested that parents associated better
muscle function with higher quality of life, indicating
that parents value quality more than length of life.
This finding is consistent with both anecdotal reports
and an interview study of parents of children involved
in clinical trials,41 in which parents expressed a
preference for better quality of life for their child
over a longer life span.
We found that the presence of a serious risk could
be compensated for by a treatment that stops or slows
progression of weakness, even absent any other
benefits. The burden of DMD may be associated with
parents’ willingness to accept a serious risk for a
noncurative treatment. The data support a limit to
parents’ risk tolerance, however: for the levels of
benefit provided in the experiment, they would not
accept a treatment with 2 serious risks.
Table III. Best-worst results.
Attribute description Best Worst Best-worst
Relative b-w
Score 5.E. T-test P-Value
Effect on muscle function
Stops the progression of weakness 628 2 626 877 0.013 69.441 o0.001
Slows the progression of weakness 571 0 571 0.800 0.015 53.357 o0.001
Does not change progression of weakness 68 125 57 0.080 0.019 4.149 o0.001
Lifespan
5 veargain in expected lifespan 348 17 331 0.464 0.020 22.741 o0.001
2 veargain in expected lifespan 299 3 291 0.408 0.019 21.186 o0.001
No extra gain to expected lifespan 12 93 81 0.113 0.014 8.269 o0.001
Knowledge about the drug
2 years of post-approval drug info available 109 69 40 0.056 0.019 3.015 0.001
1 year of post-approval drug info available 20 4 16 0.022 0.007 3.288 0.001
No post-approval drug info available 41 56 IS 0.021 0.014 1.524 0.064
Nausea
No increased chance of nausea 19 26 7 0.010 0.009 1.044 0.148
Causes loss of appetite 1 95 94 0.132 0.013 10.272 o0.001
Causes loss of appetite with occasional vomiting 17 217 200 0.280 0.019 14.981 o 0.001
Risk of bleeds
No increased risk of bleeds 3 11 -8 0.011 0.005 2.143 0.016
Increased risk of bleedinggums and increased
bruising
0 190 190 0.266 0.017 16.079 o0.001
Increased risk of hemorrhagic stroke and lifelong
disability
0 514 514 0.720 0.017 42.807 o 0.001
Risk of heart arrhythmia
No increased risk of heart arrhythmia 5 32 27 0.038 0.008 4.498 o0.001
Increased risk of harmless heart arrhythmia 1 122 121 0.169 0.014 11.943 o0.001
Increased risk of dangerous arrhythmia and
sudden death
0 551 561 0.786 0.015 51.131 o0.001
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Our community-engaged process contributed to
successful recruitment of sufficient numbers of care-
givers for a complex, time-intensive survey in only 5
weeks, notwithstanding the fact that the study focuses
on a rare disease. The caregivers’ children represented
a range of ages and disease stages, and thus our
outcomes reflect the preferences of parents with
children across the disease course. Although the
development of an appropriate experimental design
is a complex task, it is one that is well suited to be led
by advocacy organizations with expert input and
collaboration.
Limitations
There are several limitations to the study. First, the
study sample, although likely to be representative of
caregivers whose children are enrolled in clinical trials,
may not be generalizable to the broader DMD com-
munity. However, we have demonstrated that this



































Levels 0.877 0.800 0.464 0.056 0.0220.408 –0.11 –0.02 –0.01 –0.01 –0.03–0.13 –0.26 –0.16–0.28 –0.72 –0.78–0.08
Slows None 5yr 1yr2yr 2yrNone None Mild Mild MildMod Sev SevNone None None
Figure 2. Relative best–worst scores for attribute levels. Mod ¼ moderate; Sev ¼ severe.
Table IV. Relative attribute importance.
Attribute Maximum Minimum Difference Percent*
Effect on muscle function 0.877 –0.080 0.957 28.7
Life span 0.464 –0.113 0.577 17.3
Knowledge about the drug 0.056 –0.021 0.077 2.3
Nausea –0.010 –0.280 0.270 8.1
Risk of bleeding –0.011 –0.720 0.709 21.2
Risk of heart arrhythmia –0.038 –0.786 0.748 22.4
Sum 3.338 100
*Percent relative importance calculated as the difference between the maximum and minimum utility for each attribute
divided by the sum of all such differences.




personality traits and had adequate numeracy to reduce
concern about numeracy bias in survey responses.
Although the recruitment of caregivers (or patients)
through advocacy groups has a risk of bias, it also has
real benefits over qualitative approaches. Using the
model process, we plan to refine the experiments and
conduct a larger study with a more representative
parent group and a neuromuscular clinician group.
Especially important in our next study is to elicit
treatment preferences from affected teenagers and
adults, anticipating that DMD patients and caregivers
may not assess benefit and risk in the same way.19
Second, although the study used a rigorous ap-
proach to attribute identification, the simulated treat-
ments described in the experiment may not represent
the benefit and risk profile of therapies that are
ultimately approved for DMD. As with all stated-
preference experiments, it remains unknown whether
the presence or absence of additional attributes would
influence the results. On the spectrum of patient
centered to clinically centered specification of attrib-
utes, we favored the former to be consistent with the
goals of patient-centered outcomes research and ex-
plore attributes meaningful to our caregiver partic-
ipants. In our future studies, and when more is known
about the benefits and risks of treatment, we aim to
incorporate more clinically centered attributes while
continuing to maintain a priority on utilizing mean-
ingful attributes.
Third, we conducted an aggregate analysis, and
important structures in preference heterogeneity may
have been overlooked. We have previously reported
the differences in treatment preferences by stratifying
data according to child’s ambulation status.55
Although there was a small but significant difference
when completing such a stratification, this could have
been explained by scale differences between the 2
groups. In follow-up studies, we will aim to have a
larger sample size to allow for both stratification and
segmentation analysis,56 which will enable being able
to adequately describe preference heterogeneity.
Fourth, we used a simple technique for estimating
preferences, compared with more advanced regression
techniques. As a supplemental analysis (not reported
here), we reanalyzed our data by using a conditional
logit. One obvious difference between the methods is
that conditional logit requires using effects coding for
each attribute, making each attribute have the same
mean. As such, although each attribute remains on a
ratio scale, the translocation of the origin inherent in
effects coding implies that level importance cannot be
compared across attributes. The advantage of our
simple approach is that all preference weights can be
estimated directly (ie, without using effects coding), and
hence they all sit on the same ratio scale. We modified
these results to make them comparable to the condi-
tional logit (ie, we subtracted the attribute mean from
each attribute level), and they produced nearly identical
results to the conditional logit, with both methods
having identical ordering (Spearman’s ρ ¼ 1.0) and
near perfect correlation (Pearson’s ρ ¼ 0.997).
Finally, because BWS is a relatively new stated-
preference method, there is the possibility that it may
present a distorted version of preference. However,
there is growing interest in the method given its
simplicity compared with more traditional conjoint
analysis methods, which may affect respondent effi-
ciency (ie, do responses to choice tasks reflect respond-
ents true preferences?). We plan to validate these results
against a simple conjoint analysis that was conducted
as part of this study, but more research is needed to
compare BWS and conjoint analysis methods.
Implications
The study findings are highly relevant to industry
and regulators who are conducting benefit–risk assess-
ments for potential DMD therapies. Emerging results
from clinical trials suggest a slowing of motor decline,
as measured by using the 6-minute talk test, and no
known effect on life span.13 Caregivers’ significant
and yet finite risk tolerance has regulatory
implications as well; however, given the modest risk
profile emerging from many DMD clinical trials, our
finding of high tolerance for adverse effects and drug-
related uncertainty is also relevant.
This study intended to leverage the FDA’s ongoing
commitment to identifying methods of systematic
patient engagement and, more specifically, their com-
mitment to the use of statistical methods exploring
and comparing benefits and risks to systematically
quantify patients’ anecdotal reports.57 PPMD was
able to report the outcome of this study to FDA
representatives in both private and public meetings.
Equally important, PPMD reported the results back to
the DMD community through social media, a
webinar, and in-person meetings and conferences. As
the FDA evaluates new drug applications for DMD
therapies, they should be mindful of the value that
Clinical Therapeutics
634 Volume 36 Number 5
59
parent decision makers place on even moderate
benefits to function, their tolerance for considerable
risk, and their tolerance for uncertainty.
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Abstract
Background Through Patient-Focused Drug Develop-
ment, the US Food and Drug Administration (FDA) doc-
uments the perspective of patients and caregivers and are
currently conducting 20 public meetings on a limited
number of disease areas. Parent Project Muscular Dystro-
phy (PPMD), an advocacy organization for Duchenne
muscular dystrophy (DMD), has demonstrated a commu-
nity-engaged program of preference research that would
complement the FDA’s approach.
Objective Our objective was to compare two stated-
preference methods, best-worst scaling (BWS) and con-
joint analysis, within a study measuring caregivers’ DMD-
treatment preferences.
Methods Within one survey, two preference-elicitation
methods were applied to 18 potential treatments incorpo-
rating six attributes and three levels. For each treatment
profile, caregivers identified the best and worst feature and
intention to use the treatment. We conducted three analyses
to compare the elicitation methods using parameter esti-
mates, conditional attribute importance and policy simu-
lations focused on the 18 treatment profiles. For each,
concordance between the results was compared using
Spearman’s rho.
Results BWS and conjoint analysis produced similar
parameter estimates (p\ 0.01); conditional attribute
importance (p\ 0.01); and policy simulations (p\ 0.01).
Greatest concordance was observed for the benefit and risk
parameters, with differences observed for nausea and
knowledge about the drug—where a lack of monotonicity
was observed when using conjoint analysis.
Conclusions The observed concordance between
approaches demonstrates the reliability of the stated-pref-
erence methods. Given the simplicity of combining BWS
and conjoint analysis on single profiles, a combination
approach is easily adopted. Minor irregularities for the
conjoint-analysis results could not be explained by addi-
tional analyses and needs to be the focus of future research.
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Key Points for Decision Makers
The application of best-worst scaling (case 2), where
treatment profiles are shown and respondents are
asked to identify the best and worst attribute, allows
for the addition of simple, complementary conjoint-
analysis techniques to assess the intention to use
potential therapies.
This approach is useful in regulatory decision
making, especially in the context of rare diseases,
where populations are limited and replication studies
may be difficult.
The application of conjoint analysis techniques
confirms our previous findings that caregivers of
children with Duchenne muscular dystrophy will
tolerate risks if emerging treatments can slow the
progression of disease or extend the child’s life.
1 Introduction
Duchenne muscular dystrophy (DMD) is a rare neuro-
muscular disorder that occurs in 1.3–2.9 per 10,000 males
[1–4]. Despite the burden of the disease [5–9], treatment is
limited to off-label use of corticosteroids as there are no US
FDA-approved therapies [1, 10–12]. This said, several
potential therapies are under investigation [12, 13]. To
inform regulatory review of these therapies, Parent Project
Muscular Dystrophy (PPMD), an advocacy organization
focused on finding a cure for DMD, led several collabo-
rative efforts to advance regulatory science and decision
making [14, 15]. This included applying stated-preferences
methods to quantify caregiver preferences for benefits and
risks [19]. Subsequently, PPMD submitted a patient-initi-
ated FDA draft guidance for DMD in June 2014 that
includes an engagement framework and guidance on the
use of stated-preference methods to inform drug develop-
ment and regulatory review [15].
These efforts are complementary with the FDA’s effort
to integrate the patient perspective in its drug development
and approval process [16, 17]. The Patient Drug User Fee
Act (PDUFA) V provides resources for dedicated review of
patient input to extend patient influence beyond an advi-
sory capacity [16]. The FDA initiated patient and caregiver
engagement activities through a commitment to obtain the
patient perspective, through Patient-Focused Drug Devel-
opment public meetings, on 20 disease areas during the
course of PDUFA V [16]. DMD was not one of the disease
areas chosen, but the FDA noted that there are many more
disease areas than can be addressed during the public
meetings, and encouraged stakeholders to generate patient/
caregiver input on their disease area that is relevant to the
PDUFA commitments [18]. They have also sought expert
guidance on measurement techniques for quantifying
preferences [17].
PPMD responded to the FDA’s encouragement to gen-
erate input through their community-engaged research
program on DMD treatment preferences. Specifically,
PPMD developed a framework for feasible community-
engaged benefit-risk assessment that included best-worst
scaling (BWS) [19]. BWS is a recently developed method
that is used with increasing frequency in health research
[20–28]. Here we aim to compare this approach with
conjoint analysis, a more common stated-preference tech-
nique [29]. Specifically, we used a simple form of conjoint
analysis that asks respondents if they would accept each of
the profiles shown in the BWS experiment.
In BWS, respondents are asked to consider a profile and
to select the best and the worst attribute [30]. There are
different variations of BWS. A BWS object case (case 1)
assesses relative preferences for a series of items that could
otherwise be evaluated with a rating scale [30]. A BWS
profile case (case 2) asks respondents to evaluate one profile
at a time and therefore offers greater comparability to dis-
crete-choice experiments or choice-based conjoint analysis
[30]. Regardless of type, collecting two responses (best and
worst choice) elicits more data about the respondent’s
preferences for items than can be obtained through conjoint
analysis, which asks respondents to accept or reject a given
commodity under a set of conditions [31]. The essential
assumption is that the choice of the best and worst item
represents the farthest difference between the degree of
importance among any items on an underlying ranking of
item importance [32]. BWS places greater emphasis on item
importance, whereas conjoint analysis emphasizes trade-
offs and more closely represents a real decision [33].
Previous studies have validated preference elicitation
methods against a conjoint analysis task [32, 34]. Past
studies comparing BWS and more established preference
elicitation methods report mixed results [35–38]. Com-
parisons have found that the BWS object case has advan-
tages over other methods such as superior discriminatory
power without additional respondent burden and higher
predictive validity [36]. An empirical comparison of BWS
profile case and other discrete-choice experiments dem-
onstrates that both methods produce similar preference
patterns when rescaled [38]. To the best of our knowledge,
there have been no empirical comparisons of a BWS profile
case and a simple conjoint analysis where the respondent
can accept or reject (i.e., opt out) a treatment.
In the experiment, we aimed to determine the accep-
tance of clinically relevant treatment options with varying
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levels of benefits and risks. By including BWS and a
conjoint analysis experiment, we aimed to exploit the
complementary strengths of both types of experiments
[39]. Specifically, incorporating the conjoint analysis
question is useful because the BWS is limited in that it
provides no information about preference for a given
therapy [39]. The addition of the conjoint analysis question
provides a second analysis that supports our BWS analysis,
while also providing important independent data and psy-
chological benefits to the respondents through asking about
the most relevant endpoint—intention to use the treatment.
The objective of this paper is to compare BWS and con-
joint analysis to determine whether they produce similar
results and to determine whether a combination approach is
feasible and useful for quantifying benefits and risks in the
context of treatment preferences. This has the potential to
contribute both to the methodological literature on using
BWS in health and to advancing our understanding of
treatment preferences for rare disorders.
2 Methods
The study was conceptualized and designed by a collabo-
rative team consisting of members of PPMD and a team of
academic collaborators [19]. The study was part of a larger
effort intended to explore DMD-related worries and pref-
erences for treatment options among caregivers of children
with DMD. The components to the study included a BWS
experiment for analysis of worry prioritization (object case)
and an experiment that included both conjoint analysis of
therapy acceptance and BWS for measuring treatment
preferences (profile case). The former is not described here.
The study, which was reviewed and deemed exempt by
the Western Institutional Review Board, drew from a
sample that was recruited using PPMD and Duchenne-
Connect, a disease-specific patient registry for patients with
DMD. In addition, snowball recruitment was used. Study
participants were eligible if they were aged at least 18
years, a caregiver for at least one child living with DMD,
living in the USA, and able to complete an online survey in
English. The survey included basic demographic questions
about the caregivers and affected children, including a
disease progression item that represented impact of the
disease on the child’s function.
2.1 Experimental Design
Using a community-engaged approach, the research team
identified six relevant treatment attributes, or categories of
Fig. 1 Survey instrument
example task: combined best-
worst scaling and conjoint
analysis
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characteristics (shown in Table 2), each with three levels.
The levels indicate varying degrees of change to represent
no increased risk, mild to moderate risks, or severe risks;
and no change, modest change, and moderate change in
benefit [19]. The development of the attributes and levels
was informed by multiple stakeholders, an oversight
group, and the study team. Additional details on this
community-engaged, multi-stakeholder approach have
been previously published [19]. The final selection of
attributes and levels is reasonable considering the current
pipeline of potential DMD therapies, with the exception
of the highest risk levels that represent much greater
risk than what has been associated with therapies in
trial.
We systematically designed each of the hypothetical
treatment options to vary among three levels across the six
attributes to form a BWS experiment (profile case) [40].
We applied a 3^6 main effects orthogonal design, identified
from the SAS database of orthogonal arrays [41]. Orthog-
onal designs focus on statistical efficiency and are com-
monly used and accessible methods [42, 43]. The minimum
number of treatment profiles necessary to ensure no cor-
relations between the attributes was 18 [44].
We presented the 18 potential treatment profiles in the
experiment such that each treatment profile could be con-
sidered separate from the rest. We elicited treatment pref-
erence using BWS by asking caregivers what parts of each
treatment profile they considered to be the best and the
worst. For each treatment profile, immediately following
the BWS choice task, we asked the respondents an addi-
tional conjoint analysis choice question—if they would use
the treatment for their child if it were available (and under
the hypothetical scenario of no out-of-pocket costs and the
treatment being provided by their physician rather than as
part of a clinical trial). Their choice set for answers were
‘yes’, ‘no’, and ‘I don’t know’. Figure 1 illustrates an
example of the paired BWS and conjoint analysis task from
the survey instrument.
2.2 Statistical Analysis
We ran three types of analyses to compare the result
from the two elicitation formats. Specifically, we com-
pared all parameter estimates and the conditional attri-
bute importance, and conducted comparative policy
analysis.
First, we calculated parameter estimates for each level
of each attribute, facilitated by effects coding the data. In
the BWS analysis, we used conditional logistic regres-
sion, with the dependent variable as the participants’
choice of best and worst feature of each profile, again
using effect coding [21]. Using logistic regression for the
conjoint analysis, the dependent variable was the
participant’s choice to accept or reject the therapy rep-
resented by the treatment profile. We analyzed the
respondent’s choice set dichotomously by combining ‘no’
and ‘I don’t know’ into one response group. There is no
consensus on the use of a ‘don’t know’ response in
discrete-choice experiments, but this conservative
approach is reasonable because, in a real-world scenario,
indecision defaults to rejection; and in an experimental
setting when forced to choose, respondents resort to ‘no’
[45, 46]. We analyzed the data using robust standard
error to account for clustering at the individual level. To
illustrate concordance, we both reported and plotted the
parameter estimates to visually examine the patterns.
Given the natures of the respective regressions for the
BWS and conjoint analysis data, it is important to note
that the results are on different scales. Rather than nor-
malize these scales, we compared these estimates using
Spearman’s rho (although Pearson’s rho gives similar, if
not more convincing, results).
Second, we estimated conditional attribute importance
for both methods by calculating the difference between the
highest and lowest parameter estimates for each attribute
Table 1 Characteristics of participants and affected child(ren)
(n = 119)
Participant characteristics Mean (SD) or %a
Participant
Caregiver age, years 43.7 (7.7)









Less than 4-year college degree 31.1







One affected child 92.4
Participated in clinical research/trial 92.0
Ambulatory 63.9
Ambulatory = ability to walk independently outside for at least short
distances
a Data are presented as mean (standard deviation) or percentage
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and dividing it by the sum of all differences. Calculating
the importance of each attribute is a function of the levels
chosen within the experiment, rather than being more
generalizable. This said, both elicitation formats in this
study used the same profiles, defined across the same level,
and hence offer a valid method for comparison. Again, the
relative concordance between the two sets of conditional
importance was compared using Spearman’s rho.
Finally, we conducted comparative policy analysis
across the 18 profiles that were presented in the choice
tasks. For the conjoint analysis, we simply used the prob-
abilities that caregivers accepted each of the 18 profiles.
These probabilities would provide an indication of inten-
tion to use particular drugs, which provides practical and
policy-relevant information. For the BWS, we calculated
‘net utilities’ for each treatment profile from the BWS
experiment. These represent overall value of an entire
profile rather than for an individual item. To calculate net
utilities, we applied the BWS item parameter estimates
from the regression results and applied them to the items
making up each treatment profile. The sum of the param-
eter estimates for each treatment profile represents the net
utility for that treatment profile. These net utilities were
compared with the probabilities of acceptance using
Spearman’s rho.
3 Results
Excluding five caregivers who did not complete the
experiment, the final analytic sample consisted of the 119
caregivers who completed the entire survey. The mean age
of survey respondents was 43.7 years (standard deviation
[SD] 7.7), and most were biological mothers looking after
one affected child living in the home. Caregivers also
tended to be highly educated and high-income earners, with
68 % of the sample having at least a college degree and
almost half of the sample (47 %) having an income of over
$US100,000 per year. More than 90 % reported that their
child had participated in clinical research or a clinical trial.
See Table 1 for characteristics of participants and affected
children.
Results of the BWS experiment using best-minus-worst
scoring (maximum difference) have been published previ-
ously [19]. For comparison purposes with conjoint analysis
(see Table 2), we present BWS results using conditional
Table 2 Comparison of best-worst scaling and conjoint analysis results
Attributes and levels Best-worst scaling Conjoint analysis
Coefficient SE Coefficient SE
Effect on muscle function
Stops the progression of weakness 0.860 0.08 1.447 0.07
Slows the progression of weakness 0.353 0.07 1.161 0.08
Does not change the progression of weakness -1.213 0.12 -2.608 0.13
Lifespan
5-year gain in expected lifespan 0.581 0.07 0.942 0.06
2-year gain in expected lifespan 0.118 0.06 0.717 0.06
No extra gain in expected lifespan -0.698 0.08 -1.658 0.09
Knowledge about the drug
2 years of post-approval drug information available -0.187 0.08 0.301 0.05
1 year of post-approval drug information available 0.168 0.05 0.066 0.04
No post-approval drug information available 0.019 0.08 -0.366 0.07
Nausea
No increased change of nausea -0.185 0.07 0.707 0.06
Causes loss of appetite 0.164 0.06 0.070 0.05
Causes loss of appetite with occasional vomiting 0.021 0.08 -0.777 0.06
Risk of bleed
No increased risk of bleeds 0.772 0.08 1.429 0.06
Increased risk of bleeding gums and increased bruising 0.268 0.07 0.302 0.06
Increased risk of hemorrhagic stroke and lifelong disability -1.039 0.11 -1.731 0.08
Risk of heart arrhythmia
No increased risk of heart arrhythmia 0.716 0.08 1.280 0.06
Increased risk of harmless heart arrhythmia 0.417 0.07 0.724 0.07
Increased risk of dangerous arrhythmia and sudden death -1.133 0.11 -2.004 0.09
SE standard error
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logit analysis, the results of which are relatively consistent
with the best-worst scaling results [19]. Overall, the
parameter estimates from the two elicitation formats were
concordant (Spearman’s q = 0.907; p\ 0.01). Figure 2
presents a graphical representation comparing preference
weights across the two methods.
Table 3 presents the conditional attributes importance for
each attribute, using both BWS and conjoint analysis. The
conditional attribute importance was 27 % for stopping/
slowing the progression of weakness across both studies, 21
and 23 % for risk of bleed, and 21 and 24 % for risk of heart
arrhythmia for the BWS and conjoint analysis experiments,
respectively (see Table 3). The conditional attribute impor-
tance was concordant across BWS and conjoint analysis; the
Spearman’s rho was 0.943 (p\ 0.01).
Finally, the concordance between BWS and conjoint
analysis was again confirmed through comparative policy
analysis, and rank ordering was concordant (p\ 0.01). As
seen in Table 4, the four treatment profiles with the highest
net utilities all had a probability of acceptance greater than
80 % from the conjoint experiment. This concordance
demonstrates the complementary nature between the two
methods. It is clear that the net utility estimates for a given
treatment profile, derived from the BWS parameter esti-
mates, corresponds to the probability of intention to accept
a specific therapy. Similarly, the four profiles with the
lowest net utilities all had a probability of acceptance less
than 20 % from the conjoint experiment.
4 Discussion
We evaluated the concurrent use in the same survey of a
conjoint analysis experiment with a BWS experiment, and
compared the results. Our data indicate that the two
methods are concordant, particularly in terms of individual
item parameter estimates for the benefits and risks (see
Fig. 2), conditional attribute importance (see Table 3), and
net utility of treatment profiles compared with probabilities
of accepting the treatment (see Table 4). The items with
the highest and lowest utility are remarkably consistent
across methods, and the treatment profiles most and least
accepted are concordant with the treatments with the
highest and lowest net utility.
We observed some important differences using the two
methods. This is most apparent when looking at the
parameter estimates for the attributes ‘knowledge about the
drug’ and ‘nausea’, in which the graph (Fig. 2) is not
monotonic but changes direction. The highest-level benefit
for ‘knowledge about the drug’ (2 years of post-market
information) has a part-worth utility observed using BWS
of 0.30 (p\ 0.05), while using conjoint analysis it is-0.19
(p\ 0.05). For the lowest level of ‘nausea’ (none), the
observed part-worth utility for BWS is 0.71 (p\ 0.05), and
for conjoint analysis it is -0.18 (p\ 0.05). In these two
instances, the rank order of attribute importance flips
(Table 3). We conducted two post hoc analyses (stratified
analysis based on disease severity and two-group latent
Fig. 2 Comparison of parameter estimates based on best-worst scaling and conjoint analysis. BWS best-worst scaling
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class analysis to identify subtypes based on associations
with the responses) to attempt to explain the heterogeneity
in item acceptance. Disease severity was defined in terms
of ambulation status, in which children were considered to
be ambulatory if they could walk independently outdoors
for short distances (such as to the car) or if they were too
young to walk. The lack of monotonicity for these two
items in the conjoint analysis could not be explained by
post hoc analysis, leading us to assume that it was due to an
unobserved framing effect, where participants may have
reacted to a particular choice in different ways depending
on whether it was presented as a loss or as a gain.
Alternatively, the differences between the two methods
indicate that, while respondents value knowledge about the
drug and nausea, these variables may not impact the actual
choices that caregivers may make. Future research should
evaluate differences between these two methods, and
across other elicitation methods such as more traditional
paired-profile conjoint analysis methods.
The data on the intention of caregivers to accept or reject
particular treatments not only provided complementary data
to BWS, but also relevant information for industry and reg-
ulators regarding the proportion of caregivers whomight use
therapies with different benefit–risk profiles. The results
suggest that a large percentage of parents anticipate using a
drug that would stop the progression ofweakness, even given
a loss of appetite and occasional vomiting together with an
increased risk for mild bleeds. In contrast, about one-third
anticipate using a drug that includes two serious risks, even
given the highest benefits (stops progression and 5-year gain
in lifespan). Less than 20 % anticipate using a drug that
offers a 2-year gain in lifespan with no benefit to weakness,
when associated with one serious risk.
The next phases of PPMD’s ongoing preferences studies
will allow us to address some of the limitations associated
with this study. This sample of caregivers tended to be
highly educated and earning high incomes. Future research
will utilize large samples of a more diverse group of
caregivers to be adequately powered for adjusted logistic
regression models and to investigate the heterogeneity in
the sample. In this study, presenting the BWS experiment
before the conjoint analysis experiment may have affected
the results, as may the order of presentation for the
Table 3 Comparison of conditional attribute importance
Conditional attribute importance (%)
Best-worst scaling Conjoint analysis
Effects on muscle function 26.6 26.9
Lifespan 17.1 16.6
Knowledge about the drug 4.4 4.6
Nausea 9.7 4.5
Risk of bleeds 20.7 23.5
Risk of heart arrhythmia 21.5 23.9
Total 100 100















18 0.96 6.106 Stops 5 year 2 year None None None
11 0.84 3.040 Slows 2 year 1 year Mild Mild Mild
7 0.82 1.646 Stops None None Mild None Mild
15 0.81 3.444 Slows 2 year None Mod None None
1 0.78 0.660 Stops None 1 year Mod Mild None
6 0.67 -0.224 None 5 year 1 year Mod None Mild
17 0.64 -0.380 None 5 year None Mild Mild None
16 0.55 0.681 Stops 2 year 2 year Mod Severe Mild
9 0.52 1.437 Slows 5 year None None Severe Mild
4 0.48 0.803 Stops 2 year None None Mild Severe
2 0.46 -0.075 Slows 5 year 2 year Mod Mild Severe
10 0.34 -0.299 Slows None 1 year None None Severe
12 0.33 -0.577 Slows None 2 year Mild Severe None
3 0.32 -1.210 Stops 5 year 1 year Mild Severe Severe
8 0.18 -1.569 None 2 year 1 year None Severe None
13 0.18 -2.095 None 2 year 2 year Mild None Severe
14 0.09 -2.232 None None 2 year None Mild Mild
5 0.05 -9.144 None None None Mod Severe Severe
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treatment options and attributes/levels. In future research,
we can randomize the order of the experiments and the
presented treatment options.
A potential limitation of conjoint analysis is that it is
subject to ceiling or floor effects. However, we calculated
the probabilities that caregivers would accept or reject a
therapy given a particular treatment profile. As seen in
Table 4, the variability in probability of taking the treat-
ment across treatment profiles, and the fact that no treat-
ment was universally accepted or rejected, indicates that
caregivers responded to the experiment reasonably and
made appropriate trade-offs when considering their choice.
A final limitation is that we compare BWS using the
conditional logit analytic approach, which is more com-
putationally intensive than the maximum difference ana-
lytic approach. Previously we analyzed the data using both
approaches [21, 47], and, since they are highly correlated
[20, 26], we presented results from the more accessible
maximum difference approach [19]. Given that we con-
ducted the BWS analysis two ways, rescaled the parame-
ters and calculated correlations to find the two analytic
approaches to BWS to be virtually identical [19], we felt
confident that using the conditional logit analytic approach
for comparing BWS with conjoint analysis would not
qualitatively change the results.
5 Conclusions
This study demonstrates the concordance in the preferences
estimated via two stated-preference techniques, BWS and a
simple conjoint analysis. Substantively, this provides
important confirmation of our previously published results
on caregivers’ benefit–risk trade-offs for DMD therapies.
The combination of BWS and conjoint analysis experi-
ments in a single survey is a useful approach because it
allows for the interpretation and application of the data to
understand risk tolerance, meaningful benefits, and explore
intention to use specific therapies. Our data support the
utility of this combination approach for treatment prefer-
ences research that is intended to inform regulatory deci-
sion making.
These results and the method we propose have important
implications for patient-centered drug development.
Experiments using BWS together with conjoint analysis
might be especially useful in quantifying patient and
caregiver preferences. These combined experiments pro-
duce results that inform sponsors, regulators, and the
broader rare disorder community. They are especially
important in the case of progressive, life-threatening con-
ditions with limited treatment options, where regulators
may be less able to imagine how a ‘typical’ patient or
caregiver might weigh benefits and risks. The ongoing
benefit–risk research led by PPMD demonstrates that
patient and disease advocacy groups can contribute to the
literature on benefit–risk, while also providing leadership
in furthering community-centered approaches and scientific
methodologies to advance the FDA’s commitment to pro-
moting transparency in benefit–risk assessment and patient-
centered drug development.
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Duchenne muscular dystrophy (DMD) is a progressive, fatal pediatric disorder with significant 
burden on parents. Assessing disease impact can inform clinical interventions.  
Best-worst scaling (BWS) was used to elicit parental priorities among 16 short-term, DMD-
related worries identified through community engagement. Respondents viewed 16 subsets of 
worries, identified using a balanced, incomplete block design, and identified the most and least 
worrying items. Priorities were assessed using best-worst scores (spanning +1 to -1) 
representing the relative number of times items were endorsed as most and least worrying. 
Independent-sample t-tests compared prioritization of parents with ambulatory and non-
ambulatory children. 
 
Participants (n=119) most prioritized worries about weakness progression (BW score 0.64 
p<0.001) and getting the right care over time (0.25, p<0.001). Compared to parents of non-
ambulatory children, parents of ambulatory children more highly prioritized missing treatments 
(0.31 vs. 0.13, p<0.001) and being a good enough parent (0.06 vs. -0.08, p=0.01), and less 
prioritized child feeling like a burden (-0.24 vs. -0.07, p<0.001).  
Interventions to reduce negative parental impact may be most effective in conjunction with care-
related interventions for the child, regardless of disease stage. We demonstrate an accessible, 
clinically-relevant approach to prioritize disease impact using BWS, which offers an alternative 
to the use of traditional rating/ranking scales.  
INTRODUCTION
Understanding patients’ and caregivers’ experience of disease impact has implications for 
clinical care provision, public health programs, and policy development. The associations of 
perceived disease impact with health and psychosocial outcomes are well-described (for 
example, see Baines and Wittkowski 2013; McAndrew et al. 2014). Quantifying 
patients’/caregivers’ preferences is an important issue for clinicians (dosReis et al 2014; Black 
2013) and models of patient-centered care (Haywood 2006) and shared decision making (Politi 
and Street 2011) mark an increasing focus on assessing patients’/caregivers’ perspectives and 
using the resulting data to inform healthcare delivery and decision making. Measuring 
patients’/caregivers’ views avoids clinician/researcher bias and encourages a focus on reducing 
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symptoms, minimizing disability, and improving quality of life (Black 2014). Special attention to 
disease impact is included in the Food and Drug Administration’s Patient-Focused Drug 
Development Program (U.S. Food and Drug Administration), raising the visibility and importance 
of assessing impact of disease for clinical trial sponsors and disease community stakeholders. 
These concepts are familiar to genetic counselors, for whom exploring a clients’ lived 
experience is defined as a Practice-Based Competency (Accreditation Counsel for Genetic 
Counseling 2013). 
 
In research settings, disease impact is often assessed using qualitative approaches or standard 
quantitative measures of severity, burden, and quality of life. In the regulatory context, patient 
and caregiver testimonial is another common approach. Each approach comes with strengths 
and limitations. Qualitative approaches are excellent for obtaining a deep and nuanced 
understanding of disease impact and often generate hypotheses to be tested in a generalized 
population in subsequent studies, while quantitative research using validated measures allow 
generalizable data to be systematically collected and compared across populations (Creswell et 
al. 2011; Razafsha et al. 2012). In this study we employed a quantitative stated preferences 
method, best-worst scaling (BWS), to prioritize disease impact in Duchenne muscular dystrophy 
(DMD).  
 
Duchenne muscular dystrophy (DMD) is a rare, life-threatening disorder with pediatric onset 
(Bushby et al. 2010). Affected individuals, primarily males, have progressive loss of functional 
muscle fibers that result in weakness, loss of ambulation that typically occurs in the teen years, 
and premature death in the 20s-30s (Bushby et al. 2010; Flanigan 2014). Though the use of 
corticosteroids and advances in respiratory support and cardiac care have substantially 
impacted the health of individuals with DMD (Bushby et al. 2010; Eagle et al. 2002; Flanigan 
2014), patients and parents are still faced with significant burden related to disease progression, 
ongoing care demands, and financial impact (Boyer et al. 2006; Daoud et al. 2004; Hatzmann et 
al. 2008; Kenneson and Bobo 2010; Landfeldt et al. 2014; Pangalila et al. 2012; Reid and 
Renwick 2001). 
 
The study aimed to document parents’ prioritization of short-term, disease specific worries when 
caring for an individual with DMD, and to identify if worry prioritization varies based on the 
child’s ambulation status (representing disease progression). In addition, we describe parents’ 
79
physical and mental health status. Duchenne worry can be conceptualized as an emotion-
focused illness representation, as defined by Leventhal's Common-Sense Model of Health and 
Illness Self-Regulation (McAndrew et al. 2008). The model proposes individuals as active 
problem-solvers who, when faced with a threat such as DMD in their children, engage in a 
dynamic process of developing and refining cognitive and emotion-focused illness 
representations that influence coping efforts (McAndrew et al. 2008). The data presented here 
are part of a larger project that also evaluated the treatment preferences of parent/guardian 
caregivers (Hollin et al. 2014; Peay et al. 2014a). An overarching objective of the research 
program was to model a replicable, community-engaged approach to obtaining preference and 
priority data from a sample of parents and guardians.  
METHODS 
A central aspect of the research program was the community-engaged approach that involved 
stakeholders in development of the survey instrument and dissemination of findings (Peay et al. 
2014a). The study was lead by Parent Project Muscular Dystrophy (PPMD), an advocacy 
organization focused on finding a cure for Duchenne muscular dystrophy. A disease-community 
oversight team comprising PPMD staff (a clinician, a scientist experienced in drug development, 
and two caregivers of individuals with DMD) collaborated with the research team to design and 
implement the study.  
 
We employed BWS Case 1 to prioritize worries when caring for an individual with DMD. Worry 
is defined as thoughts and images that are negatively affect-laden and relatively 
uncontrollable (Borkovec et al. 1983). Worry is clinically meaningful in that it may be related to 
an increase in behaviors that the worrier believes will protect his or her health, or in this case, 
the health of the child (McCaul and Goetz 2008); for example, Magnan and colleagues (2009) 
describe benefits of non-pathological worry that include motivation for positive health behaviors 
by increasing the salience of a health threat and acting as a cue to action.  
 
BWS is a stated preference method grounded in Random Utility Theory that is based on how 
people make choices of extremes from within a choice set (Louviere and Flynn 2010). BWS 
Case 1, also known as the object case or object scaling, is relatively new to healthcare research 
(Flynn 2010). It is used to assess the relative preferences for a series of related items that could 
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otherwise be evaluated using a rating scale (Flynn 2010). In designing a BWS study a detailed 
set of related items, called attributes, are typically developed through qualitative stakeholder 
engagement (Bridges et al. 2011). The attribute set can be developed to include items that are 
each expected to be highly relevant to the majority of the study population. Instead of presenting 
these items as a scale and asking respondents for level of endorsement, which would likely 
result in highly skewed data and poor discriminative ability, BWS Case 1 quantifies prioritization 
among items selected to be highly relevant. Advantages of BWS over rating scales and ranking 
exercises have been summarized by Erdem and Rigby (2013). 
 
In a BWS survey instrument, attributes are presented in subsets that are chosen based on a 
balanced incomplete block design (Ross et al. 2014) to ensure equal probability of selection for 
each attribute. The respondent is asked to select the most relevant or favorable (the “best”) and 
the least relevant or favorable (the “worst”) attribute among each subset. The underlying 
assumption is that this choice represents the farthest difference between the degree of 
importance among any items on an underlying ranking of item importance (Louviere and Islam 
2008). An example choice task is shown in Figure I.  
 
Consistent with our overarching objective, BWS represents a pragmatic methodology that 
allows deep understanding of one component of illness impact while also allowing quantitative 
ranking and group comparison. Though BWS is typically utilized to identify preferences among 
fact-based or cognitive attributes, there are examples of BWS being used to prioritize control-
based and worry-based attributes, for example related to food safety (Erdem and Rigby 2013), 
and to prioritize among quality of life attributes (Flynn et al. 2007) that have affective 
components. By asking participants to choose among extremes, BWS minimizes the chances of 
introducing false assumptions about decision making (Flynn et al. 2007). BWS requires 




In designing the survey we used standards outlined in the ISPOR checklist for conjoint analysis 
(Bridges et al. 2011) and specific guidance on the use of BWS (Flynn 2010; Louviere and Flynn 
2010). As described by Johnson and colleagues (2009), development of the attributes should 
include careful consideration of the disorder symptoms and severity; the target population 
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should be involved in development of attributes through qualitative methods; and the resulting 
experimental attributes should then be pilot tested and refined. However, to achieve our 
overarching aim of a replicable, feasible model, we were unable to employ extremely complex, 
time and resource intensive development processes, such as that described by Grewal and 
colleagues (2006). Instead we employed a pragmatic community engaged approach with input 
from a wide range of stakeholders.  
 
PPMD invited stakeholder informants to participate in the survey development. We solicited 
open-ended responses from 5 highly-engaged parent advocates about their most important, 
current DMD-related worries. The parents were chosen to represent caregivers of children and 
adults with DMD of different ages and disease stages. The worry narratives provided by the 
parent informants were compiled, redundant items were eliminated, and statements were 
grouped under themes. These statements were evaluated, refined, and reduced by the PPMD 
oversight team and the study team, drawing on the diverse personal, clinical, and research 
experience of the teams; the determinations were informed by a review of the literature. The 
next step, thematic analysis and additional item reduction and refinement, resulted in a list of 16 
worry items grouped under 4 worry domains—the child’s affect and emotion; medical concerns 
about the child; family and social worries; and parent well-being. Patient advocates and experts 
representing neurology, clinical genetics, biopharmaceutical companies, and social/behavioral 
science reviewed and revised the items, which were finalized once no further amendments were 
suggested. Though there are no published studies specific to DMD-related worries, the final 
worry domains and items are supported by published literature about DMD impact and burden 
(Boyer et al. 2006; Daoud et al. 2004; Hatzmann et al. 2008; Kenneson and Bobo 2010; 
Landfeldt et al. 2014; Pangalila et al. 2012; Reid and Renwick 2001). 
The final worry items were randomized into 16 combinations of response sets, each comprising 
6 worry attributes. For each of the 16 combinations, participants were asked: “In the past 7 
days, choose which you have been most worried about and which you have been least worried 




Figure I. Sample choice task 
     
 For each list of worries, please tell us which one you have been most worried 
about in the past 7 days, and which one you have been least worried about in 
the past 7 days. Even if you are really worried about all of them, or not too 
worried about any of them, please choose the most and least worrying item. 
In the past 7 days, choose which you have been most worried about and 
which you have been least worried about. 
 







 My child getting weaker  
 
 
 Managing my uncertainty about my child’s future  
 
 
 Affording care my child needs within the family budget  
 
 
 Having time for myself  
 
 
 My child feeling happy  
 
 
 My child having good friends  
 
 
Cognitive interviews with seven parents of individuals with DMD of varying ages and disease 
stages were used to assess comprehension, refine terminology, and explore the acceptability of 
the instrument; this is described in detail elsewhere (Peay et al. 2014a). During the interviews, 
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participants endorsed the face validity of the worry items (i.e., the items represented their 
significant worries) and consistently indicated more difficulty choosing an item of least worry 
than and item of most worry, suggesting successful item development. The worry statements 
and domains are shown in Table I.   
 






















In addition to the BWS tasks, the survey included participant demographics and health status, 
measured using the SF-12 (Ware et al. 1996). The SF-12 is scored into Physical and Mental 
Worry Item Domain 
 My child getting weaker  
Medical concerns 
 Getting the right care for my child over time  
 My child missing out on new treatments  
 Affording care my child needs within the family budget 
 My child feeling happy  
Child affect/emotion 
 My child having good friends  
 My child not being able to express deep worries  
 My child feeling like burden on the family  
 Managing my uncertainty about my child’s future 
Parent wellbeing 
 Being a good enough parent for my child 
 Me handling the emotional demands of Duchenne 
 Having time for myself  
 The wellbeing of my other children  
Family and social 
 My child becoming independent from me over time 
 Effect of Duchenne on my closest relationships  
 Feeling isolated from other families  
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Health Composite Scores (PCS and MCS, respectively) that range from 0 to 100, where a zero 
score indicates the lowest level of health and 100 indicates the highest level of health. Norm-
based scoring facilitates interpretation in that individual respondent sores below 45 and group 
mean score below 47 are below the average population range (Optum SF-12v2 Health Survey: 
Advantages of Norm-Based Scoring). We also obtained information about the health status and 
care information for the child with DMD, including age, number of affected children in the family, 
ambulation status, prior research experience, and whether the child has experienced a life-




Participants were parents or guardians of at least one living child with DMD. They lived in the 
United States, were at least 18 years of age, and were able to complete an online survey in 
English. The affected child could be any age or at any stage of disease.  
The survey was administered online using the Qualtrics survey system from January 17, 2013 
to February 21, 2013. Recruitment occurred using newsletter notices, social media, word-of-
mouth, and through emails from Parent Project Muscular Dystrophy and the DuchenneConnect 
self-report registry. The anonymous survey was determined to be exempt by the Western 
Institutional Review Board (# 1-756840-1). 
DATA ANALYSIS 
The dependent variable in BWS is the participants’ judgment about the extremes (in this case, 
most and least worrying items) in each profile that is presented to them (Molassiotis et al. 2012). 
The simplest analytic technique focuses on the number of times an attribute was chosen as best 
and as worst over all of the choice tasks. The analytic output, which we call the relative best-
minus-worst (BW) score, can be calculated by subtracting the number of times a feature was 
chosen as worst from the number of times it was chosen as best, then dividing by the total 
number of times it was available to be chosen (Flynn et al. 2007). 
Such simple methods have demonstrated a very high level of correlation with more complicated 
regression-based techniques (Gallego et al. 2012; Louviere and Flynn 2010). Like all techniques 
to estimate ordinal, multinomial outcomes, scoring assumes equal spacing between things that 
were chosen as best (BW score=1) and those chosen as worst (BW score=-1). The BW score is 
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estimated as a mean across the sample. This allows us to report the standard errors for these 
means and conduct t-tests to determine whether the scores were significantly different than 
zero. Additional information about the relative best-minus-worst analysis has been described 
elsewhere (Peay et al. 2014a).  
 
Next, we conducted a stratified analysis by calculating BW scores for parents/guardians with 
ambulatory children and those with non-ambulatory children. We used Spearman’s rho to 
compare the correlation of the rank order of worry items between the two groups. Finally, we 
conducted t-tests on BW scores for each worry, hypothesizing no statistically-significant 
differences across the ambulatory and non-ambulatory groups.  
RESULTS 
One hundred and nineteen caregivers who self-identified as being a parent or guardian of an 
individual with DMD included in the analysis. When dichotomized into an “ambulatory” group, 
defined as those who could walk independently outdoors for at least short distances, and a 
“non-ambulatory” group, defined as those who could not walk outdoors without help, 64% of 
children were in the ambulatory group and 36% in the non-ambulatory group. Table II 
summarizes the characteristics of the sample. Participants were predominately Caucasian, 
married, biological mothers, and had one affected child. There were no significant differences 
between the sample characteristics collected from the ambulatory and non-ambulatory groups 
except for ages of parent participants (M= 40.5, SD=6.1 for parents of ambulatory children 
versus M= 49.1, SD 7.1 for parents of non-ambulatory children, p<0.01) and their children (M= 










Participant characteristics     
Parent age in years 40.5 (SD=6.1) 49.1 (SD=7.1) <0.01 
Child age in years 8.8 (SD= 3.5) 18.0 (SD=6.3) <0.01 
Parent characteristics     
Relationship to child(ren) 
     Biological mother 68.4% 65.1% 0.72 
     Biological father 26.3% 32.6% 0.47 
     Adoptive mother 5.3% 0.0% 0.13 
     Adoptive father 0.0% 2.3% 0.18 
Marital status 
     Married/long-term relationship 93.4% 83.7% 0.09 
     Divorced/Separated 6.6% 14.0% 0.19 
     Widowed 0.0% 2.3% 0.18 
Race 
     Caucasian 89.5% 95.3% 0.27 
Education 
     High school/GED 6.6% 0.0% 0.09 
     Some college 10.5% 20.9% 0.12 
     Technical school 3.9% 7.0% 0.47 
     Associated degree 5.3% 11.6% 0.21 
     Four-year college degree 43.4% 41.9% 0.87 
     Graduate/professional degree 28.9% 18.6% 0.22 
Income 
     <$25,000 3.9% 9.3% 0.24 
     $25,000-$50,000 6.6% 11.6% 0.34 
     $50,000-$75,000 22.4% 11.6% 0.15 
     $75,000-$100,000 18.4% 18.6% 0.98 
     >$100,000 47.4% 46.5% 0.93 
Child characteristics     
Number of affected children 
     One child 94.7% 88.4% 0.21 
     Two or more children 5.3% 11.6% 0.21 
Research participation 
     Clinical research 53.3% 65.1% 0.22 
     Clinical trial 29.3% 41.9% 0.17 
Had life-threatening emergency 
     Yes 14.5% 25.6% 0.14 
Ambulatory= ability to walk independently outside for at least short distances. Note: In some cases, percents do not add to 
100% because of missing values. 
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The SF-12 health status results indicate that our participants were physically healthier than the 
general population, with physical component scores above normative scores in 72% and at or 
below norm in 28%. However, 57% of participants had mental component scores (MCS) that 
were below the norm, 35% in the normative range, and 8% above the norm. 45 participants 
(40%) were identified to be at increased risk for depression compared to 20% in the normative 
group. The mean MCS for parents of non-ambulatory children (M=44.4, SD 11.9) was 
significantly higher than the mean score for parents of ambulatory children (M=39.8, SD=11.7) 
on independent-samples t-test, t (117)= 2.05, p=0.04, two tailed. 
WORRY PRIORITIZATION 
Figure II shows the worry prioritization task’s best-worst scores. In the total group, worry about 
“my child getting weaker” was identified as most concerning (BW score 0.64, p<0.001). 
Respondents also prioritized “getting the right care for my child over time” (0.25, p<0.001) and 
“child missing out on new treatments” (0.25, p<0.001); each of the three most prioritized items 
were under the “medical concerns” domain. “My child feeling happy” was the most prioritized of 
the child affect/emotion domain (0.16, p<0.001). “Managing my uncertainty about my child’s 
future” was the most prioritized of the parent wellbeing domain (0.13, p<0.001). In the family 
and social domain, which overall was not highly prioritized compared to the other domains, “the 
wellbeing of my other children” was the most prioritized (-0.04, p=.01). The least prioritized 
items were “Having time for myself” (-0.56, p<0.001) and “Feeling isolated from other families” (-
0.30, p<0.001).  
 
Priorities for parents of ambulatory and non-ambulatory children are also shown in Figure II. 
Parents of ambulatory children prioritized “missing out on new treatments” significantly more 
than parents of non-ambulatory children, t (118)= 3.34, p<0.001, two tailed. Parents of 
ambulatory children were also more likely to prioritize “being a good enough parent” than 
parents of non-ambulatory children t (118)= 2.50, p=0.01, two tailed. In contrast, parents of non-
ambulatory children were more likely to prioritize “child feeling like a burden on the family” than 
parents of ambulatory children, t (118)= 3.50, p<0.001, two tailed. Finally, in comparing the rank 










score P value 95% CI
My child getting weaker 0.637 0.000 ( 0.67 , 0.60)
Getting the right care for my child over time 0.254 0.000 ( 0.29 , 0.22)
My child missing out on new treatments 0.245 0.000 ( 0.29 , 0.20)
My child feeling happy 0.161 0.000 ( 0.20 , 0.12)
Managing my uncertainty about my child's future 0.127 0.000 ( 0.16 , 0.09)
Afforiding care my child needs within the family bud 0.065 0.000 ( 0.10 , 0.03)
My child having good friends 0.038 0.025 ( 0.08 , 0.00)
My child not being able to express deep worries 0.025 0.061 ( 0.06 , 0.01)
Being a good enough parent for my child 0.012 0.319 ( 0.06 , 0.04)
The wellbeing of my other children 0.038 0.013 (0.00 , 0.07)
Me handling the emotional demands of Duchenne 0.049 0.003 (0.01 , 0.08)
My child feeling like a burden on the family 0.179 0.000 (0.14 , 0.22)
Effect of Duchenne on my closest relationships 0.217 0.000 (0.18 , 0.25)
My child becoming independent fromme over time 0.232 0.000 (0.20 , 0.27)
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DISCUSSION
Assessing disease impact is necessary to understand the experience of patients and 
caregivers, improve care provision, and inform policy. In our study describing parental DMD-
related worry, respondents ranked the child’s disease management as of greatest immediate 
worry, followed by worry about the child’s affect. The impacts of DMD on the family and parents’ 
wellbeing were less prioritized. In interpreting the results it is important to keep in mind a 
primary strength of Best-Worst Scaling: it allows prioritization among items that may each be 
valued. Thus family and parent wellbeing may be highly important, but comparatively not as 
important as child disease management. 
 
Parents of non-ambulatory children had higher SF-12 MCS scores than parents of ambulatory 
children, which suggests adaptation to the disorder over time. Overall, the worries prioritization 
was similar between groups. Though both groups prioritized child medical items, the higher 
prioritization of worry about “missing out on new treatments” by parents of ambulatory children 
may reflect increased optimism for new treatment opportunities juxtaposed with a perception of 
a limited window during which treatment may be most effective (Peay et al. 2014b). In contrast, 
parents of non-ambulatory children may be resigned to fewer treatment opportunities for their 
children (Murray 2014) and focus more worry on their children feeling like a burden on the family 
as their symptoms progress.  
STUDY LIMITATIONS 
There are several limitations to the study. First, the recruitment of caregivers through advocacy 
groups, while pragmatic and efficient, has a risk of selection bias. Second, we did not publish 
the preliminary, qualitative work where we identified the worry items and domains, though this 
has been done for other studies (for example, Ross et al., 2014) and is ideal. In addition, the 
domains were determined based on expert consensus and in future studies should be validated. 
Third, we conducted an aggregate analysis and pre-specified stratification by ambulation status, 
and important structures in preference heterogeneity may have been overlooked. Future 
research should consider a larger sample size to allow for additional stratification and 
segmentation analysis to adequately describe preference heterogeneity. Finally, future research 
should elicit DMD-related priorities from affected teenagers and adults, anticipating that DMD 






We found high prioritization of worries about disease management in caregivers who manage 
their children’s DMD and make treatment decisions. Taken together with the parents’ SF-12 
results, the data present a parent population exhibiting negative psychosocial impact that is 
likely related to caring for a child with DMD. For genetics providers and other health 
professionals, a primary goal in assessing illness representations is to identify outcomes that 
are potentially alterable and inform service provision (Hale et al. 2007). Regardless of the child’s 
disease progression, the strong prioritization of worries about weakness progression suggests 
that interventions that aim to reduce negative psychosocial impact on parents may be most 
effective when provided in conjunction with care-related interventions for the affected child. 
RESEARCH RECOMMENDATIONS 
 
To our knowledge this study represents the first published use of BWS to prioritize among 
emotion-focused illness representations. Here we present a feasible, replicable community-
engaged approach that demonstrates how BWS Case 1 provides an appealing alternative to 
quantitative rating scales. BWS Case 1 has been shown to outperform rating scales (Lee et al. 
2007) and it has a particular strength in requiring participants to discriminate among items 
(Louvierre and Flynn 2010). It may be especially compelling for use in clinical settings because 
it allows estimation of preferences at an individual patient level (Louvierre and Flynn 2010), 
facilitating the development of clinical interventions. As we have shown, BWS benefits from a 
straightforward analytic approach without the need for specialized software and the results are 
intuitively understood. Thus BWS represents a rich, accessible analytic tool for clinicians and 
clinical researchers that can be used effectively across a wide range of clinical applications.  
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Expectations and experiences of investigators
and parents involved in a clinical trial for
Duchenne/Becker muscular dystrophy
Holly L Peaya,b, Aad Tibbenb, Tyler Fishera, Ethan Brennaa and Barbara B Bieseckera
Background The social context of rare disease research is changing, with increased
community engagement around drug development and clinical trials. This engage-
ment may benefit patients and families but may also lead to heightened trial expec-
tations and therapeutic misconception. Clinical investigators are also susceptible to
harboring high expectations. Little is known about parental motivations and expec-
tations for clinical trials for rare pediatric disorders.
Purpose We describe the experience of parents and clinical investigators involved
in a phase II clinical trial for Duchenne and Becker muscular dystrophy: their expec-
tations, hopes, motivations, and reactions to the termination of the trial.
Methods This qualitative study was based on interviews with clinical investigators
and parents of sons with Duchenne and Becker muscular dystrophy (DBMD) who
participated in the phase IIa or IIb ataluren clinical trial in the United States. Inter-
views were transcribed and coded for thematic analysis.
Results Participants were 12 parents of affected boys receiving active drug and 9
clinical investigators. High trial expectations of direct benefit were reported by par-
ents and many clinicians. Investigators described monitoring and managing parents’
expectations; several worried about their own involvement in increasing parents’
expectations. Most parents were able to differentiate their expectations from their
optimistic hopes for a cure. Parents’ expectations arose from other parents, advo-
cacy organizations, and the sponsor. All parents reported some degree of clinical
benefit to their children. Secondary benefits were hopefulness and powerful feelings
associated with active efforts to affect the disease course. Parents and clinical investi-
gators reported strong, close relationships that were mutually important. Parents
and clinicians felt valued by the sponsor for the majority of the trial. When the trial
abruptly stopped, they described loss of engagement, distress, and feeling unpre-
pared for the possibility of trial termination.
Limitations This was a retrospective study of one clinical trial. We were unable to
recruit participants whose children received placebo. The interviews occurred during
a time of significant uncertainty and distress for many of the participants.
Conclusion This pilot study reflects complex outcomes of strong community
engagement. The findings highlight a need for renewed education about, and sup-
port for, clinical trial termination and loss of drug access. The primary positive out-
come was demonstration of strong relationships among committed parents and
study teams. These relationships were highly valued by both parties and may
suggest an ideal intervention opportunity for efforts to improve psychological
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well-being. A negative outcome attributed, in part, to community engagement was
inappropriately high trial expectations. More optimistically, high expectations were
attributed, in part, to the importance of hope and powerful feelings associated with
active efforts to affect the disease course. Clinical Trials 2013; 0: 1–9. http://
ctj.sagepub.com
Background
Advances in research are leading to promising
potential therapeutics for the treatment of rare dis-
orders. Simultaneously, the social context of rare
disease research is changing, with increased commu-
nity engagement around drug development and
clinical trials. Greater knowledge and personal
involvement for patients and families may come
with significant feelings of hopefulness and respon-
sibility, and with enhanced assumptions about
access and involvement in the clinical trial process.
Greater involvement may also encourage unrealistic
expectations of the patient/family role in trial
execution and of the treatment under trial. Family
well-being may be threatened when expectations
are unrealistic and when boundaries are unclear.
Values, motivations, and relationships among
clinical trial partners
Clinical trial participants
Commonly cited reasons for participating in clinical
trials are altruism (e.g., contributing to science and/
or helping others with the disorder) and the poten-
tial for personal benefit [1,2]. Recent studies suggest
that the potential for personal benefit is at least as
common, if not more common, a motivator as altru-
ism [2–4]. Personal benefit as a motivator may reflect
inappropriately high expectations for a successful
trial outcome.
Bioethics scholars and clinical investigators have
raised concerns about informed decision making by
individuals with life-threatening disease and limited
treatment options [5,6]. One particular concern is
therapeutic misconception:
... when individuals do not understand that the defin-
ing purpose of clinical research is to produce generaliz-
able knowledge, regardless of whether the subjects
enrolled in the trial may potentially benefit from the
intervention under study or from other aspects of the
clinical trial. [7]
Others have highlighted the importance of opti-
mism and hope to clinical trial participants which
may not stem from ignorance or confusion, that is,
may not reflect therapeutic misconception [8–10];
yet unwarranted situational optimism continues
to raise concerns about vulnerability to exploitation
of research participants and concerns about
uninformed decision making [10]. The concept of
therapeutic ‘misestimation’ (an over- or underesti-
mation of benefit or risk in a clinical trial) has been
proposed as a further distinction to account for
unwarranted optimism without therapeutic miscon-
ception [9].
Parent decision makers in pediatric trials
The majority of data on motivations and percep-
tions of trial participation come from adults making
decisions about their own participation. A recent
synthesis of 22 qualitative studies of pediatric oncol-
ogy clinical trials [11] concluded that informed con-
sent is difficult to achieve due to the complexity of
the protocols, parents’ emotional distress, and their
feelings of dependency on the child’s physician. Par-
ents frequently and inaccurately attributed thera-
peutic intent to research procedures in these studies.
Parents reveal desires to act in best interest of the
child and fear of making the ‘wrong decision’ about
their child’s participation in a clinical trial [11].
The clinician investigator
Several studies have identified role ambiguity among
healthcare providers engaged in clinical research,
which arises from a struggle to balance the responsi-
bilities associated with being a clinician and a
researcher [12–14], and may lead to conflicts of
interest and therapeutic misconception and may
undermine the authenticity of the consent process.
Unwarranted optimism/therapeutic misconception
has been identified among clinical investigators
executing trials [7,15].
Purpose
We sought to explore the dynamic nature of stake-
holder relationships in a clinical trial sponsored by a
small biotech company for Duchenne and Becker
muscular dystrophy (DBMD). Duchenne muscular
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dystrophy (DMD) is a progressive, ultimately fatal
neurological disorder with a strong advocacy and
support community. Becker muscular dystrophy
(BMD) is a less severe disease manifestation that is
caused by mutations in the same dystrophin gene.
A study of 19 participants and their parents in a
European trial provided data on the impact of parti-
cipating in an exon-skipping trial for DBMD [16].
The impact was rated as positive (42%) or neutral
(35%) by the majority of parents, and all participat-
ing families were determined to have adequate
knowledge and realistic expectations of the clinical
trial [16].
The ataluren clinical trial
In 2005, PTC Therapeutics reported a successful phase
I trial with PTC 124 (ataluren), a compound designed
to promote ribosomal read-through of premature stop
codons in messenger RNA (mRNA) [17]. Early in
2006, PTC Therapeutics initiated a 28-day phase IIa
clinical trial in 38 participants, and in 2008 initiated a
48-week phase IIb international randomized study
with placebo, low dose, and high dose arms. Partici-
pants were 5 years of age or older and had the ability
to walk 75 m unassisted, among other inclusion cri-
teria. There were 15 US study sites. In 2009, enroll-
ment closed after 174 patients were recruited.
In March 2010, the sponsor reported that preli-
minary results showed no statistically significant
improvement to the primary endpoint, the 6-min
walk test, for participants on the high dose. All trials
of ataluren in DBMD were stopped and the investi-
gators unblinded the study. In April 2010, detailed
data analysis was presented, suggesting that low-
dose ataluren may have clinical benefit [17].
At the time of the interviews for this study, the
dosing of trial participants was unblinded. Parents
of participants had been informed of the data sug-
gesting benefit of low-dose ataluren. When we
started interviews, boys in the trial had lost access to
the drug and future access was unknown. Midway
through the interview study, an open-label study
was initiated for trial participants. Although our
initial aim was to explore the experience of parents
and clinician investigators involved in a clinical trial
for a rare disorder, we were also able to explore parti-
cipation in a trial that came to an abrupt, unex-
pected end. To date, an open-label trial (http://
www.clinicaltrials.gov/ct2/show/NCT01247207?term=
ataluren&rank=9) continues for participants in the
phase IIa and IIb trials.
Study aims
This study aimed to describe the experience of par-
ents and clinical investigators who were involved in
a phase II clinical trial of ataluren for DBMD. Speci-
fically, we describe expectations, hopes, and motiva-
tions of each group, as well as reactions to the
termination of the trial.
Methods
We conducted semistructured telephone interviews
with clinical investigators and parents of sons with
DBMD who participated in the phase IIa or IIb ata-
luren clinical trial in the United States. The topics
explored during the interviews – experiences in the
trial, hopes, and expectations; perceptions of bene-
fit; and relationships among stakeholders – were
informed by the literature and clinical and anecdo-
tal experience. Because these sources suggested that
expectations and hopes for a clinical trial may differ,
we asked participants to describe both their hopes
and expectations.
Using NVivo 8 QSR, a qualitative analysis software
package, the responses were analyzed by two inde-
pendent investigators (T.F. and E.B.) to ensure cod-
ing consistency and high intercoder reliability.
Discrepancies in the coding were discussed until
reconciliation was achieved. All analyses were based
on consensus codes. We conducted thematic analy-
sis within and between the parent group and the
clinician investigator group. Major themes that
arose from the analysis and illustrative quotes are
presented.
Parent participants were recruited through advo-
cacy organizations and snowball recruiting. Clinical
investigators at the 15 US clinical trial sites were
directly contacted. Nine investigators and 12 par-
ents of individuals in the ataluren trial were inter-
viewed between October 2010 and June 2011. We
continued recruitment of the investigators until we
achieved the highest possible participation after
making three requests of each study site. We contin-
ued recruitment of parents until we achieved satura-
tion (i.e., information redundancy). The sons of all
parent participants received active drug (low or high
dose) during the trial. We made a second attempt to
recruit parents whose children were on placebo, but
we were unsuccessful. This is described later as a
limitation of this study.
Results
Participants
The study included 6 fathers and 6 mothers of
11 boys with DMD (including 1 mother–father pair)
and 9 clinical investigators. All participated at US
study sites.
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Expectations and hopes for the clinical trial
Parents
As previously described, we asked participants to dif-
ferentiate between expectations and hopes.
Although participants’ default terminology was
‘hope’, most parents were able to clearly differenti-
ate between expectations and hopes. Participants
described expectations in terms of ‘what I thought
would happen’ or ‘feeling confident about’ versus
their hopes as an optimistic view toward the best
possible outcome.
Most of the parents reported and demonstrated
being well informed about the trial. They reported
multiple sources of information that contributed to
the formulation of their expectations: their own
research into the drug; information from advocacy
organizations and parent communities; communi-
cation with the sponsors’ representatives and access
to their promotional materials; and communication
with clinicians. Parents frequently referenced the
drug safety profile and results from animal studies.
All parents reported expecting some direct benefit
of the drug, usually described as slowing or stabiliz-
ing progression of the disorder. Two parents
described finding it difficult to manage their
expectations.
I did my research so thoroughly that I was convinced
that it was a cure. When you look at the information
that they presented in the lab with the animals and
stuff. (Father 107)
Well, I think we understood the benefits ... that the
transcription process of the DNA would start working
and read over the stop code and then he starts develop-
ing full-length dystrophin. As far as the actual, you
know, what that would mean to him for his muscular
ability, we really had no idea whether it would be dra-
matic or inconsequential. But if it would just mean he
would at best get stronger or at a minimum at least
maintain strength or something, yes. (Father 111)
Almost all parents hoped for significant improve-
ment in strength, endurance, school performance,
and/or quality of life. Many discussed the trial repre-
senting the possibility for a cure; while some
believed this to be a reasonable hope, others identi-
fied it as overly optimistic. Parents further described
the ability to have hope for improvement in their
sons as an important secondary benefit.
I think we hoped that he’d be fixed. I mean the ulti-
mate hope that this change with the skipping over his
premature stop codon would instantly make him strong
and that all his issues that are related to muscular dys-
trophy, the cognitive issues and everything would just
disappear and, I think that’s a little naı̈ve. But that’s the
big hope. So still, and I think as far as expectations go,
we would have been happy with just knowing that he
was going to retain some strength longer, and have
some improvement on all fronts. (Mother 108)
Clinical investigators
Five of nine investigators reported starting the trial
with expectations for some degree of improvement
or stabilization of the disease course. Two investiga-
tors reported modest expectations and hopes based
on past clinical trial experience. Several investigators
reported that relationships with trial participants
increased their hopes and described developing an
emotional investment in the outcome. Three parti-
cipants voiced retrospective concerns about having
been too positive with the families.
I think that I allowed myself to get more optimistic
then was warranted ... I was more emotionally ...
invested in it than I had intended to be and was actu-
ally quite hopeful that we were going to get something
... The thing that I hope that I can do a better job of is
kind of maintaining my equanimity more [during
future studies]. (Investigator 2)
I was exceedingly hopeful that there would be some
very positive outcomes. The [stop codon read-through]
theory sounded great. And I thought that looking at
the studies it was relatively safe. So I was actually hop-
ing for a wonderful improvement in overall strength
and stamina for the boys. (Investigator 6)
All of the investigators reported that the parents
in their cohort expected benefit. Many found the
degree of parental expectation and hopefulness con-
cerning and difficult to manage.
I think the Duchene boys and the parents were hoping
that it would slow the disease down so they would
become Becker, and you know not go into a wheelchair
at age 12, 10 to 12, I think that’s what they were hop-
ing. (Investigator 1)
The parents’ expectations were unrealistic. They were
hoping for a cure. They were sending information to
one another. A 50/50 chance for improvement would
have been more realistic. (Investigator 5)
Most of the clinicians referenced efforts that they
took to help mitigate parents’ expectations, but sev-
eral voiced concerns that they did not do enough to
promote reasonable expectations. Several clinicians
described high ‘DMD community’ expectations that
made it difficult to moderate their own expectations,
as well as those of parents.
My concern on that front was more that we were rais-
ing expectations into the patient population ... We wer-
en’t keeping a lid on the expectations ... and I don’t
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know how you avoid it, and we all hope that we are
not supposed to be coercive right, dealing with research
subjects. I’m inherently coercive, that’s just part of my
scene, I mean whether I want to be or not. I mean it,
the patients support us in that role ... we’re supposed to
be finding treatments for them. (Investigator 2)
I’ve seen this in many of the studies that we do. Their
emotions get in the way. And when they hear ‘experi-
mental treatment’, they only hear the ‘treatment’ part
of it. (Investigator 3)
Motivations and decision making
Parents
Uniformly, parents’ primary motivation for enrol-
ling was the potential for benefit. Parents described
a feeling of investment in the trial, excitement at
being involved, and enthusiasm at having some-
thing to do to attempt to alter the disease course.
I was excited, I have to tell you. I was excited because I
had another potential tool to help me with my son’s
disease. (Father 100)
Less than half of the parents mentioned altruism
as one of their motives.
Any positive gain, you have to do it for the other boys
coming up, you know? So you just – you feel com-
mitted ... you hope and pray that it could be with your
boy, but if not, then future boys. (Father 107)
Most of the parents reported an easy decision or a
‘non-decision’ to join the clinical trial, that is, they
never considered not enrolling their sons if they
were accepted. However, parents also discussed their
responsibility to understand the trial, specifically
the risks and possible side effects. Few parents
reported their clinician having a significant role in
their decision making; rather, the clinicians supplied
additional information and support. All of the par-
ents perceived the risks as very low based on drug
safety information. Even given the uncertain time
during which we conducted the interviews, there
was little evidence of decisional regret, except for
wishing the children had fewer biopsies and
blood draws. For most parents, the most difficult
decisions related to managing the trial logistics and
demands.
[The decision to participate] was a no-brainer. (Mother
109)
Most of the parents spoke knowledgably about
the drug mechanism of action and discussed feeling
that the drug ‘should work’. Many parents described
positive attributes of their child’s dystrophin
mutation, given its compatibility with the drug’s
mechanism of action. Several parents described feel-
ing ‘lucky’ to have a child with the ‘right’ type of
mutation for the trial. Several reported that their
providers reinforced these perceptions.
To be honest I was so excited to have him have the pos-
sibility of a trial and I did not have a ton of concerns.
At one point post diagnosis ... right after they found
out that it was a stop mutation they said ‘we’ve got the
worse possible news, but the best within the worse pos-
sible news’ and that ‘there is this drug ...’. (Mother 112)
Clinical investigators
Most of the clinicians actively sought out an oppor-
tunity to participate as a trial site. It was gratifying
and exciting to offer something other than standard
management, especially given the disease course.
Many clinicians were motivated by the novel, tar-
geted approach of the drug.
It made me so excited. I thought it was a wonderful
opportunity-history in the making! Working with the
kids, it reminded me that I am a clinician primarily and
that we were going through this together, sharing the
intimate details of their lives. (Investigator 5)
All of the clinicians perceived that parents
enrolled their children in hopes of benefit to the
child.
I think that they ultimately believed that this was going
to alter the course of their kids’ disease ... there is no
confusion on that for me, you know that was specifi-
cally stated to me over and over again. ‘My son has to
get in this study, I mean this is critical for him, we
know he is fortunate to have an appropriate genetic
cause, and you know if he doesn’t get in the study, he’s
going to die’. And it didn’t much matter what I said.
(Investigator 2)
Pressures of a progressive disorder
Parents and investigators spoke about the pressures
of a progressive, fatal disorder, and how these pres-
sures played a role in decisions about and expecta-
tions of clinical trials. There were recurrent themes
of ‘time being the enemy’ in DBMD. Parents felt a
responsibility to participate in research before their
children lost the ability to walk, and clinicians felt
responsible for educating families about trials and
offering participation. The ultimate pressure was
knowing that ‘doing nothing’ was commensurate
with accepting disease progression and early death.
Having Duchenne muscular dystrophy, it’s all about
the time. Once they are in a chair then everything goes
downhill quickly for them far as their health ... I just
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started researching and wanted to be in [the trial] as
quickly as I can, whether, you know – not even weigh-
ing out the bad side effects, ’cause I already know all
the side effects [of DMD] for him. (Father 107)
Perceptions of benefits
Parents
The parents delineated direct and indirect benefits
of trial participation. All parents reported some
degree of direct benefit for their boys, ranging from
obvious improvements to subtle changes. These
benefits included improved strength, endurance,
and cognitive performance. A few parents described
being unsure about whether there was benefit until
they noted declines following the sudden end of
access to the drug.
It felt like we had seen such tremendous improvement,
we had no doubt in our mind that – that he was bene-
fiting from it. (Mother 101)
I felt like he was working with me and he was stronger.
He also felt that way ... And I said, well let’s be cautious
with this subjective type of measure ... about two weeks
after he was off the medication he felt he got back to
the stage before [the trial started]. So that gives a lot of
confidence that the medication does have benefit. And
we got the parameters like CK dropping and all these
things. (Father 104)
The parents also described important secondary
benefits including positive relationships with the
study team and the psychological benefits of hope-
fulness and active engagement in an effort to change
the course and outcome of DMD.
Clinical investigators
The clinical investigators described widespread par-
ental perceptions of benefit; several reported that
they also perceived benefit to cognitive performance
or strength in certain patients.
Reactions to trial ending
Parents
Parents reported anger, shock, and distress when the
trial was stopped. The parents described feeling
powerless and that they lost the hopefulness that
the trial offered. The halt was sudden and unex-
pected. Parents expected such a sudden halt only if
where there were drug safety concerns, which was
not the case. Several parents were able to appreciate
that ‘these things happen’ in clinical trials and it
‘depends on the data’.
The trial had stopped and I was in a state of shock ...
One minute you’re participating in a study, you think
you’re making a difference, you think it’s going along
well and by the way, I’m kind of a skeptic but I really
felt there was no question that this drug was having
benefit for my son. (Father 100)
When he called up and said stop taking the medicine, I
felt that conversation was worse than the diagnosis
phone call when they told me he had muscular dystro-
phy ... hope goes a long way, and to take that from a
family is just pretty devastating ... The shattering part
was because it was his cure. (Father 107)
Almost all parents expressed a belief that the deci-
sion to stop the trial was also traumatic to the spon-
soring company and the clinician investigators.
Until the trial stopped, parents felt that they had a
good relationship with the sponsor, with abundant
communication and recognition of their important
role in a team effort. At the termination of the trial,
parents wished for more communication from the
sponsor about decisions and the path forward. Some
parents came to be impressed over time with the
sponsor’s willingness to engage the parents through
advocacy forums. Other parents felt that the part-
nership between the sponsor and the parents totally
broke down and that the sponsor no longer valued
them.
Several parents noted the need to better prepare
participants for the possibility of a trial ending
abruptly.
I think I was never prepared that the trial would end. I
never in my mind had thought that was even a remote
possibility and I think that would be the advice that I
would give [to other parents] to help to understand that
the clinical trials is a not an FDA approved drug. Just
because things look good doesn’t necessarily mean that
it’s gonna end the way you think it’s gonna end. And,
you need to prepare yourself for that, or prepare your
son for that too. (Mother 112)
Clinical investigators
The clinicians reported generally good experiences
with the sponsor until the trial halted. Most investi-
gators felt that the decision to stop the trial was
abrupt, and the urgency was unnecessary given the
lack of safety concerns. Many investigators felt that
the company was evasive about the decision and
wished that they had been consulted.
The investigators had the difficult role of inform-
ing families about the trial end and asking them to
return the drug. Most clinicians reported having to
manage the parents’ shock and anger. Clinicians
described that the negative effects of the trial ending
were exacerbated by parent and DBMD community
perceptions of drug benefit.
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Well they think the low dose is working ... they never
bought the negative results. And they are adamant to
varying degrees that ataluren is still the best hope for
their kids and that the FDA is not being fair and not
allowing them to continue on with it, and PTC is not
advocating it adequately for them ... And that was from
absolutely day one, when this broke, we were just bom-
barded with complaints and concerns and a statement
that this couldn’t be true because our kids are doing so
much better, this just has to be rectified, you are killing
our kids. (Investigator 2)
Willingness to participate in another clinical trial
All but two parents reported that they would partici-
pate in a future clinical trial, citing one or more of the
following: positive experiences during the ataluren
trial, the psychological benefits of attempting to exert
control over the disease course, and the psychological
benefits of hope. Two parents were unsure and
ascribed their uncertainty to the fact that their chil-
dren had lost the ability to walk, limiting their elig-
ibility for trials of interest. Several parents would pay
more attention to the time commitment and logistics
in a subsequent trial. Half of the participants sponta-
neously offered that they would ‘do it all again’.
Relationships among stakeholders
An overarching theme was the importance of rela-
tionships and information sharing among the stake-
holders. Parents and clinicians described the mutual
importance of their relationships to the success of
the trial and to psychological well-being.
They [the clinical trial team] were just so nice and so
hopeful ... And they’re family, you know. (Father 106)
We became almost like a family because we saw them
so frequently and I saw them every time they came.
And it was just not the boy’s excitement, it’s really the
family’s excitement I enjoyed, my experience with the
families, their enthusiasm for this trial. (Investigator 4)
Parents noted that industry sponsors and clini-
cians should expect to have regular, organized com-
munication with families. The parents were aware
of and understanding about the communication
restraints on the industry sponsors and appreciated
that not all information could be shared. Similarly,
many clinicians said that the sponsor should have
consulted them more often; they felt that their per-
spectives and experiences would have proved valu-
able to the clinical trial.
Limitations
This was a pilot, retrospective study of experiences
in one clinical trial. We were not able to recruit any
parents whose children received placebo, and thus,
we have no ability to compare or contrast their
views to those of parents whose children were on
active drug. Although we had a good response rate
from the clinical investigators, with 12 investigators
from 15 sites participating, we did not achieve
saturation on all of the topics. It is important to
evaluate these data in light of the time when these
interviews occurred – one of significant uncertainty
and distress for many of the participants.
Conclusion
This pilot study describes complexities of an increas-
ingly collaborative clinical trial experience for rare
pediatric disorders. Although this is an exploratory
study, the themes identified in this study have
implications for sponsors, researchers, advocacy
organizations, and families as they embark upon
partnerships to facilitate the development of novel
therapeutics. Before the ataluren trial was halted, it
represented a successful effort toward mutual
empowerment that reflected calls for increased par-
ticipation in the research process by affected indivi-
duals, family members, and advocacy groups
[18,19]. However, it is important to recognize differ-
ences in the values and motivations of the stake-
holders [20], including industry, scientists,
clinicians, and patients who must work together to
uphold the integrity of the clinical trial. Differing
interests became striking during and after the trial
termination, when parents and clinicians reported a
loss of power and control that was distressing and
confusing.
Parent participants displayed remarkable knowl-
edge of the drug under trial and the clinical trial
process. Yet, overall, they were not prepared for the
most likely outcome of any clinical trial – a failure
to show the required effect on the primary study
endpoint. This study highlights a need for renewed
emphasis on education about, and psychological
support for, a nonsuccessful trial and the resulting
loss of access to the drug.
The parents’ decision making about trial participa-
tion was driven by the progressive nature of the dis-
order. Although parent expectations were high and
they hoped for a cure, their expectations should be
interpreted in light of the importance of hope and
the powerful feelings associated with being able to
engage in active efforts to affect the disease course.
Unlike the findings of Garralda et al. [16], there was
suggestion of therapeutic misconception among the
parents, in that parents generally described the
study in terms of individual benefit rather than an
effort to gain generalizable knowledge. Yet, the par-
ents’ focus on individual benefit seemed to reflect
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emotional engagement rather than a misunder-
standing of the trial goals, suggesting a dissonance
between their cognitive understanding and emo-
tional representation of the trial. The parents’ emo-
tional investment resulted in notable therapeutic
optimism and misestimation.
We also found evidence of therapeutic misestima-
tion in the clinician population. The investigators
were in the difficult position of having to monitor
and manage the expectations and hopes of the par-
ticipants. Several clinicians worried about their own
involvement in increasing parents’ expectations
during the trial. Yet the parents reported that their
expectations originated primarily from sources other
than the clinicians – notably, the sponsor and the
‘community’. This assertion should be cautiously
interpreted given the retrospective nature of the
study and the multifaceted and subconscious nature
of variables that contribute to expectations. The
effect of overly optimistic advocacy communities
on DBMD clinical trial participants has been raised
by Woods et al. [21], who suggest that a ‘collective
therapeutic misconception’ may be propagated by
neuromuscular disorder advocacy organizations to
patients and families.
This study reinforces the importance of engaging
clinical trial participants or their proxy decision
makers around both expectations and hopes to
achieve a more measured understanding of decision
making and therapeutic optimism. Our results sup-
port those of Jansen et al. [22], who found that parti-
cipants showed optimistic bias related to benefit but
less so related to cure. Our participants had high
expectations for benefit, but most were able to dif-
ferentiate between those high expectations and
their hopes for a cure.
The interviews suggest that the mechanism of
action of the drug under trial may have increased
expectations for some parents and clinicians. Hen-
derson et al.’s [7] data suggest that subjects’ impres-
sions of technical aspects of the intervention may
affect expectations and lead to therapeutic miscon-
ception. This is specifically relevant to the DBMD
community, as several other mutation-specific thera-
pies are under trial or in pre-clinical development.
A central theme was the importance of the highly
valued ‘family-like’ relationships that developed
between the participants and the study site teams.
Similarly, Kost et al. [2] found that the factor most
associated with a positive view of the research
experience was developing a close relationship with
the study team. In this study, the benefits of close
relationships were a group of engaged, committed
participants who took their trial participation ser-
iously and had great trust in the study team, and a
group of engaged, committed clinicians who were
eager to be involved in clinical trials and recruit
patients with a true hope of benefit. These
relationships were especially important to partici-
pants when their perceived control or feelings of
empowerment were threatened. Possible downsides
of the close relationships may be inaccurately
enhancing the expectations and hopes of parents
and some of the clinician investigators, and insuffi-
cient emotional distance between the clinicians and
the families involved in this study. Parent–clinician
relationships may provide an ideal intervention
point for efforts to improve participant and family
well-being related to clinical trial participation.
Future research that includes a broader range of
clinical trials is needed to better understand motiva-
tions, expectations, hopes, and how benefits are
defined and valued in pediatric clinical trials for pro-
gressive, fatal disorders. These studies may explore
the associations among perceived vulnerability, con-
trol, and stakeholder relationships and roles. Data
from future studies may also inform important ethi-
cal considerations about benefit–risk determinations
(e.g., the extent to which family–clinician relation-
ships within a clinical trial context should be con-
sidered as secondary benefits). Ultimately, such
research may further inform ways to maintain the
benefits of an enmeshed clinical trial community
while minimizing the associated risks.
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Objective: Little is known about how parents who consented to children’s participation 
experience benefits and burdens during clinical trials. This understanding may facilitate 
informed consent and maintain participation. 
Methods: Using interviews, we explored benefit/burden assessments of parents of children with 
Duchenne muscular dystrophy (DMD) during and after trials. 
Results: Fifteen parents described a complex, dynamic process of defining, evaluating, and 
assessing “net benefit”. Most parents perceived direct DMD-related benefits. They monitored for 
benefits but felt hampered without trial data and due to DMD’s progressive course. Participants 
expressed frustration that outcome measures did not reflect outcomes of importance. Other 
perceived benefits included altruism, close relationships with the research team, and optimism. 
Burden was variable across trials, including time and travel, financial impact, insufficient 
communication, and clinical procedures. 
Conclusions: Our results suggest the importance of a reasonable match between parents’ 
expected and experienced benefits. Parent decision-makers may be particularly motivated to 
perceive benefits to justify exposing children to burden and risks. Dynamic benefit-risk 
assessment resulted in sufficient motivation to remain in the trial even when participation was 
burdensome. With rare disorders such as DMD, recruitment and retention concerns are 
especially relevant and must be balanced against feasible, unbiased, and yet permissive trials. 
INTRODUCTION
Duchenne muscular dystrophy (DMD is a recessive degenerative muscular disease that occurs 
in approximately 1 in 3,500 males.1 On average, diagnosis occurs at age 5 with loss of 
ambulation occurring between the ages of 7 and 13.2 The average life expectancy is in the late 
20s.3 Those affected and their caregivers face significant burden related to disease progression, 
ongoing care demands, and financial impact.4-7 There is no cure for DMD, nor are there any 
FDA-approved therapies.2 However, there are several potential treatments that are currently 
being studied in clinical trials and others in pre-clinical development.8
Caregivers may look to these new potential treatments as a way to maintain optimism when 
faced with a progressive, fatal disorder,9-11 and caregivers whose children are enrolled in trials 
may be motivated by hope for the potential benefits these trials offer.9 Clinical trials for DMD 
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provide a complex and compelling model for exploring perceived trial benefit through the lens of 
a parent proxy decision maker.
A number of studies focused on a range of pediatric disorders have examined aspects of 
caregivers’ perceived benefits of pediatric trials. Many of these studies focus on the role of 
expected or anticipated benefits as one of the variables influencing a caregiver’s decision to 
allow his or her child to participate in a trial.12,13 Few studies have collected data during the 
course of the study or after it concluded to examine participants’ perception of the benefits 
actually obtained.14,15 As a result, we know little about how participants experience and value 
the benefits of participating in a trial. This study was designed to better understand and define 
meaningful trial benefits and how parent decision-makers balance benefits and burden. 
Understanding how benefits are weighed against burden during the course of a trial may inform 
efforts to achieve patient-centered drug development and reduce trial withdrawal rates. These 
are issues that may be particularly relevant for rare disorders, which may have strong disorder 
communities but limited numbers of potential trial participants.
METHODS
This study employed a community-based participatory research approach, in which 
stakeholders contributed their expertise, as equal partners, to explore an issue of importance to 
the community and integrate the knowledge gained with action to benefit the community 
involved.16 A multi-stakeholder research advisory team led the study. All major decisions during 
the course of the study, including development of the study protocol, study processes, 
development of the interview guides, and the thematic interpretation were made by the research 
advisory team. 
The participants were parents of sons with DMD who were currently involved in, or who had 
taken part in, a clinical trial within the past three years in the United States or Canada. 
Participants were at least eighteen years of age and able to complete an interview in English. 
Parents who participated in a previous pilot study9 were excluded from this study. Participants 
were recruited through an advocacy organization, a patient registry, and using snowball 
recruiting. They were invited to participate in an interview to discuss their trial expectations and 
experiences. We continued recruitment and interviewing until we achieved saturation (i.e., 
information redundancy) on our topics of primary interest. 
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The study design was an exploratory qualitative study using semi-structured interviews. The 
interview topics included trial expectations and hopes, decision-making, experiences in the trial, 
and perceived benefits; only the latter are reported here. The interviews were conducted 
between June and October, 2012 and averaged approximately 50 minutes. 
Two independent investigators (HS and HLP) used NVivo 9 QSR, a qualitative analysis 
software package, to code responses. Inter-coder agreement was above 90% and 
discrepancies in the coding were discussed to clarify codes, identify true differences in 
interpretation, and facilitate reconciliation. All analyses were based on consensus codes. We 
conducted thematic analysis within the parent group, with attention to differences in themes 
based on the trial in which participants were involved. Coded passages and emerging themes 
were explored and categorized by the Research Advisory Group. Major themes that arose from 
the analysis and illustrative quotes are presented.
This study was approved by the Western Institutional Review Board.
RESULTS
Participants
A total of thirteen mothers and two fathers of children with DMD, representing participation in six 
clinical trials, participated in the interview study. All participants’ children had DMD, and their 
ages ranged from six to fifteen. Eleven children participated in trials of novel, mutation-specific 
drugs that aim to alter the dystrophin protein product; two in trials of other novel drugs that 
target secondary effects of the disease; and two in trials of drugs previously-approved for other 
indications that target secondary effects. Nine parents reported that their children were on active 
compound; three did not know; and four reported knowing or suspecting that their child had 
been on or was currently receiving placebo. Most participants’ children were still enrolled in the 
trial. Three were involved in an extension study, two in a trial that had ended, and two were 
unsure of the trial status. We do not provide additional details about participants because of the 
risk of identification in a rare disease trial.  
Trial Experience Themes
The interviews explored parents’ experience of trial participation through questioning about 
perceived benefits, burden, and risks or threats of participation. Parents’ descriptions of the 
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experience of the clinical trial included multi-dimensional discussions of the benefits of 
participation—defining ways the child and family benefited; how benefit was measured or 
evaluated; and how benefit was valued against burden and risk.
Defining the Benefits of Clinical Trial Participation
Direct benefit to the child
When asked to describe their clinical trial experience, most participants reported direct benefits 
to the child. Parents defined direct benefits as stabilization or slowing of disease progression; 
acquiring new motor skills; improved cardiac outcomes; and/or quality-of-life improvements such 
as more energy. For all but two parents, benefit to the child was described as the key motivator 
for maintaining their child’s enrollment in the trial. 
When asked about specific benefits of trial participation:
Five parents noticed new motor skills in their children that they attributed to the study 
drug. These parents were confident in their appraisal of physical benefit to their child. 
Eight perceived that their child’s disease progression had stabilized or slowed (six 
described motor stabilization and two described cardiac stabilization). Two parents 
noted declines after the child was taken off the drug, which reinforced their perception 
that the drug caused stabilization. Most of these parents expressed somewhat less 
confidence in their perceptions of benefit than the five parents who noticed new motor 
skills.
Two perceived that the child did not receive physical benefit. One parent, who reported 
that his/her child started on placebo, explained that all participants had crossed over to 
active drug, and thus the parent was still expecting some benefit. The other felt the child 
had not and would not receive any physical benefit.
Access to the Experimental Drug
Access to the experimental drug was considered a trial benefit. The majority of parents 
expected a successful trial outcome and continued access to the experimental drug. Those who 
participated longer or whose participation was complete described that initial optimistic 
expectations of trial success were somewhat tempered over time. Several found their 
expectations for a continued drug access threatened by unfilled trials, safety concerns, and 
perceived problems with appropriate blinding. Participants who became more pessimistic about 
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the long-term access to the drug tested in their trial, however, remained optimistic about other 
DMD trials’ chances of success.
Relationships with the Trial Team
The large majority of parents reported close relationships with members of the clinical trial team 
as an important benefit to the family. The relationships were described not only as an ancillary 
benefit to the child due to enhanced access to medical expertise, but also as a primary 
psychological and tangible benefit to the parents. 
“It just means a lot that it seems personal to them. They seem to really care, and really 
hope that this works. And again, not only does that hope kind of spill over to you a little 
bit, but there's just something about the fact that someone that is not related to you 
cares...And it makes you, you're kind of endeared to those people because they seem to 
care so much…. I'm like, ‘we would do anything that you guys would ask of us, because 
you guys have made this a great experience.’” Parent 100
The close relationships represented being more than “just a number” and the clinicians having a 
high level of commitment to the children. Four parents described systematically seeking out and 
nurturing these relationships to extend or increase the benefits. 
“I've developed very close friendships with most of the staff that we see…I'm extremely 
proactive, I make a point of trying to build friendships with these people outside of clinic 
because now we're kind of friends they tell me things that [they wouldn’t] if they only saw 
me twice a year and I made no effort in-between...I know these people, I know their 
families, you know I correspond with them personally outside of you know their job...I've 
been very fortunate that certainly we as parents are not left in the dark and they've been 
very accommodating...but only so because of the type of parents we are, like I said if I 
were somebody that just showed up to clinic and left...you'd know nothing, it's because 
I've really gone out of my way to stay on top of things, and I want these people to look at 
us, not just as patients, but as part of their social circle.” Parent 105
Parents valued close relationships that made them feel appreciated and improved their access 
to clinical expertise and information about the trial; for some parents this resulted in conflicting 
desires to have informal social relationships with investigators while concurrently admiring their 
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professional persona. In parallel, parents described the relationships leading them to be strongly
committed to the clinical trial team and by extension, the clinical trial. 
Psychosocial benefits of the clinical trial
Parents described several psychosocial benefits to the family (the parents and the child). Almost 
all parents reported psychological benefits of active efforts to intervene in the progressive 
disease course; positive feelings associated with altruism; an enhanced sense of optimism; and 
enjoying the significant “together time” required by participation. Four described social benefits 
to their children based on interactions with other children with DMD through the trial. 
Evolving definitions of perceived trial benefits 
Half of the parents described changes to their priorities and expectations during the course of 
the clinical trial that impacted their perception of benefits. These changes came from external 
sources (e.g., short-term or permanent loss of access to the drug) and/or from disease 
progression in the affected child (e.g., loss of ambulation). As a result, parents described 
adapting over the course of the trial to focus more on altruistic reasons for participating and/or 
ancillary benefits. Several of these parents described exploring options for a new clinical trial 
that might provide more direct benefit.
Evaluating for Benefits during Clinical Trial Participation 
Many parents undertook systematic efforts to evaluate for benefit of clinical trial participation.
“When he was doing his six-minute walk test, for example, I was timing it. I was counting 
how far he was going from test-to-test, to see, is he going further? Is he stronger? And 
so I was kind of monitoring [him] myself, to see if there was improvement.” Parent 111
Several parents were wary of the effect of their strong desire for benefit on their ability to be 
objective, and tried to balance being as neutral as possible, tempering expectations, and 
maintaining optimism. 
“I think as a parent, psychologically, you just want to see something. And so I would 
watch him and I'd be, like, ‘Did I just see that? Is that new?’ I was driving myself crazy to 
the point you actually have to remove yourself a little bit. Because you want to see 
something so badly…at one point I was, like, Okay, we're participating in this, I have to 
stop looking for signs.” Parent 118
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Most parents described that other people directly aided them in their evaluation efforts and/or 
supported their impressions: healthcare providers not involved in the trial, relatives, teachers, 
and other parents of individuals with DMD. However, their evaluation efforts were complicated 
by the natural history of DMD, since DMD has significant phenotypic heterogeneity and includes 
normal plateaus and losses. Parents felt that their ability to monitor their child for benefit was 
challenged by not receiving clinical data during or after the trial. 
Many parents expressed frustration with the trial outcomes and measurements. They reported 
that parents and professionals look at benefit differently, and care about different outcomes. 
“I think to [professionals] an improvement just means that the muscle, I don't know, 
reacts faster or doesn't deteriorate as quickly. I don't think they often think about the day-
to-day benefits to [my son] and his self-esteem and quality of life.” Parent 115
Similarly, several parents who perceived benefit were frustrated by their inability to convince the 
clinical trial team and sponsors. 
“There's no way for us to prove to them how much better he's doing in his daily life… it's 
been frustrating a little bit when they tell us they're not sure that it has benefit and we are 
sure that it does.” Parent 104
The Valuing of Benefits during Clinical Trial Participation
Placing value on the trial experience appeared to be a dynamic process, where the perceived 
benefits were weighed against the trial burden; potential for side effects and harms; and
perceived likelihood of trial success. Though negatives of trial participation are described 
below, most participants did not express decisional regret, and the experience of trial 
participation appeared to be highly valued by more than half of the participants. Even 
participants who were less positive still placed positive values on the experience that included 
altruistic perceptions of being part of something “bigger” that would lead to benefits to the 
community. Many parents perceived a responsibility to maintain the trial’s integrity, and felt that 
there should be reciprocal benefits— that is, benefits to the child from the trial, and to the trial 
from the child’s participation. 
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“… you're part of a bigger system and you've got to be protective of the study. And I 
think that's the difference. But it's not just about you and your child and your doctor 
anymore. It's you, your child, the doctor, and the study.” Parent 101
Trial burden
Although parents’ perceptions of trial burden varied by trial, common themes related to time 
requirements, travel burden, and insufficient communication. Parents noted specific burdens 
that were serious enough to threaten their continued participation in the trial that included 
financial pressures; poor communication from the sponsor during the trial; lack of social support; 
perceiving the child to be on placebo; and lack of perceived trial benefit to the child. 
Overall, one of the trials was described as more burdensome than the others. Most parents 
perceived the time and travel requirements as burdensome, but many reported being prepared 
for these burdens and adapting to them during the course of the trial. Most parents described a 
negative impact of the trial time and travel burden on their ability to work or their work 
performance. Three described significantly more time burden on the family than expected, and 
three others felt that the duration of their trial experience was longer than expected. 
Insufficient communication with the sponsor (for most parents) and study sites (for three 
parents) added to the trial burden, and in several cases threatened the willingness of parents to 
keep their children enrolled in the trial. Parent interviewees expressed discomfort that 
communication with other participating families was “against the rules.” (The informed consents 
of several trials represented in this study required that participants not share information about 
their trial experience with peers.) All interviewees described some communication with other 
families during the trial, though several described these discussions as guarded or limited in 
scope, especially related to comparisons of assumed trial randomization and perceived benefit. 
Most parents who recognized a significant physical benefit for their child described some 
associated guilt.
“There was communication [with other families in the trial], but…we were just very 
guarded in how we responded...when people said, do you see any difference in <child’s 
name removed> ...it was sort of like, oh yeah, maybe, but we're not sure, even though 
inside ourselves we knew we were seeing a difference, and we were pretty sure he was 
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on the high dose of the meds...we didn't really share that with anybody else in the trial.” 
Parent 104
Most parents (10) felt that communication with other participant families about the trial 
experience made it a more positive experience and helped with evaluation of benefit. 
“It's just nice to have someone else that knows what you're going through. … And it was 
just interesting, because you know how your experience was, and the things that you 
noticed, and you wonder all the time, are other people noticing this? Is someone else 
noticing this little bitty thing, or is it just me? Or am I trying to read into something that's 
not there because I want it to be working?” Parent 100
Four parents voiced a need for a safe and ‘legal’ environment for participant families to interact 
with each other, perhaps moderated by a professional who would correct misinformation and 
clarify confusion.
Other burdens described were financial burden due to disrupted work schedules and/or 
unreimbursed travel costs (a very significant burden for a subset of participants), overly-rigid 
protocols, placebo randomization, and difficult interactions with contract research organizations. 
Several parents were frustrated at not understanding the trial timeline, which challenged their 
motivation to stay involved; this was especially true of parents who perceived limited benefit, 
who wanted to know that “an end was in sight.” A few participants who perceived the greatest 
burden also expressed disappointment that the study failed to meet their expectations in other 
ways as well; this subset reported that the benefits of study participation were not perceived as 
outweighing the burden and they had considered withdrawing from the study.
Most parents felt there was minimal to moderate burden to the child participating, with the
exception of the muscle biopsies that were required in some trials and considered a significant 
burden. In general, most parents perceived the trial to be a positive or neutral experience for the 
child. 
Side effects and harms
Though parents perceived low and manageable trial risks, they continued to be alert for 
potential harms during the course of the trial. They describe being vigilant for: specific risks and 
side effects thought to be associated with the drug; exacerbation or progression of DMD 
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symptoms; and more general threats to the child’s quality of life. The side effects they reported 
their children experiencing included weight gain, feeling sick to the stomach, having erections, 
and skin reactions. In studies involving muscle biopsy, the procedure was perceived as 
considerably burdensome to the child. Two participants felt strongly that their child being 
randomized to placebo was a harm. 
Several parents described being most concerned about potential risks after the decision-making 
process, especially during the early part of the trial. For most of the parents, ongoing 
perceptions of minimal risk motivated them to remain engaged in the trial. Most families agreed 
that the only thing that would prompt them to withdraw their child from the study were serious 
side effects or pain. 
ASSESSMENT OF NET BENEFIT
After defining meaningful benefits, evaluating for those benefits during the trial, and valuing 
benefits versus risks, parents came to an overall assessment of net trial benefit. Parents 
represented this assessment of net benefit as a dynamic process of coping with choosing to put 
the child in a trial, and their associated psychological need to have a meaningful experience for 
the child. The assessment of net benefit was described as a parental responsibility. Further, 
parents described feeling that it was their responsibility to navigate the trial risk and processes 
so the child had access to benefits, in several cases against the expressed wishes of the child. 
“At one point <child’s name removed> looked at me when he was getting an injection, 
and he said, ‘Promise me once this trial is over, you won't make me go in any other 
clinical trials.’...That night, I said to him, ‘Do you remember you asked me that question? 
If this clinical trial doesn't work, or it does work and there's another clinical trial that 
comes up that we think might help you, I will want to do it because as far as I’m 
concerned, I'm never giving up. If I think there's something that can help you, I can't 
promise you that I'm not going to try it, even if it's hard, even if it's painful because that's 
my job.’” Parent 101
DISCUSSION 
There are few studies that explore parent decision-makers’ perceptions of the accrual of 
benefits and burden during or after the course of the trial. In this study, which extends a pilot 
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study of parents in one Duchenne trial,9 participants described a complex and dynamic process 
of defining, evaluating, and assessing the value of benefits as an ongoing process of coping 
with their decision to enroll their child in a DMD clinical trial. Though primary benefits to children 
were the most valued, psychosocial benefits to the family and close relationships with the 
clinical site teams were also important. Assessment of benefit changed as children progressed 
in their disease, as trials advanced, and as aggregate trial data became available. Specifically, 
parents described focusing more on altruistic benefits over time, apparently reflecting an effort 
to cope with a “shifting reality” about the trial and child’s prognosis. 
Parents represented dynamic efforts to manage the decision to enroll their child in a clinical trial 
and maintain a child’s participation that reflected their need for a meaningful trial experience. 
The process and outcome of assessing trial “net benefit” is important to understand, because 
perceived benefit was described as a motivation to stay involved in the study, even when 
participation was burdensome. It is in the best interest of all stakeholders to encourage a match 
between expected and perceived benefits to maintain trial participation, sustain 
participants’/caregivers’ feeling of responsibility to the trial, and promote family wellbeing. A key 
component of that match is in how benefits are understood prior to decision making and during
informed consent. Nancy King17 describes a compelling need to promote more reasoned 
discussion about potential trial benefits by distinguishing different types of benefits as well as 
the associated dimensions: nature, magnitude, and likelihood. Findings like ours promote the 
ability of researchers and regulators to improve informed consent by framing types of potential 
benefits congruent with how participants may experience them, while also striving to quantify 
the associated dimensions of benefit. 
This study suggests one common point of mismatch in a clinical trial—between clinical 
outcomes defined by the trial sponsor and the quality-of-life related benefits that parents value, 
and for which they evaluate their child during the course of the trial. While it is important for 
sponsors and clinician investigators to reinforce the reasoning behind choosing specific trial 
outcomes, researchers should anticipate and address the parents’ frustration in this regard. 
Based on our study, we would expect less discrepancy in trial outcomes that directly reflect the 
child’s quality of life. Adding an additional dimension to King’s recommendations17 about
describing benefit, how benefits are ascertained and measured, may assist potential 
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participants in anticipating mismatch while also facilitating their understanding about which 
benefits “count” toward a successful trial outcome. 
To some extent, the trial burden described by our participants could be reduced to improve the 
benefit/burden balance. Clear targets for improvements in communication and social support for 
participating families were evident. Parents were uncomfortable with the prohibition present in 
several of the studies against sharing their trial experiences with others, which limited their 
ability to receive and give support. Parents described the need for more communication and 
support about the trial processes and outcomes, especially in the context of logistically and 
emotionally-challenging trials. Efforts to facilitate and encourage appropriate peer 
communication and social support related to trial participation might reduce an individual 
parent’s mismatch between expected and perceived benefits through the peer group process of 
defining “reasonable” expectations for benefit during the course of the trial. 
Many of the aspects that challenged parents’ perceptions of trial benefit were largely outside of 
the control of the sponsor, including lack of benefit to the child, overall drug efficacy, and loss of 
drug access during the course of the trial. In cases of challenges outside of their control, 
sponsors might build upon the strong relationships between participating families and clinical 
site teams to facilitate anticipatory guidance during informed consent and the course of the 
study, and site team communication and support in the case of an adverse outcome. In our 
study, the relationships between parents and clinical teams impacted the evaluation of trial 
burden and benefits and appeared important to maintaining trail participation.
LIMITATIONS
The primary limitation is that parents interviewed represent “first adopters” of clinical trials for 
Duchenne muscular dystrophy and their experiences and perceptions may differ from other 
parents of children with DMD. There is also a potential for bias in reporting perceived benefits 
due to the high emotion associated with many of our interview topics.
CONCLUSION
Though DMD represents a complex clinical trial situation, there is no reason to assume that the 
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themes identified here are unique. Major themes that emerged from this study may be 
especially relevant to other progressive pediatric disorders. Parent decision-makers may be 
particularly motivated by the chance for their child’s benefit and trial success, which may help 
justify decisions to expose the child to burden and risks. For rare disorders, issues of adequate 
recruitment and retention are especially relevant and must be balanced against feasible, 
unbiased, and yet permissive trials. While high perceived benefit likely keeps families engaged 
and enthusiastic about trial participation, the downside is that if those perceived benefits are not 
realized with an approved drug, it may lead to serious challenges to the wellbeing of families. 
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ABSTRACT
Objective: This interview study explored parents’ deliberation and decision making about 
children’s participation in Duchenne muscular dystrophy (DMD) clinical trials. 
Methods: Semi-structured interviews conducted with parents and clinicians in U.S. or Canada 
were assessed using thematic analysis. 
Results: Fifteen parents involved in six trials and eleven clinicians involved in ten trials were 
interviewed. Parents described benefit-risk assessments using information from advocacy, 
peers, scientists, clinicians, and sponsor materials. Strong influence was attributed to the
progressive nature of DMD. Few considered the possibility of trial failure. Most made decisions 
to participate before the informed consent process, but none-the-less perceived making an 
informed choice with little to lose for potential gain.
Clinicians described more influence on parental decisions than attributed by parents. Clinicians 
felt responsible to facilitate informed decisions while maintaining hope. Both clinicians and 
parents reported criticisms about the informed consent process and regulatory barriers.
Conclusions: The majority of parents described deliberation processes leading to informed 
choices that offered psychological and potential disease benefits. Anticipatory guidance about 
the potential for trial failure might facilitate parents’ deliberations while aiding clinicians in 
moderating overly-optimistic motivations. Regulators and industry should appreciate special 
challenges in progressive pediatric disorders, where doing nothing was equated with doing 
harm.
INTRODUCTION  
Clinician investigators and clinical trial sponsors benefit from an awareness of motivations to 
participate in trials and participants’ decision making processes.1 A unique aspect of pediatric 
clinical trials is that parents and caregivers make choices on behalf of their children, and the 
values and beliefs underlying proxy decision making may not be the same as for adults deciding 
about their own participation.2 As such, investigators aim to facilitate informed parental decision 
making in pediatric trials.
Elwyn and Miron-Shatz (2009) describe decision making as a process of pre-decision 
deliberation followed by the act of making the determination.3  Deliberation includes obtaining 
information and appraising one’s own knowledge, imagining alternative outcomes, predicting 
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one’s emotional state in the future, and constructing preferences about the decision.3
Determination is coming to an intention to enact the decision.3  
Based on existing research, the deliberation process for parents consenting to their child’s 
participation may be represented by weighing perceived benefits against risks.4 Perceived 
benefits have been found to include access to new treatments;4,5 treatment at no cost;4 access 
to the best treatment options;4 increased hopefulness;4 the ability to help others; and increased 
knowledge.4,5 Perceived harms included randomization; and time demands and general 
inconveniences.4 
A pilot study of one clinical trial for Duchenne muscular dystrophy (DMD) found that 
expectations for individual benefit drove the deliberation process, and parents described strong 
pressures to enroll their children due to the illness trajectory.6 DMD is a rare neuromuscular 
disorder that causes progressive muscle weakness and death typically in the late 20s.7,8 There 
are no Food and Drug Administration approved therapies, but many potential therapeutic 
approaches are in clinical trial.9 Extending the scope and depth of the pilot, this study explored 
decision making deliberation and determination of parents who consented to a range of DMD 
trials for their sons, as well as the perspectives of clinicians on clinical trial teams. The overall 
study objective was to identify potential intervention targets to improve informed decision 
making and wellbeing in families living with DMD.
METHODS 
This retrospective, explorative qualitative study was guided by a Research Advisory Group 
using a community-based participatory research (CBPR) approach, a process by which 
stakeholders act as equal partners to identify and explore a phenomenon of importance to the 
stakeholder community.10 Semi-structured interviews with clinicians and parents were 
conducted between June and October, 2012. Both sets of interviews averaged approximately 
50 minutes. Parent participants had sons with DMD who participated in a trial within the past 
three years in the United States or Canada; participants in the previous pilot study6 were 
excluded. Participants had to be at least 18 years of age and able to complete an interview in 
English. The second group comprised clinicians active in DMD trial teams over the past three 
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years. One clinician also participated in the pilot study;6 that clinician was a principal investigator 
on more than one trial and he/she discussed other trial(s) for this interview. 
Both groups were recruited through an advocacy organization, a patient registry and the 
associated provider portal, and using snowball recruiting. They were invited to participate in an 
interview to discuss clinical trial expectations, decision making and experiences; only decision 
making is described here. 
Two independent investigators (HS and HLP) developed the research codebook and used 
NVivo 9 QSR software to code responses. Inter-coder agreement was above 90% and 
discrepancies in the coding were discussed to promote reconciliation. We then conducted 
thematic analysis within and between the parent group and the clinician group. Emerging 
themes and representative, de-identified coded passages were explored and categorized by the 
Research Advisory Group. This study was approved by the Western Institutional Review Board.
RESULTS
Fifteen parents of children diagnosed with DMD and eleven clinicians participated in the 
interviews. Information about the participants can be found in Table I. 
Table I: Demographics of parent and clinician participants
Parent Participants (15)





6-15 years Novel, mutation-specific 
drugs (11)
Other novel drugs that 
target secondary effects 
(2)
Previously-approved 
drugs for other 
indications (2)




Unsure of trial status 
(2)
Clinician Participants (11)









drugs for other 
indications (6)
Supplements (2)
10 Current or previous 
trial PI (6)




The trials represented included a mix of placebo-controlled and non-randomized trials. Nine 
parents reported that their children were on active compound; three did not know; and four 
reported knowing or suspecting that their child had been on or was currently receiving placebo. 
The clinician participants represented a range of experience, from less than 10 years (three) to 
more than 20 years (four). 
All of the participants completed the entire interview.  
Parents’ Deliberation Process
The interviewer asked parent participants to think back and describe their decision-making 
process. 
Obtaining information
During the deliberative process, parents obtained information about clinical trials from advocacy 
groups and advocacy conferences; sponsor websites and materials; professionals involved in 
the research; other parents; outside professionals perceived as impartial; the child’s clinician; 
and scientific publications. Five participants described first hearing about the clinical trial from 
their child’s healthcare team, but only one parent described decision making based 
predominantly on information from their child’s clinician. 
Most parents described clinician investigators as objective, realistic, and honest. Few parents 
attributed decision-making pressures to their healthcare providers. Three parents encountered 
clinicians who they described as too enthusiastic; i.e., whose hope and enthusiasm about the 
trial encouraged high expectations from the parents. Two parents experienced “over-selling” of 
the clinical trials during communications with sponsors or sponsors’ representatives.
Participants described the informed consent (IC) process as minimally or not at all important to 
their decision making; that is, they informed themselves and made their determination to enroll 
their children before they engaged in the IC process. However, parents learned new information 
about the study processes and logistics during IC, and most positively described the consent 
discussions as extremely detailed about the timeline and procedures. On the other hand, the IC 
documents were frequently described as too long, difficult to read, and technical; and the key 




All parents described emotional, time-related pressures due to the progressive and fatal nature 
of DMD, including the child permanently losing abilities and missing a limited window of trial 
eligibility. Several described additional pressures of having to choose when children qualified for 
more than one trial. Most parents expressed distress about the long wait required for drug 
approval, which was perceived to be primarily due to unnecessary regulatory barriers and 
industry delays. This had enhanced salience because parents expected that treatment benefits 
may be reduced as the disease progressed. 
“I’m sitting here watching time tick by knowing that every month that goes by, my kid is 
less likely to be able to take advantage of this drug if it does work.  And I find it 
excruciating and unconscionable.” Parent 101
Assessment of potential benefits and risks
Parents felt that undertaking a benefit/risk assessment was a requirement for making a “good” 
decision. Parents described the importance of doing research and understanding possible risks 
and side effects. Nine parents expected specific, defined physical benefits to their child as they 
were making their clinical trial decisions; most were participants in mutation-specific trials. Five 
described more general expectations for some type of individual benefit to the child. Only one 
participant consistently conveyed no expectation for individual benefit. 
All participants described optimistic hopes for a better outcome for their child, as well as hopes 
for a successful trial outcome. Though most participants reported altruistic influences on their 
decision making and a feeling of responsibility to participate, few described these as influential 
motivators in their assessment of potential trial benefits. 
The widespread perception of low or manageable risks associated with all of the trials played a 
large role in parents’ decision making. However, a few parents described being frightened by 
potential side effects, and seven parents worried about allowing their child to be a “guinea pig” 
or to be used as a means to an end. Many parents addressed conflicting desires to have 
immediate access to experimental drugs, willingness to accept risk, and concerns about risks 
and side effects. This conflict was less commonly described by parents making decisions about 
previously-approved drugs, where the risk/side effect profile was perceived to be well known.
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“I want to avoid getting hurt badly with something that's rushed too fast. I don't know 
what the right answer is, but it's balancing that being a hundred percent sure versus 
trying.  We're running out time.  I know the clock ticking.” Parent 111
Half of the parents involved in placebo-controlled trials considered the potential to be 
randomized to the placebo arm as an overt risk of participating. Several perceived the most 
significant risk as a threat to the child’s quality of life due to trial burden. 
Rarely-described deliberation factors 
Notably, only a few parents worried about a failed trial or loss of drug access while making trial 
decisions, and none as a major decision-making factor. Few parents described trial logistics, 
processes, or demands on their families as a significant part of their decision making. Only two 
parents reported considering barriers to eligibility for other trials due to participating in the trial. 
Parents’ Decision Determination
For most participants, the result of the benefit/risk assessment was that they had little to lose for 
potential gain, and thus decision making was described as relatively straightforward. Only two 
participants described their decision as anything other than an “obviously right” choice. Parents 
reported psychosocial benefits to their determination that included increased optimism and a 
feeling of empowerment to impact the progressive disease course.  
Some parents made a determination to participate in a trial and then searched among available 
studies, while others described making a determination to target one specific trial. In both cases 
parents viewed their decisions as rational and felt themselves to be educated decision makers. 
Though several parents felt that they did not have access to all of the information that they 
wanted to make fully informed decisions, such as earlier-phase trial data, participants 
demonstrated being well informed about the objectives of clinical trials in general, as well as 
their specific trial. Most participants made statements alluding to an understanding of the goal of 
clinical trials (obtaining generalizable knowledge and better understanding DMD), and in no 
cases did their decision making seem to stem from a misunderstanding about the purpose of 
clinical trials.
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Clinicians’ Role in Parental Decision Making
Clinician Perspective: Their Responsibility in Decision Making
Clinicians reported feeling responsible for allowing parents to maintain their enthusiasm and 
hope, while also helping them make determinations based on realistic expectations of the study 
processes and likely outcomes. They were challenged to find the right balance among 
protecting families, acting in their best interest, and fostering a successful trial. Clinicians aimed 
to use the clinician/patient relationship to protect families and help them make good decisions. 
Three clinicians further stated that the relationship between the family and the investigator was 
the primary reason for parents’ decisions to consent; parents want to please clinicians and meet 
their expectations. 
Clinician Perspective: Information Communication
All clinicians described trial education as important for deliberation, for reducing decisional 
regret, and keeping families in the trial long term. Specific educational topics that they strove to 
integrate into parents’ deliberation included: trial processes, time commitment and burden; the 
chance of the trial ending early; understanding the implications of a placebo-controlled trial; 
understanding equipoise; the proposed mechanism of drug action; early phase data; potential 
side effects and harms; how to assess benefit and risk; trial eligibility; and effects of participating 
on eligibility for future phases/trials. Clinicians reported several factors that constrained them in 
their educational roles: concerns about the public’s ability to interpret complex information; the 
length/complexity of required information in the informed consent; institutional or sponsor 
constraints in what they were permitted to tell parents; lack of access to proprietary information 
needed to facilitate informed choices; and having to counter-act overly optimistic messages 
from trial sponsors. 
Clinicians also reported barriers in their communication with families interested in trials. Seven 
described a disconnect between what they say and what families hear, such as parents not 
wanting to hear about risks or ignoring discussions of trial burden. On the other hand, clinicians 
described some parents as having negative reactions to receiving incomplete information about 
the potential drug, even though such limitations are inherent to a trial. Many clinicians 
expressed a preference for a different approach to trial deliberation; for example, four wished to 
have discussions over a longer duration to reinforce key messages and encourage parents to 
Chapter 8
136
listen objectively; two wished to communicate a more holistic “big picture” understanding of 
trials; and two wished for more “relaxed” conversations with potential trial participants about trial 
intent.  
Clinician Perspective: Information Framing
When clinicians described discussing clinical trials with potential participants, they reported 
using a varied mix of optimistic, future-oriented statements about potential for a new DMD 
treatment; realistic statements about the goals of the trial; optimistic statements about the 
possible benefits of the clinical trial; descriptions of risks and side effects; and attempts to 
manage parent’s expectations (see Table II). Most described a personal need to offer their 
patients “something more” and to give families more cause for optimism through access to 
clinical trials.
Table II: Clinicians’ descriptions of communicating about the trial’s potential
“I try to give [parents] permission to be the most hopeful of all the treatment team because I 
think that is the parent’s right.  But I think that most of the parents from time to time manifest or 
talk about things in an unrealistically hopeful manner, who would just say, “Come on, Doc, this 
is going to be the cure and my child's going to be okay, right?” On the rare occasion where 
they won't come out with that themselves, then I try to take a deep breath and say, “Let's talk 
about what the realistic options and possibilities and the fact that we won't really know for any 
one individual what the outcome would be...even if the statistics look good, individuals do 
differently.” 200 
“We wouldn't do it if we didn't think [the drug] had a good chance of working, but that we don't 
know if [the trial] will succeed, and there might be side effects that are not favorable.” 203
“I have a couple phrases that I try to routinely use to make sure that I emphasize to the 
parents that while I'm enthusiastic about the prospect of this particular drug, that it's important 
that they recognize that there's no proof that this drug works in humans. It might cause some 
increase in dystrophin, but there's no evidence yet that that's going to result in a clinical 
benefit….hopefully it's a trusting situation and I know that my opinion carries a lot of weight.” 
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“….And pointing out that the goal is not to cure the children, but hopefully make the lifespan 
into a child with Becker muscular dystrophy, rather than Duchenne.  And then I take it one 
step further saying maybe in another ten years there'll be another breakthrough that will even 
enhance this medication and the children will even do better. But then I quickly add that's my 
fantasy and maybe my fantasy will be real, it might not be real.  But at least if this medication 
does work, we're going to make a significant [improvement], will increase the longevity and 
hopefully the quality of life….And I say, there's good theories as to why this might benefit your 
child, but the reason we do clinical trials is because we just don't know. So I try to be very, 
very cautious and maybe be less than enthusiastic about how this is going to help their child. I 
emphasize that this is a clinical trial.  This is research. It's exciting that their children are 
involved in the clinical trial, but no guarantees about helping the children at all.  But it's better 
than not doing something.” 207
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Part 3: Informing clinical trial processes and informed consent using a community-based 
participatory research approach 
DISCUSSION 
Extending the findings of the pilot study,6 in a range of DMD trials we found that the majority of 
the parents perceived themselves to have made a good and informed choice about their child’s 
trial participation after undertaking a benefit/risk assessment. Informed choice results from 
having sufficient understanding of relevant information and choosing a course of action 
consistent with one's values and beliefs.11 However, parents’ deliberation process appeared to 
be complicated by strong pressures due to the progressive and ultimately fatal DMD course. 
This is consistent with prior research reflecting the influence of child’s illness severity and 
availability of treatment options on parents’ treatment decisions.12
Parents described determinations to enrol their children that simultaneously offered them 
essential psychological benefits and some possibility for disease benefit. Altruism was also a 
common, but not a strong or independent, motivator. Few parents described considering the 
possibility of trial failure or loss of access to the drug during their deliberation process.
Clinicians described having more influence on parental deliberations than was attributed by the 
parents. They felt a strong sense of responsibility to help parents make informed decisions while 
simultaneously allowing them to maintain hope for individual benefit. The ways that clinicians 
described framing their discussions with families reflects their attempts to achieve this delicate 
balance, while managing their own need to “offer something more” to their patients and families.
Parents and clinicians had criticisms about regulatory and industry barriers. Parents expressed 
a strong desire for more permissive inclusion criteria and policies that speed up the drug 
development timeline. Many displayed risk tolerance in the face of a progressive disorder, a 
finding that has been demonstrated in DMD caregivers.13 Parents and clinicians requested less 
complexity in the informed consent documents and increased flexibility and an extended 
timeline for the informed consent process. 
Chapter 8
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The primary limitation of the study is that it includes retrospective questioning. We asked 
parents to think back to their decision-making process. The timing of the deliberation and 
informed consent varied; for some parents that process occurred relatively close to the date of 
the interview, while for others it occurred several years in the past. Once a determination to 
participate is made, it is possible that parents re-frame their perceptions to be consistent with 
their decision.14 The potential for retrospective bias may be especially relevant given the high 
emotion associated with many of our interview topics. Parents interviewed came from a group of 
early acceptors of clinical trial participation for their children, and their experiences and 
perceptions may differ from other parents of children with DMD.
CONCLUSION
Though parent participants demonstrated a good overall understanding of clinical trials, our 
interviews identified potential trial benefits as strong deliberative influences that were not 
moderated by reasonable expectations for trial success. When constructing their decision 
determination based on relevant information, parents most valued the chance for benefit to their 
child and their belief in the possibility of a different future. While this may represent what has 
been termed “therapeutic error,”14 parents did not display therapeutic misconception in that they 
presented an understanding of the overarching intent of clinical trials. 
Clinicians, sponsors, and advocacy organizations should aim to facilitate a more nuanced 
weighing of potential benefits and negative outcomes during trial deliberation, for example 
through engaging in anticipatory guidance (“what if?” scenarios) about potential negative trial 
outcomes. Though parents’ optimistic perceptions make such discussions difficult, well-crafted 
anticipatory guidance may allow parents to “try on” outcomes with the benefit of time for 
reflection and guidance from professionals and peers. These discussions may also aid clinicians 
who, through their efforts to allow families to maintain hope, may inadvertently give implicit 
permission for parents to hold overly optimistic motivations as primary to their deliberative 
process. This may facilitate informed choices that maintain psychological benefits to the parents 
while providing some protection against decisional regret if the child does not benefit, the trial 
fails, and/or the child loses access to the drug under trial. 
139
This research reinforced an additional challenge to developing interventions. Similar to the pilot 
study,6 parents reported participation determination well before the IC process and with only 
moderate levels of influence from clinicians. This was a barrier to clinicians, who felt it was their 
obligation to help families make informed decisions, and yet were frustrated with parents who 
“wouldn’t listen” at the time of IC. Though clinicians expressed a laudable desire to have more 
time and flexibility to support trial deliberation, our study suggests that approaches outside the
clinical setting should also be implemented. Consistent with the CBPR approach of this study, 
we recommend efforts to build collaborative partnerships in developing and implementing 
interventions that take into account the powerful influences of cross-family communication, 
advocacy organizations, clinicians, researchers and sponsors. 
Finally, this study highlights the need for regulators and industry to appreciate the special 
challenges and pressures that arise in progressive pediatric disorders, where doing nothing was 
equated with doing harm. Our results provide support for requests that sponsors, institutional 
review boards, and regulatory bodies display more flexibility, permit less restrictive inclusion 
criteria, encourage adaptive trial design, and speed access to potential therapeutics for rare 
disorders.15-17 These efforts could permit patients and families to have a wider range of 
decisions instead of a perceived “one-time” opportunity with potentially life-or-death implications, 
and may address aspects of the informed consent process that are perceived to be “broken”.18
Our study suggests a powerful opportunity for families and clinician investigators to advocate 
together for feasible but progressive changes to trial design and regulatory practices, based on 
their shared motivations for increased trial access and improved trial experiences.  
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Summary, Discussion and Implications
This thesis presents a series of translational research studies. They employ a diverse set of 
research methods to explore topics of importance to a patient community. In this section we 
summarize the outcomes and implications of each study, after which the community-engaged
research (CEnR) approaches employed in the studies are rated and reviewed.
A common limitation shared by all of the studies was the use of PPMD and the 
DuchenneConnect self-report registry for recruitment. Families who opt into participating in a 
disease advocacy organization or a self-report registry, and who then opt to participate in a 
social science study, may not be representative of families managing Duchenne and Becker 
muscular dystrophies. Future research would benefit from additional consecutive in-clinic 
recruitment to improve the range of perspectives that are included in qualitative research and to 
ensure generalizable quantitative research. 
Advocacy and programmatic implications
The overarching objective of the studies was to inform PPMD’s interventions and/or policy and 
advocacy approaches. Though the impact varied, all were successful in that objective. 
Achieving the objective was facilitated through the use of a range of community engagement 
approaches. 
Mothers’ wellbeing studies (Chapter 2) provided clinically-relevant data about mothers’ unmet 
support needs and adaptation to caregiving for a child with DBMD. The pragmatic and positive 
focus of the study aims and instruments reflected stakeholders’ attitudes that caring for a child 
with DBMD comes with benefits, and clinical interventions should highlight strengths and 
wellbeing rather than burden and deficit. 
Mothers identified many areas of resilience and support. We identified a need to improve use of 
respite care. Findings also showed that the least-met support needs are related to coping with 
challenging emotions associated with DBMD. Predictors of psychological adaptation included 
greater resilience and endorsement of positive impact of DBMD on the family. Though existing 




Study results include unexpected findings about mother’s age, child’s disease progression, 
psychosocial support needs, and adaptation. We found opposite effects of mother’s age (with 
younger age predictive of higher adaptation scores) and child’s functional status (with worse 
functional status associated with, but not an independent predictor of, higher adaptation scores) 
on mothers’ psychological adaptation. The results suggest that while mothers may be able to 
attribute more benefit to the DBMD experience and perceive lower unmet needs as their 
children’s symptoms become more advanced, their resilience may be challenged as they age. 
Additional exploration is needed to better understand the effects of increasing mother’s age and 
worsening child’s functional status on psychosocial needs, care facilitators, and psychological 
adaptation.
Clinical implications from the study on mothers’ wellbeing include the need for systematic 
exploration of caregivers’ unmet support needs, especially those related to coping with DMD-
related uncertainty and fear. Efforts to improve mothers’ adaptation should focus on fostering 
resilience and enhancing benefit finding through identification of positive aspects of living with 
DBDM. Clinicians may be able to identify specific caregiving needs and customize interventions 
based on the use of simple, targeted questions similar to the questions used in this study.
Summaries of the research findings have been shared through Parent Project Muscular 
Dystrophy forums, including social media and the PPMD annual conference. Data presented in 
this thesis informed a wellness intervention at PPMD’s annual conference in 2013 and was used 
to support two grant proposals on caregivers’ wellbeing. In late 2014 we initiated a carrier 
mothers’ program guided by the study results through DuchenneConnect, a longitudinal patient 
and caregiver self-report registry. In addition, the longitudinal mothers’ wellbeing study is 
ongoing. To extend the results from the first two years of data collection, the third year’s survey 
included measures on uncertainty, spirituality, and hope. 
In the treatment preferences and impact study (Chapters 3-5), using Best-Worst Scaling 
methodology we found that caregivers were willing to accept increased risk for a serious or fatal 
outcome when balanced with a non-curative treatment, even absent lifespan improvement. The 
addition of a simple conjoint analysis as a second stated preferences method validated the 
major findings and provided important, policy-relevant information about intention to use specific 




worries, concluding that the most pressing concerns entailed worries about symptom 
progression and access to medical care, followed by the child being happy. Worries related to 
parents’ wellbeing and family and social impact were relatively less prioritized. Best-Worst 
Scaling represents a compelling method to explore and quantify disease perceptions and impact 
that is rarely used in health-related social science studies.
Of the studies presented in this thesis, the treatment preferences study had the most 
remarkable advocacy and policy impact. We described a model process for advocacy 
organizations aiming to promote patient-centered drug development. Study results were 
distributed to the U.S. Food and Drug Administration (FDA) personnel at several in-person 
forums to inform their assessment of emerging DMD therapies. The study has been cited by 
FDA personnel, who identified it as a replicable template for other advocacy organizations to 
follow1 and stressed the need for such research to be conducted by other organizations.2
Several biopharmaceutical companies have used or plan to use the data from this study in their 
regulatory processes. The study was also cited in the U.S. House of Representatives Energy 
and Commerce Committee 21st Century Cures Initiative and described in a Committee 
hearing.3  
The study results provided PPMD with a compelling message for FDA engagement. This led the 
FDA to urge PPMD to develop draft guidance for DMD—a first for a rare-disease advocacy 
group. It was submitted to the FDA on June 2014. The guidance begins with a chapter on 
benefit/risk assessment, which includes a summary of the results and advises sponsors to 
measure patient/caregiver preferences as part of their drug development and regulatory 
submission processes.4  
Since completing the study, the authors have presented the results at more than 20 professional 
and advocacy venues. Almost a dozen advocacy organizations in other disease areas have 
indicated their intent to use it as a model. As a representation of ongoing impact, in November 
2014 PPMD announced a collaboration with Santhera Pharmaceuticals to develop a new 
benefit/risk study focused on pulmonary therapies for Duchenne.5  
Decision making in clinical trials (Chapters 7-8) is an area of considerable interest for clinical 
trial sponsors, clinical trial site teams, institutional review boards, and advocacy organizations. 
Our studies highlighted the complexity of clinical trial decision making, especially in the context 
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of a rare, progressive pediatric disorder, where our parent participants equated doing “nothing” 
(i.e., not participating in a trial) with doing harm. Parents’ decisions were strongly influenced by 
the chance for individual benefit to their children, but the participants did not display classically-
defined therapeutic misconception. The adaptive optimism engendered by the availability of trial 
participation was another anticipated benefit—and one that was highly valued by both parents 
and clinicians on clinical trial teams. Parents reported undertaking a benefit-risk assessment 
and developing intentions to participate in clinical trials before the informed consent process. 
Clinicians described more influence on parental decisions than attributed by parents. They 
reported feeling responsible to facilitate informed decisions while maintaining parents’ optimism. 
Based on the findings we suggest that clinicians, sponsors, and advocacy organizations 
develop approaches to engage families in anticipatory guidance about potential negative trial 
outcomes, anticipating that these efforts may assist clinicians in having balanced discussions 
with families while providing some protection against decisional regret. 
We also provide a report of how parents assessed and valued perceived benefits during clinical 
trial participation, which has implications for their continued investment in the trial. Participants 
described a complex, dynamic process of defining, evaluating, and assessing “net benefit” as an 
ongoing coping process. Most perceived individual benefits to their children, as well as other 
benefits that included altruism, close relationships with the research team, and enhanced 
optimism.
Results from both interview studies informed the development of a quantitative survey about 
clinical trial decision making, for which recruitment has recently closed. To inform future 
research, we are in process of using the qualitative and quantitative results to adapt Leventhal’s 
common-sense model of self-regulation, which describes responses to and management of 
health threats6. The revised model will propose that decisions about disease management 
include expectations and hopes as cognitive and emotional appraisals that inform parallel
cognitive and emotional processing. This will provide a framework to assess decision making 
influences and processes in the clinical trial context. We next plan to develop and evaluate a 





Data from these studies have been presented to clinical trials sponsors in group and individual 
settings; to relevant organizations such as the Patient Centered Outcomes Research Institute 
and through the Clinical and Translational Science Award (CTSA) program; to clinician 
investigators at the World Muscle Society and other professional forums; and to patients and 
families through PPMD forums. The data have been used to inform the development of new 
educational content for patients and families and to justify sessions on trial expectations at the 
PPMD annual conference. Finally, themes from the study have been integrated into research 
exploring clinical trial decision making in other disease communities (spinal muscular atrophy, 
fragile X syndrome and HIV). 
Implications for Community-Engaged Research Approaches
Table 2 presents a rating of the approaches used in this thesis on the CEnR continuum. We 
found that community engagement at level 1 or higher on the continuum is important to posing 
and answering questions of importance. The utility and feasibility of higher levels of community 
engagement varied based on the program’s timeline, budget and needs. The community-based 
participatory research (CBPR) approach we used in the clinical trial study was extremely 
beneficial, but required a supporting timeline and budget that may not always be feasible. In the 
treatment preference study, the researchers and advisory team chose to target community 
engagement around communicating about the need for, and implications of, the study and for 
identifying the attributes and levels used in the instrument. We found that ‘hybrid’ community 
engagement approaches were natural for research conducted within an advocacy organization, 
and took advantage of PPMD’s community reach and respect.
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Lessons on Community Engagement
Following are some of the important lessons we learned about community engagement.
In the mothers’ welling study, our engagement efforts highlighted the importance of 
framing the disease experience. Findings underscore the need to re-orient negative 
predictor and outcome variables used in traditional disease impact studies to positive 
predictor and outcome variables that are focused on wellbeing. 
In the treatment preferences study, the importance of researcher flexibility when faced 




engagement, not everyone in the community was in agreement about the value of 
providing quantified data to regulators. Thus, we added a complimentary approach 
(PPMD’s “Share your Story” outreach, which resulted in an FDA-focused resource called 
“Patients are Waiting”7) to increase community acceptance and demonstrate our 
appreciation for the power of patient and family testimony.
The clinical trials studies highlighted the benefits of a highly-engaged CBPR approach 
for addressing complex ethical issues with implications for a wide range of stakeholders. 
Incorporating a wide range of experienced stakeholders in the process helped to frame 
ethical challenges in an acceptable way and suggested future research and 
interventions that should be satisfactory to the community. 
The community engagement undertaken in these studies had an important, and sometimes 
dramatic, impact on the study objectives, aims, design, analysis, interpretation, and 
dissemination. There is likely not a one-size-fits-all approach to community engagement. 
Instead, engagement must be done meaningfully so stakeholders have a real chance to 
understand and influence the research agenda. Long-term engagement requires education and 
support to expand parents’ and caregivers’ research imaginations, so they can be active 
participants in setting a research agenda. Researchers must be open to change and appreciate 
that their perspectives and research experiences will expand and grow as a benefit of the 
engagement.
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Samenvatting, Discussie en Implicaties
In dit proefschrift worden een aantal translationele studies beschreven waarin 
onderzoeksmethoden worden gebruikt die van belang zijn voor patiënten met Duchenne/Becker 
spierdystrofie (DBMD) en hun verzorgers (stakeholders). In dit hoofdstuk worden de 
bevindingen en implicaties samengevat. Ten slotte wordt besproken op welke wijze de inbreng 
van DBMD patiënten, families, en andere stakeholders in deze studies kan worden 
gerealiseerd. 
Een beperking van alle in dit proefschrift beschreven studies was dat deelnemers aan de 
studies werden geworven via het PPMD (Parent Project Muscular Dystrophy) en de 
DuchenneConnect self-report registry. Families die lid zijn van een patiënten organisatie of 
Vereniging en die deelnemen aan een sociaal-wetenschappelijk onderzoek zijn mogelijk niet 
representatief voor de totale Duchenne/ Becker gemeenschap. Toekomstig onderzoek kan baat 
hebben bij werving via de (poli-)klinieken, waarmee een breder beeld kan worden gevormd en 
de generaliseerbaarheid van de bevindingen groter is.  
Advocacy and Programmatische Implicaties
Het overkoepelende doel van deze studies was het richting geven aan en het ondersteunen van 
het beleid van de PPMD en patiëntenorganisaties. Geconcludeerd kan worden dat elke studie 
hieraan een belangrijke bijdrage heeft geleverd. Het doel kon worden bereikt door de actieve 
betrokkenheid van DBMD patiënten, families, en andere stakeholders.
Het welzijn van moeders (Hoofdstuk 2). In deze studie werden de psychosociale behoeften 
van moeders van een of meerdere kinderen met Duchenne/Becker spierdystrofie onderzocht. 
Specifiek werd gekeken naar de behoefte aan rust en ontspanning, het vermogen om zorg te 
verlenen, en de mate van aanpassing met betrekking tot de zorg voor een kind met DBMD. De 
positieve focus van het doel van de studie en de gebruikte vragenlijsten weerspiegelden de
instelling van de deelnemende moeders: zorgen voor een kind met DBMD heeft ook zijn 
positieve kanten en klinische interventies moeten zich meer richten op de kracht en welzijn van 
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moeders dan op de last die de ziekte met zich mee brengt en gevoelens van onvermogen om 
zorg te bieden.  
Wij vonden bij de moeders diverse vormen van zorgkracht, vooral op het gebied van sociale 
steun. Moeders hebben een grote behoefte aan momenten van rust, en aan tijdelijk ontlast te 
worden van zorg. Moeders ervoeren vooral dat geen gehoor wordt gegeven aan hoe zij met 
emoties over DBMD moeten omgaan. Voorspellers voor psychologische aanpassing  waren 
onder meer grotere veerkracht en bevestiging van de positieve impact van DBMD op het gezin. 
Hoewel de huidige literatuur vooral de nadruk legt op de last van de ziekte, vonden wij dat de 
perceptie van de last van de ziekte niet voorspellend was voor de mate van aanpassing.   
Het onderzoek toonde enkele onverwachte bevindingen met betrekking tot de leeftijd van 
moeders, het beloop van de ziekte, psychosociale steun, en psychologische aanpassing. In de 
longitudinale studie vonden wij tegengestelde effecten van de leeftijd van moeders (jongere 
leeftijd voorspelde betere adaptatie) en de functionele conditie van het DBMD-kind (slechtere 
conditie voorspelde betere adaptatie) op de psychologische adaptatie. De resultaten tonen dat,
terwijl moeders in staat zijn positieve waarde toe te kennen aan hun ervaring met DBMD en 
tegelijkertijd ervaren dat er minder aandacht is voor hun behoeften wanneer de symptomen van 
het DBMD-kind ernstiger worden, hun veerkracht onder druk komt te staan naarmate zij ouder 
worden. Verder onderzoek is nodig om beter te kunnen begrijpen wat de effecten zijn van 
toenemende leeftijd en verergering van de functionele conditie van het kind op de 
psychosociale behoeften en noden, bevorderende factoren voor zorg, en psychologische 
adaptatie. 
Klinische implicaties van de cross-sectionele en prospectieve studies over het welzijn van 
moeders zijn onder meer de behoefte aan systematische exploratie van factoren die de zorg 
bevorderen. Het gaat dan vooral om coping met DMD-gerelateerde onzekerheid en angst.
Interventies om de adaptatie van moeders te verbeteren dienen gericht te zijn op versterking 
van hun veerkracht, en het kunnen zien en waarderen van de positieve aspecten van het 
hebben van een kind met DBDM. Clinici kunnen bij moeders onderzoeken, met gerichte vragen 
zoals die gebruikt werden in deze studie, wat hun specifieke noden en behoeften zijn. 
Samenvattingen van de onderzoeksbevindingen zijn verspreid via de PPMD forums, zoals 




beschreven in dit proefschrift  werden gebruikt voor een wellbevinden-interventie op de 
jaarlijkse conferentie van de PPMD in 2013, en voor twee subsidieaanvragen over het welzijn 
van zorgverleners. Eind 2014 is op basis van dit proefschrift via DuchenneConnect, een 
programma gestart voor moeders van DBMD-kinderen. De longitudinale studie naar 
welbevinden van moeders is met een jaar uitgebreid waarbij ook gegevens worden verkregen 
over onzekerheid, spiritualiteit en hoop.  
Hoofdstukken 3-5 beschrijven de studie naar voorkeuren voor behandeling en impact, In dit 
onderzoek werd gebruik gemaakt van de Best-Worst Scaling methode. Wij vonden dat 
verzorgers van een DBMD-kind bereid waren een verhoogde kans op een ernstige uitkomst 
tijdens een klinische trial te accepteren wanneer zij konden meedoen met een non-curatieve 
behandeling, zelfs zonder verbetering van levensverwachting. De studie leverde belangrijke 
informatie op voor beleid inzake het voornemen om specifieke klinische trials te starten. In de 
‘zorgen’ studie zijn we erin geslaagd de meest belangrijke ‘zorgen’ te onderscheiden. 
Geconcludeerd kon worden dat de meest dringende zorgen betrekking hadden op 
symptoomprogressie, en toegang tot medische zorg, gevolgd door zorgen om het geluksgevoel 
van het kind. Van minder belang leken zorgen gerelateerd aan het welbevinden van ouders en
de impact op het gehele gezin. Best-Worst Scaling is een krachtige methode om ziekte-
percepties en ziekte-impact te exploreren en kwantificeren. De methode wordt nog weinig 
gebruikt in gezondheid-gerelateerde sociaalwetenschappelijke studies. 
Van de in dit proefschrift beschreven studies had de behandelingspreferentie studie de meeste
impact op zowel patiënten vertegenwoordiging als overheidsbeleid. We beschreven een 
procesmodel voor patiëntenorganisaties hoe geneesmiddelen op patiëntgerichte wijze kunnen 
worden ontwikkeld. De bevindingen werden voorgelegd aan vertegenwoordigers van de FDA 
(Food and Drug Administration) zodat deze konden worden gebruikt bij de beoordeling van 
toekomstige DMD therapieën. FDA-medewerkers vonden de het model eveneens toepasbaar 
voor andere patiëntenorganisaties1 en benadrukten de behoefte aan nader onderzoek door 
andere organisaties.2 Enkele biofarmaceutische bedrijven hebben het model uit deze studie 
gebruikt of willen dat gebruiken voor regelgeving. De studie werd ook geciteerd in de U.S. 
House of Representatives Energy and Commerce Committee 21st Century Cures Initiative en
beschreven in een Committee Hearing.3  
De PPMD had met de bevindingen van deze studie belangrijke argumenten in een overleg met 
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de FDA. Dit leidde er toe dat FDA de PPMD verzocht om een voorlopige handleiding te 
ontwikkelen voor DMD— de eerste voor een patiëntenorganisatie voor een zeldzame ziekte.
Deze werd in juni 2014 aangeboden aan de FDA. De handleiding begint met een hoofdstuk 
over benefit/risk assessment, dat een samenvatting bevat van de bevindingen en dat sponsors 
adviseert om patiënt/verzorger preferenties mee te laten wegen in het proces van ontwikkeling 
van geneesmiddelen en regelgeving.4  
Na afloop van de studie hebben de auteurs hun bevindingen gepresenteerd op meer dan 20 
congressen en bijeenkomsten van patiëntenverenigingen. Twaalf  patiëntenorganisaties van 
andere ziekten hebben belangstelling getoond voor gebruik van het model. Een voorbeeld van 
blijvende impact is de in november 2014 aangekondigde samenwerking tussen de PPMD en 
Santhera Pharmaceuticals om een nieuwe benefit/risk studie te doen naar pulmonaire therapie 
voor Duchenne.5  
Besluitvorming in klinische trials (Hoofdstukken 6-8) is een gebied van toenemend belang 
voor sponsoren van klinische trials, onderzoekteams, ethische beoordelingscommissies, en 
patiëntenorganisaties. Onze studies toonden de complexiteit van besluitvorming in klinische 
trials, vooral binnen de context van een zeldzame, progressieve pediatrische ziekte. De 
deelnemende ouders stelden “niets doen” (d.w.z. niet deelnemen aan een trial) gelijk aan 
“schade toebrengen (doing harm)”. De beslissingen van ouders werden sterk beïnvloed door de 
kans op voordeel (benefit) voor het kind, maar de ouders toonden niet de therapeutische 
misconceptie. Optimisme volgend op de beschikbaarheid van een klinische trial was een ander 
voordeel dat hoog gewaardeerd werd door zowel de ouders als de in de trial betrokken clinici. 
Ouders zeiden dat zij, voorafgaand aan het proces van informed-consent, de voor- en nadelen 
al afwogen en het voornemen ontwikkelden om aan een klinische trial mee te doen. 
Clinici dachten dat zij meer invloed hadden op het besluit van ouders dan door de ouders zelf 
aan clinici werd toegeschreven. Clinici voelden zich verantwoordelijk om geïnformeerde 
beslissingen mogelijk te maken en tegelijk het optimisme van ouders niet van hen af te nemen. 
Gebaseerd op onze bevindingen adviseren we clinici, sponsoren, en patiëntenorganisaties om 
een strategie c.q. handleiding te ontwikkelen voor deelname van families aan klinische trials 
waarbij kan worden geanticipeerd op potentieel ongewenste uitkomsten van de trial. Dit kan 
clinici ondersteunen in hun gesprekken met families en ook enige voorzorg bieden om 




We hebben ook beschreven hoe ouders de waargenomen benefits tijdens een klinische trial 
inschatten en waardeerden. Dit heeft implicaties voor de mate waarin zij in de trial blijven 
participeren. Deelnemers beschreven een complex proces van voortdurend wikken en wegen, 
en het inschatten van de voor- en nadelen. De meeste ouders zagen individuele voordelen voor 
hun kinderen, maar ook andere voordelen zoals altruïsme, nauwe band met het 
onderzoeksteam, en meer optimisme. 
De bevindingen van de beide interviewstudies hebben bijgedragen aan de ontwikkeling van een 
kwantitatieve studie naar besluitvorming bij klinische trials. Voor toekomstig onderzoek worden 
onze kwalitatieve en kwantitatieve bevindingen gebruikt voor aanpassing van Leventhal’s 
common-sense model voor zelf-regulatie. Dit model beschrijft  de reacties op, en hanteren van 
bedreigingen van gezondheid6. Het aangepaste model houdt in dat bij beslissingen over het 
hanteren van een ziekte ook rekening moeten worden gehouden met verwachtingen en hoop 
als cognitieve en emotionele waarderingen die van invloed zijn op cognitieve en emotionele 
processen. Dit biedt een kader waarmee besluitvormingsprocessen in de context van klinische 
trials kunnen worden vastgesteld. Een volgende stap is de ontwikkeling en evaluatie van een 
beslissingshulp waarmee verwachtingen en optimistische hoop in klinische trials van elkaar 
kunnen worden onderscheiden. 
Gegevens van deze studies zijn gepresenteerd aan sponsoren van klinische trials. Verder aan 
het Patient Centered Outcomes Research Institute, de Clinical and Translational Science Award 
(CTSA) program, aan clinici-onderzoekers op de World Muscle Society en andere professionele 
forums, en aan patiënten en families via de PPMD forums. De resultaten zijn gebruikt voor de 
ontwikkeling van nieuw voorlichtingsmateriaal voor patiënten en families, en gepresenteerd in 
sessies over verwachtingen over klinische trials tijdens de jaarlijkse PPMD conferentie. Tot slot, 
diverse thema’s van deze studie zijn opgenomen in studies naar besluitvormingsprocessen in 
andere patiëntengroepen (spinal muscular atrophy, Fragile X syndrome, and HIV). 
Implicaties voor CEnR benaderingen
Tabel 2 toont de benaderingen voor CEnR die in dit proefschrift zijn gebruikt. We vonden dat 
betrokkenheid van diverse stakeholders in wetenschappelijke studies op niveau 1 of hoger op
het continuüm belangrijk is voor het stellen en beantwoorden van onderzoeksvragen. De 
bruikbaarheid en geschiktheid van hogere niveaus van de betrokkenheid van de stakeholders
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varieert op basis van tijdslijn van het programma, het beschikbare budget, en de behoeften. De 
CBPR (Community based participatory research) benadering in de studie naar klinische trials 
gaf veel informatie maar vereiste veel tijd en een budget dat niet altijd beschikbaar was. In de 
behandelingspreferentie-studie hebben de onderzoekers en de adviesraad er voor gekozen om 
met een breed spectrum aan stakeholders te spreken over de behoefte aan, en de implicaties 
van de studie. Stakeholders waren ook van belang voor het bepalen van de attributies en 
niveaus van het model. Een ‘hybride’ betrokkenheid van de stakeholders bij wetenschappelijke 
studies bleek vanzelfsprekend in onderzoek binnen patiëntenorganisaties; studies kunnen dan
rekenen op medewerking en respect.
Tabel 2. Rating of Community-Engaged Research Approaches 
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Lessen over betrokkenheid van patiënten, families, en andere stakeholders in 
wetenschappelijk onderzoek
We hebben de volgende lessen geleerd over betrokkenheid van de stakeholders bij onderzoek. 
In de studie naar welbevinden van moeders werd getoond hoe belangrijk het is om de 
ziekte-ervaringen in context te zien. De bevindingen onderstrepen de behoefte om 
anders dan in voorgaand onderzoek te kijken naar positieve voorspellende en 
uitkomstvariabelen van welbevinden.   
In de behandelingspreferentie studie, werd het belang en noodzaak gezien van 
flexibiliteit bij de onderzoeker wanneer sprake is van bepaalde reacties bij de 
stakeholders. Zelfs al zij stakeholders betrokken bij de opzet van het onderzoek, dan 
nog zal niet iedereen in de stakeholders het eens zijn over de waarde van het 
verstrekken van kwantitatieve gegevens aan de regelgevers. We voegden derhalve een 
complementaire benadering toe (PPMD’s “Vertel uw Verhaal” 7) om de 
aanvaardbaarheid bij de stakeholders te vergroten en onze waardering te tonen voor de 
kracht van gezins- en familie participatie. 
De klinische trial studies toonden de voordelen van een zeer betrokken CBPR 
benadering voor het onderzoeken van complexe ethische problemen met implicaties 
voor een brede range van stakeholders. Het incorporeren van een brede range van 
ervaren stakeholders in het proces was van belang voor het kaderen van ethische 
vragen.  
De betrokkenheid van stakeholders in de in dit proefschrift  beschreven studies had belangrijke, 
soms  verstrekkende impact op de doelen van de studies, het design, analyses, interpretatie en 
verspreiding van bevindingen. Er is waarschijnlijk geen one-size-fits-all benadering voor het
betrekken van stakeholders bij wetenschappelijk onderzoek. Sterker, betrokkenheid van 
stakeholders vraagt om een aanpak die stakeholders in staat stelt om goed te begrijpen wat de 
onderzoeksagenda inhoudt en dat zij daarop invloed kunnen uitoefenen. Lange-termijn 
betrokkenheid vraagt om educatie en ondersteuning zodat ouders en verzorgers zich iets 
kunnen voorstellen bij onderzoek en vervolgens actief kunnen  participeren in het vaststellen 
van de onderzoeksagenda. Onderzoekers moeten open staan voor verandering en appreciëren 
dat hun eigen perspectief en onderzoekservaring zich alleen maar kunnen verbreden  en
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